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Section I ABSTRACT.
Increased synthesis and deposition of extracellular matrix proteins in the blood vessel 
wall are implicated in vascular disorders such as atherosclerosis, restenosis and hypertension. 
(Liau and Chan 1989). The increase in extracellular matrix proteins can be mostly attributed 
to smooth muscle cells (SMC’s) within vascular lesions (Mecham et al 1987). It is presumed 
that modulation of SMC’s from their normally quiescent, contractile phenotype to a 
proliferative synthetic phenotype results in increased synthesis of extracellular matrix 
proteins. Studies have also demonstrated that signals elicited from the extracellular matrix 
(ECM) may play a role in the regulation of this SMC phenotypic modulation (Yamamoto et 
al 1993; Hedin et al 1988). The mechanism by which ECM can alter the phenotypic state of 
SMC’s is not well understood but clearly involves the induction of intracellular signals as a 
consequence of ECM ligand - cell surface integrin binding. These signals must subsequently 
exert downstream molecular events altering gene expression and ultimately cell phenotype.
The research project presented in this thesis examined the influence various 
extracellular matrix substrates have on vascular SMC behaviour in vitro. Initial observations 
demonstrated that SMC’s cultured on different matrix substrates exhibit distinct 
morphological growth patterns. Functional differences in SMC proliferation and migration 
rates were also observed in response to seeding on different ECM surfaces.
Analysis of the expression levels of known SMC phenotypic protein markers between 
SMC’s cultured on different matrix substrates did not reveal any significant differences in 
protein expression. Slight upregulation of Myosin Light Chain Kinase (MLCK)-210 kd 
isoform was observed in SMC’s cultured on cellular fibronectin, Collagen III and Vitronectin 
substrates. The Meta-vinculin protein was upregulated in SMC’s cultured on fibronectin 
coated substrates.
In order to identify altered gene expression patterns induced by ECM adhesion, SMC 
populations cultured on fibronectin coated plastic and SMC’s grown on uncoated plastic 
were selected for analysis by the differential display technique. Differential display is a
recently developed PCR based technique that allows the identification of differentially 
expressed genes between related cell populations (Liang and Pardee 1992). Much effort was 
spent optimising the differential display procedure to overcome such limitations as primer 
redundancy and high false positive selection rates. However, as a result of the persistence of 
false positives only one gene, meta-vinculin was confirmed as being differentially expressed 
between SMC populations cultured on fibronectin coated and uncoated tissue culture plastic 
surfaces.
It was concluded that the failure to identify a significant number of fibronectin 
modulated genes was probably a result of limitations in the differential display procedure as 
carried out in this study, and may also possibly be due to the existence of only very minor 
differences in phenotype between SMC’s grown on plastic with or without fibronectin 
precoating.
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Section III Abbreviations.
aSM alpha Smooth Muscle specific isoform.
APS Ammonium Persulphate.
bFGF basic Fibroblast Growth Factor.
CDK Cyclin Dependent Kinase.
c-FHC complex - Familial Hypercholesterolemic.
CKI Cyclin Dependent Kinase Inhibitor.
CMV Cytomegalovirus.
CPM Counts Per Minute
DAG 1,2 diacylglycerol.
DNA Deoxyribonucleic Acid.
ECL Enhanced Chemiluminesence.
ECM Extracellular Matrix.
EDTA Ethylenediamine-tetracetic acid.
EGF Endothelial Growth Factor.
F-actin Filamentous actin.
FAR Focal Adhesion Kinase.
FCS Fetal Calf Serum.
GRB2 Growth factor receptor binding protein 2.
GTP Guanosine triphosphate.
HESS Hanks Balanced Salt Solution.
HGF Hepatocyte Growth Factor (Scatter factor).
HUASMC’s Human Umbilical Artery Smooth Muscle Cells.
H:W Ham’s F12AVaymouth medium (50:50 mix).
IFN-y Interferon gamma.
IGF-I Insulin-like Growth factor 1.
IL-1 Interleukin 1.
IL-6 Interleukin 6.
IP3 Inositol 1,4,5 triphosphate.
LDL Low Density Lipoproteins.
MAP Mitogen activated protein.
M-CSF Macrophage Colony Stimulating Factor.
M LCK Myosin Light Chain Kinase.
NF-kB Nuclear Factor kappa B.
PBS Phosphate Buffered Saline.
PCNA Proliferating Cell Nuclear Antigen.
PCR Polymerase Chain Reaction.
PDGF Platelet Derived Growth Factors.
PI-3 Kinase Phosphatidyllnositol 3-Kinase
PIP2 Phosphatidylinositol 4, 5 bisphosphate.
PLC Phospholipase C.
PKC Protein Kinase C.
PTCA Percutaneous Transluminal Coronary Angioplasty.
PTK Protein tyrosine kinase.
PTP Protein tyrosine phosphatase.
RGB Arginine-Glycine-Asparagene cell binding domain.
RNA Ribonucleic Acid.
RT-PCR Reverse Transcriptase Polymerase Chain Reaction
SDS Sodium Dodecyl Sulphate.
SH2 src Homology 2 domain.
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SMC’s Smooth Muscle Cells.
SSC Sodium chloride (3M), Sodium citrate (0.3M) solution.
TEMED T etramethylethylenediamine.
TF Tissue factor.
TFPI Tissue Factor Pathway Inhibitor.
TGF-P Transforming Growth Factor - beta.
TN Fa Tumour Necrosis Factor alpha.
TPA 12-0- tetradecanoyl-phorbal-13 -acetate.
VLDL Very Low Density Lipoproteins.
X-Gal 0-Nitrophenyl-p-D-Galactopyranoside (X-Gal).
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Section IV INTRODUCTION.
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IV.l INCIDENCE OF ATHEROSCLEROSIS AND RESTENOSIS.
Atherosclerosis and its complications, such as myocardial infarction, stroke, and peripheral 
vascular disease, remain the major causes of morbidity and mortality in the western world. 
Atherosclerosis is a slowly progressive disease, which begins in early childhood, this together with 
its multifactorial nature has presented a major hurdle towards elucidation of the etiology and 
pathogenesis of the disease. However, in the past two decades cellular and molecular approaches 
to the study of the cells of the vascular wall have begun to provide numerous insights into the 
mechanisms involved in the pathogenesis of atherosclerosis (Munro and Cotran 1988).
Analysis of the cellular constituents in human atherosclerotic lesions have revealed an 
altered vascular histological pattern characterized by the presence of increased numbers of 
inflammatory and smooth muscle cells (SMC’s). Such a pattern is similar to those observed at the 
sites of tissue injury. The disease was first likened to inflammation by Rayer in 1823, this concept 
was developed through the years culminating in the response to injury hypothesis which proposes 
that injury to the endothelium is the initiating factor in atherosclerosis. Injury to the endothelium in 
atherosclerosis is thought to arise by several mechanisms in response to chronically elevated semm 
levels of low density lipoproteins (LDL) and very low density lipoproteins (VLDL) a condition 
known as hypercholesterolemia. Such injury has been found to increase endothelial plasma 
membrane viscosity which may promote the attachment of monocytes and platelets thereby 
initiating an inflammatory reaction (Ross 1986).
The above theory has claimed universal acceptance because it is supported by the 
identification of smoking, a high cholesterol diet, and genetic disorders impairing cholesterol 
metabolism all of which promote hypercholesterolemia, as major risk factors predisposing to 
atherosclerosis (Lusis and Sparkes 1989). The importance of endothelial injury is further 
exemplified by the related condition known as restenosis which develops following the balloon 
angioplasty procedure, carried out to dilate occluded atherosclerotic vessels. The ballooning
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procedure results in physical injury to the endothelium and the vessel wall and in 30-40% of cases 
this injury initiates an inflammatory response similar to that observed in the original atherosclerotic 
lesion which subsequently promotes excessive smooth muscle cell proliferation which is thought 
to contribute to reocclusion of the treated vessel (Shirotani et al 1993).
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IV.2 PATHOGENESIS OF ATHEROSCLEROSIS.
Endothelial cells serve as a bamer between the blood supply and body tissues. Under 
normal conditions the endothelial cells perform a variety of critical functions including the transfer 
of metabolites between blood and tissues, the maintanence of thromboresistance and the 
regulation of vascular tone. During inflammatory reactions however, endothelial cells can 
modulate their behaviour to promote monocyte and lymphocyte adherance and subsequent 
leucocyte infiltration into tissue. Similarly during development endothelial cells become responsive 
to a variety of growth factor and cytokines and thereby regulate vascular growth (Munro and 
Cotran 1988).
It has been established fi-om in vitro and in vivo studies that if endothelial cells are bathed 
in chronically elevated levels of LDL and VLDL, rapid cholesterol exchange will occur with the 
plasma membranes of the endothelial cells, leading to subtle alterations in cholesterol, 
phospholipid, and protein ratios, subsequently altering the viscosity of the plasma membranes of 
these cells and promoting increased attachment of monocytes to the vessel wall. (Alderson et al 
1986; Edemann et al 1987). After monocytes have attached they release a variety of factors 
promoting endothelial dysfunction contributing to the localization of monocytes subendothelially. 
The adhered macrophages can damage the surrounding endothelium by releasing factors toxic for 
endothelial cells such as superoxide anions and oxidized LDL (Cathcart et al 1988). These and 
other macrophage derived growth factors and cytokines may also alter endothelial functions 
including, the loss of endothelial cell derived antithrombotic substances such as prostacyclin and 
heparin. This provides an opportunity for platelet adhesion to areas of connective tissue, thrombin 
and macrophages exposed by endothelial cell death, the adhered platelets subsequently 
degranulate releasing additional growth factors and cytokines into the area (Ross 1986).
These early events in atherosclerosis are responsible for the development of the initial 
atherosclerotic lesions, known as “fatty streaks”, - these being macroscopically distinguishable,
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cushion-like, whiteish, subendothelial intimai areas that are comprised of aggregations of lipid- 
rich macrophages and T-lymphocytes (Wick et al 1995). The development of fatty streaks occurs 
early in life. Fatty streaks can be found in the coronary arteries of half of the autopsy specimens 
from children aged 10-14 (Stary 1989). Most of these early lesions especially those in the aorta 
either disappear or remain harmless (Munro and Cotran 1988). In predisposed individuals, 
however, lesions at particular locations, quite often in coronary arteries are exposed to the 
continued release of activated endothelial as well as platelet and macrophage derived factors 
which include; b-thromboglobulin, vasoconstrictive amines, arachidonic acid metabolites, PDGF, 
EGF, FGF, TGFb, IL-1, IFN-y and other less well characterized mitogens which can augment the 
initial inflammatory processes. The chronic generation of such a plethora of factors initiates 
phenotypic modulation of local SMC's from their normal contractile phenotype into a synthetic 
phenotype.This transformation into a synthetic phenotype is characterized by the induction of 
vascular SMC migration from their normal location in the vessel media towards the intima, where 
they undergo enhanced cell proliferation and overexpress a considerable amount of extracellular 
matrix macromolecules (ECM) contributing to the subendothelial formation of what is known as 
the neointima (Thyberg et al 1990) (FIGIV.l).
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FIGIV.l - Initial Lesion Development.
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Progressive lipid accumulation by macrophages and SMC's also takes place resulting in 
foam cell development in these regions. Such events contribute to the progression of fatty streaks 
into the advanced atherosclerotic lesion known as the atheromatous plaque (Ross 1986, Clinton 
and Libby 1992). Although atherosclerotic lesions can be observed throughout the circulatory 
system, certain areas of the arterial tree are particularly prone to the development of lesions such 
as the aortic arch, the branching sites of larger vessels, as well as the carotid and coronary arteries 
(Wick et al 1995). These sites are typically subject to incresed haemodynamic stress which is 
thought to promote atherosclerotic lesion development (Sterpetti et al 1994).
The atheromatous plaque exhibits histologic variability, but a typical cellular plaque 
consists of a fibrous cap, composed mostly of smooth muscle cells, T lymphocytes and ECM 
molecules, a deeper necrotic core which contains cellular debris, extracellular lipid droplets, 
cholesterol crystals, and calcium deposits. This necrotic core often contains numerous large foam 
cells of both macrophage and SMC origin. Monocytes and macrophages are located at the 
margins of the lipid core. Around the periphery of lesions, evidence of neovascularization from the 
direction of the adventitia can sometimes be observed which may provide additional routes for
18
inflammatory cell infiltration thereby further contributing to plaque development (Munro and 
Cotran 1988) (FIG.IV.2).
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FIG.IV.2 The Atherosclerotic Plaque.
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Recent pathological studies investigating disease progression in humans has revealed that 
if atherosclerotic plaques remain intact, the advanced lesion may only slightly occlude blood flow 
and may be of no significant consequence to the health of the affected individual. Data has shown 
that most of the sudden deaths fi-om myocardial infarct are due to ruptures, particularly in the 
margins of the fibrous cap where there are more macrophages and possibly also more matrix 
metalloproteinase activity relative to ECM deposition taking place (Libby 1995). Cap rupture is 
often followed by haemorrhage into the plaque, thrombosis and occlussion of the artery (Davies 
and Thomas 1984). It therefore appears that the mechanical strength of the cap tissue is a critical 
determinant of morbidity induced by the atherosclerotic lesion. The mechanical strength of the 
plaque cap depends on the amount, and organization of the connective tissue matrix proteins. The 
principle proteinaceous constituent of this ECM include the interstitial coUagens and elastin. 
Vascular SMC’s are responsible for the synthesis and assembly of the bulk of both the collagenous 
and non collagenous macromolecules within such vessels (Libby 1995). Therefore, a loss of SMC 
synthetic activity would be expected in time to lead to degeneration and fragmentation of the 
connective tissue. Indeed histological examinations have revealed that unstable plaques prone to 
rupture contain a high macrophage to SMC ratio, whereas the more stable plaques contain a 
higher percentage of SMC's (Davies et al 1993).
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rV.3 PATHOGENESIS OF RESTENOSIS.
Transluminal angioplasty was first introduced in 1964 as a non-surgical treatment for the 
dilation of arteries narrowed by atherosclerosis (Dotter and Judkins 1964). Percutaneous 
Transluminal Coronary Angioplasty (PTCA) is now the preferred treatment for re-dilation of 
occluded coronary arteries. The procedure utilises a balloon catheter that is positioned at the site 
of arterial stenosis. Balloon inflation causes endothelial denudation, disruption of the 
atherosclerotic plaque, dehiscence of the intima and plaque fi-om the underlying media, and 
stretching and tearing of the media and adventitia, with resultant vessel dilation (Steele et al 
1985). The chief limitation of successful PTCA is reocurrence of the stenosis, or restenosis. 
Restenosis is most commonly defined as; greater than a 50 % narrowing of the diameter of the 
lumen at the site of a previously successful PTCA. Restenosis occurs in about one third of patients 
in whom a narrowed artery has been dilated and in about 60% of those in whom a chronically 
occluded artery has been dilated. It typically occurs one to three months after PTCA (Landau et al 
1994).
The process of restenosis is initiated by endothelial and deep vessel injury resulting from 
the ballooning procedure. This leads to platelet aggregation, thrombus formation, inflammation, 
and activation of macrophages and smooth muscle cells. These events induce the production and 
release of growth factors and cytokines, which results in the transformation of SMC's into a 
synthetic phenotype and subsequent migration of SMC’s from the arterial media to the intima 
where they proliferate and produce extracellular matrix, thereby resulting in a stenosis of the 
vessel lumen (Shirotani et al 1993).
Studies carried out on the rat carotid balloon injury model have facillitated the kinetic 
analysis of the vascular SMC response. These studies have led to the description of four waves 
defining the SMC response to vascular injury (Friedman et al 1977; Clowes and Schwartz 1985; 
Hanke et al 1990). The first wave consists of medial SMC proliferation and is initiated 24 hours
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after vessel injury. The release of bFGF from injured SMC’s is thought to be a driving force 
behind this proliferation. (Linder and Reidy 1991; Olson et al 1992). The migration of SMC’s 
across the internal elastic lamina to form the intima constitutes the “second wave” (Clowes et al 
1983). The time period covering SMC migration is unclear. Several molecules in addition to 
PDGF including TGFJ3, bFGF and angiotensin II may contribute to stimulating SMC migration. 
Once smooth muscle cells arrive in the intima of the rat artery, they may replicate for weeks to 
months. This replication is called the “third wave”. The neointima can be stimulated to show a 
further increase in replication as a result of increased responsiveness to mitogens, this is known as 
the “fourth wave” (Schwartz et al 1995).
Although restenosis and atherosclerosis are initiated by common inflammatory 
mechanisms the difference in time course of disease progression and the processes ultimately 
leading to morbidity indicate the importance that separate approaches need to be taken towards 
the development of therapeutic treatments for each condition. For instance it may not be beneficial 
to target the prevention of SMC phenotypic modulation, migration and proliferation as a 
therapeutic intervention against primary atherosclerosis since these events can occur as early as 
the age of 5 years, long before atherosclerosis becomes a clinical problem. In contrast SMC 
migration, proliferation and phenotypic modulation are directly involved in the development of 
restenosis and they may be very appropriate targets for therapeutic intervention. Restenosis is 
responsible for the requirement of 185,000 additional coronary angioplasty operations every year 
in the United States alone (Landau et al 1994). This condition has also recently been identified as 
a characteristic feature within vessels of transplanted organs as well as in saphenous vein and 
coronary bypass grafts, brought about by the induction of immune responses elicited in response 
to foreign antigens or injury caused by surgery (Cox et al 1991). Inhibition of SMC phenotypic 
modulation therefore has important therapeutic potential for the prevention of restenosis.
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IV.4 PHENOTYPIC MODULATION OF SMOOTH MUSCLE CELLS.
It has become increasingly evident that vascular SMC's occur in at least two distinct 
states, referred to as the contractile and synthetic phenotypes (Thyberg et al 1990). Contractile 
SMC's are so named because they have abundant myofilaments and will contract in response to 
chemical and mechanical stimuli. They are the normal SMC type found in adults. Synthetic SMC's 
obtained their name because of the extensive distribution of synthetic organelles including a 
prominent rough endoplasmic reticulum and Golgi complex within their cytoplasm. Synthetic 
SMC's are characteristic of developing fetal arteries as well as representing the predominant SMC 
phenotype found within atherosclerotic and restenoic lesions (Campbell et al 1988).
Thus it can be assumed that the normal development of an artery involves SMC 
differentiation fi-om a synthetic state into a contractile state. Reversal of this process, “phenotypic 
modulation”, occurs in situations such as arterial repair associated with the development of 
atherosclerosis and restenosis (Thyberg et al 1990).
The above observations suggest that mechanisms governing normal cell differentiation 
may play a major role in lesion development. The mechanisms that control the process of SMC 
differentiation are largely unknown, but are thought to involve the induction of intracellular 
signalling pathways initiated by hormone release as well as signals arising fi-om the surrounding 
extracellular matrix and mesenchymal cell population. The generation of these signals is believed 
to regulate gene expression through transcriptional control involving the activity of DNA binding 
proteins as well as through post-transcriptional modifications, thereby regulating the type of 
proteins produced which subsequently determines cell phenotype (Alberts et al 1989). Elucidation 
of these molecular mechanisms may identify therapeutic targets beneficial in the prevention of 
lesion development.
A variety of factors have been identified which induce SMC phenotypic modulation 
including native and oxidized LDL (Rahm et al 1992), extracellular matrix components,
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fibronectin (Hedin et al 1988), and type I collagen (Yamamoto et al 1993). A variety of 
inflammatory cytokines and growth factors are thought to act synergistically in promoting the 
synthetic phenotype. These factors include PDGF which, in addition to promoting SMC migration 
and proliferation, can also promote phenotypic modulation via the regulation of fibronectin 
dependent adhesion (Fujio et al 1993). TGF-(3 which can influence multiple SMC functions 
including the regulation of SMC proliferation and the induction of extracellular matrix production 
(Lawrence et al 1994). Macrophage derived prostaglandins and leukotrienes have also been 
shown to promote the synthetic phenotype (Sjolund et al 1984; Palmberg 1989). Thus in the 
réponse to injury hypothesis (Ross 1986), alterations in the extracellular signals as a result of 
endothelial injury would promote SMC phenotypic modulation (FIG.IV.3.).
FIG.IV.3 - The Response to Injury hypothesis.
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Isolated contractile SMC's revert back into the synthetic phenotype when they are 
established in cell culture. This transition has facillitated the identification of protein markers that 
are specific for the synthetic phenotype. Those identified so far include decreased expression of 
cytoskeletal proteins such as a  SM actin (Liau et al 1990; Piallat et al 1993), smooth muscle 
myosin heavy chains and increased expression of non-muscle myosin heavy chains (Aikawa et al 
1993; Grainger et al 1991); decreased expression of desmin (Osborn et al 1987); and induced 
expression of low levels of cytokeratins (Bader et al 1988). The expression of the cytoskeletal 
associated protein metavinculin, which normally localizes at focal adhesion sites decreases 
(Glukhova et al 1986). The expression of the actin and calmodulin binding proteins calponin and 
caldesmon are also altered during phenotypic modulation with cessation of calponin expression 
(Gimona et al 1990) and a switch in expression fi"om the high molecular weight form of 
caldesmon to the low molecular weight form (Ueki et al 1987). Decreased expression of the actin 
binding high molecular weight a  SM tropomyosin isoforms can also be observed in synthetic 
SMC’s (Chamley-Campbell et al 1977). Up-regulation in the expression of osteopontin and 
matrix gla proteins can also be observed, these proteins normally play a role in bone mineralization 
and therefore may be responsible for the calcification commonly observed within atherosclerotic 
and restenoic lesions (Giachelli et al 1993; Shanahan et al 1993).
The characterization of protein markers specific for the SMC synthetic phenotype may 
allow the identification of such cells prior to lesion development as well as provide insights into 
the altered functions of these cells. This information could prove useful in disease prognosis and 
therapy. It has also been demonstrated that spontaneous phenotypic modulation of isolated SMC's 
is prevented if the cells are grown in co-culture with a confluent monolayer of endothelial cells 
(Campbell gfa/1981; Campbell et al 1986). These results suggest that the endothelial cells release 
a factor or factors that help maintain SMC's in the contractile phenotype; loss of these factors 
during endothelial injury or following endothelial denudation would therefore assist phenotypic 
modulation.
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IV.5 PROLIFERATION OF SMOOTH MUSCLE CELLS.
The significance of SMC proliferation in the development of atherosclerotic lesions has 
recently led to some controversy. Cell kinetic studies measuring either the fi-equency of SMC’s 
able to incorporate labelled thymidine ex vivo or the number of SMC’s identified as replicative on 
the basis of staining for a replicative marker such as the proliferating cell nuclear antigen (PCNA) 
(Gordon et al 1990; O’Brien et al 1993) indicates that SMC proliferation in atherosclerotic and 
restenotic lesions occurs infi*equently or at low levels. These observations have led to the 
suggestion that the lumen narrowing associated with atherosclerotic and restenotic lesion 
formation may result mainly fi-om vascular remodelling, elastic recoil, thrombosis and ECM 
deposition rather than SMC proliferation (Schwartz et al 1995; O’Brien et al 1993). Evidence 
supporting a role for SMC proliferation in atherosclerotic lesion formation includes observations 
that lesions are monoclonal or oligoclonal (Benditt and Benditt 1973). This implies that SMC 
proliferation must occur during the formation of the lesion and that the initial group of cells giving 
rise to the lesion must be very small (Schwartz et al 1995). Also an expansion in intimai smooth 
muscle mass has been described in various human lesions (Velican and Velican 1976; Sims et al 
1989.). All of this evidence suggests that SMC proliferation must occur very early in lesion 
development either at a very low rate over several years or at a high rate in an episodic fashion 
(Schwartz eta l 1995).
The importance of SMC proliferation in the development of atherosclerosis and restenosis 
is further emphasized by the observation that a major consequence of SMC phenotypic 
modulation observed is an increase in the rate of cell proliferation (Clowes and Schwartz 1985). 
Induction of this proliferation is mediated through the activation of cell surface receptors by 
inflammatory growth factors and cytokines, released during early lesion development. Studies 
have revealed that phenotypically modified SMC's exhibit an increased capacity to respond to such 
factors through the expression of novel or increased numbers of growth factor receptors. For
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example during transformation into the synthetic phenotype the transcription of PDGF and EGF 
receptors is upregulated (Pickering et al 1993; Rahm et al 1992). Synthetic SMC's also express 
the macrophage colony stimulating factor (M-CSF) receptor {c-fms\ which is not normally 
expressed in contractile SMC's.
Activation of these growth factor receptors initiates the transduction of intracellular 
signals from the cell membrane into the cell nucleus, subsequently altering the balance of cell cycle 
control elements promoting the initiation of cell cycle progression required for cell proliferation. 
The progression of all eukaryotic cells through the cell cycle is governed by the sequential 
formation, activation, and subsequent inactivation of a series of cyclin cyclin-dependent kinase 
(CDK) complexes (Hunter 1993). Specific cyclins interact with specific CDK's and these different 
complexes each regulate progression through particular stages of the cell cycle. Thus progression 
from G1 to S phase involves CDK4/cyclin D complexes; S phase, CDK2/cyclin A, and M phase 
CDC 2/cyclin B (Nasmyth and Hunt 1993). The control of cell cycle progression is probably 
mediated by the cyclin dependent kinase inhibitors (CKI's) which tightly regulate the activity of 
cyclin/CDK complexes. Evidence exists suggesting that expression of CKI's is positively regulated 
by tumour suppressor proteins such as p53 (El-Diery et al 1993). This observation has led to the 
hypothesis that loss of tumour suppressor gene expression may subsequently decrease CKI gene 
expression, increasing the activity of G1 cyclin/CDK complexes that are required for progression 
into S phase. This hypothesis would account for the induction of uncontrolled cell growth 
associated with loss of tumour suppressor function (Hunter 1993). Such a theory is also relevant 
to the initiation of SMC proliferation accompanying restenosis as recent evidence indicates that 
induction of latent CMV infection within SMC's in response to the angioplasty procedure initiates 
the production of proteins that bind to and inactivate p53. This would result in decreased CKI 
gene expression, thereby inducing uncontrolled cell growth (Speir et al 1994). This mechanism 
also provides an explanation for the observation that virus infection is another possible risk factor 
contributing to the development of atherosclerosis (Legrand et a l\99 \).
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Studies have also implicated a role for mitogen stimulated proto-oncogene expression in 
the control of signal transduction pathways leading to cell division, both c-myb and c-myc mRNA 
expression are upregulated during serum stimulation of SMC's (Rosenberg et al 1992; Biro et al 
1993).
Many factors that are mitogenic for SMC's have been identified; these include: PDGF 
(Hedin et al 1988; Clemmons 1984); lGF-1 (Ferns et al 1991); lL-1 (Libby et al 1988; Porreca et 
al 1993); lL-6 (Seino et al 1994); EGF (Scott-Burden et al 1989; Pickering et al 1993); FGF 
(Schollman et al 1992; Salmivirta et al 1992); Thrombospondin (Majack et al 1988). TGF-(3 has 
been reported to both stimulate (Chen et al 1987) and inhibit SMC proliferation (Owens et al 
1988; Grainger et al 1994). The mechanism for the inhibition of proliferation may be mediated by 
induction of CKI's (Hunter 1993). Various vasoactive hormones such as 
epinephrine/norepinephrine, serotonin, substance P and substance K as well as endothelin have 
been demonstrated to have mitogenic efifects on SMC's (Thyberg etal 1990). Prostaglandins and 
leukotrienes can also stimulate SMC proliferation (Hajjar and Pomerantz 1992). All of these 
factors can be found at significantly higher concentrations than normal within atherosclerotic and 
restenoic lesions.
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IV.6 MIGRATION OF SMOOTH MUSCLE CELLS.
The formation of a neointima within vessels is a critical event in the pathogenesis of 
atherosclerosis and restenosis (Clowes and Shwartz 1985). Neointimal formation results from the 
accumulation of SMC's on the intimai surface of vessels. This accumulation is due to a 
combination of enhanced proliferation and directed migration of SMC's from the media to the 
intima (Bomfeldt et al 1994). Both of these activities can be stimulated by a number of cytokines 
and growth factors produced within the lesion, often by modulated SMC's themselves, giving rise 
to autocrine stimulation, or they may be derived from circulating cells and platelets.
Chemotactic factors so far identified for SMC's include PDGF, the most potent 
chemotactic factor identified to date (Ferns et al 1990), EGF (Higashiyama et al 1993), IGF-1 
(Bomfeldt etal 1994), IL-1 (Thiery and Boyer 1992), TGF-|3 (Bell and Madri 1989), fibrinogen 
(Naito et al 1989), and oxidized LDL (Autio et al 1990). The precise mechanisms responsible for 
growth factor induced chemotaxis of SMC's is not clear. However, evidence that most of the 
receptors for the above chemotactic factors belong to the protein tyrosine kinase receptor family 
leads to reasonable speculation that the induction of intracellular signals by tyrosine kinase activity 
is fundamental to initiation of SMC motility (Shimokado et al 1994).
Ligand binding to tyrosine kinase receptors stimulates receptor dimerization and tyrosine 
autophosphorylation, this subsequently leads to activation of phospholipase C (PLC), probably 
through the association of SH2 domains in PLC with specific phosphorylated tyrosine residues in 
the carboxyl terminal portion of the tyrosine kinase receptor. PLC activation mediates the 
hydrolysis of the plasma membrane phospholipid, phosphatidylinositol 4, 5 bisphosphate (PIP2) 
into two products with intracellular second-messenger functions; inositol 1,4,5 trisphosphate (IP3), 
which induces the release of calcium ions from internal stores and 1,2 diacylglycerol (DAG), 
which serves as a cofactor in the activation of protein kinase C (PkC) (Clyman et al 1994). The
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phosphorylated tyrosine residues in the carboxyl terminal portion of the receptor can also interact 
again through SH2 domains with other intracellular proteins such as; GTPase activating protein, 
PI-3- kinase. Nek, GRB2, syp and the GTP binding proteins rac and rho, generating a variety of 
intracellular signalling cascades.
Phosphatidylinositol 3-kinase (PI 3-K) is an intracellular enzyme that phosphorylates the 
D-3 position of the inositol ring of phosphatidylinositol, phosphatidylinositol-4-phosphate, and 
phosphatidylinositol-4,5-bisphosphate (Kapeller and Cantley 1994). PI 3-K is composed of two 
subunits, pi 10 and p85. The pi 10 subunit is the catalytic subunit that contains a lipid kinase 
domain. The p85 subunit can interact with the cytopasmic domains of receptors (Pawson 1995). 
p85 also contains proline rich sequences capable of mediating the binding of proteins containing 
SH3 domains such as the intracellular tyrosine kinases abl, Ick, jyn, and lyn. The p85 subunit itself 
contains an SH3 domain, and in vitro studies have demonstrated SH3-dependent binding of p85 
to proline rich sequences in the motor protein dynamin (Gout et al 1993). PI 3-K has also recently 
been demonstrated to play a role in the regulation of p i integrin activity (Shimizu et al 1995). 
Thus, the p85 subunit of PI 3-K contains several structural motifs that allow PI 3-K to be coupled 
to a multitude of cell surface and intracellular molecules; for this reason it appears that a wide 
variety of cellular functions including mitogenesis and migration may be dependent on PI 3-K 
activity.
The transduction of these signals to the genes controlling cell motility are believed to 
induce cytoskeletal reorganization but the precise molecular mechanisms are unknown. However, 
it has been postulated that the induction of profilin release and a decrease in the expression of actin 
binding proteins alters F-actin polymerization and cross-linking respectively, thereby promoting 
changes in cell shape and subsequent migration (Machesky and Pollard 1993; Lee et al 1993).
Extracellular matrix plays a major role in controlling the migration of most cell types. 
Studies in vitro have revealed that SMC migration is enhanced on surfaces coated with gelatin 
(Autio et al 1990), fibronectin (Higashiyama et al 1993), type IV collagen (Dimilla et al 1993)
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and type V collagen (Shimokado et al 1994). The activity of the SMC chemotactic factors TGF- 
P, EGF and to some extent PDGF are mediated through modulation of extracellular matrix; TGF- 
P is thought to promote SMC migration by increasing the expression of various extracellular 
matrix components such as types I, m  and V collagens (Lawrence et al 1994; Ritzenhaler et al 
1993), fibronectin (Ignotz and Massaque 1986), elastin (Liu and Davidson 1988) and 
proteoglycans (Chen et al 1987). TGF-p also increases the expression of integrin receptors on the 
SMC surface that mediate cellular interactions with the extracellular matrix. In addition this 
cytokine represses the synthesis of extracellular matrix degrading proteases and induces the 
expression of inhibitors for such proteases all of which can regulate cell migration (Streuli et al 
1993). The binding of EGF to its receptor and subsequent stimulation of SMC migration is 
enhanced when EGF is bound to heparan sulphate proteoglycans present in the extracellular 
matrix (Higashiyama et al 1993). One of the many effects PDGF confers upon SMC's is 
reorganization of integrin distribution, this was found to reduce the attachment strength of cells to 
fibronectin, thereby assisting migration (Fujio etal 1993).
For the majority of cells to migrate in vivo they need to be able to degrade surrounding 
extracellular matrix barriers in order to reach their target destinations. Proteolytic enzymes fi*om 
all four classes of proteases have been implicated in this extracellular matrix turnover. Two main 
groups of enzymes; the plasmin/plasminogen activator system of serine proteases and the matrix 
metalloproteinases most likely play a role in assisting SMC migration through the vessel media 
(Grobmyer et al 1993). Plasmin can degrade extracellular matrix components directly (Liotta et al 
1981) or through the activation of matrix metalloproteinases (Kleiner and Stevenson 1993). 
Plasmin is formed by the actions of tissue-type and urokinase-type plasminogen activators, the 
release of plasminogen activators fi’om macrophages, endothelial and SMC's within atherosclerotic 
and restenoic lesions maybe an important regulator of SMC migration (Grobmyer et al 1993). 
Evidence also suggests that degradation of fibronectin, collagen and elastin by the action of
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proteolytic enzymes generates fragments of these matrix molecules that can act as chemotactic 
factors further assisting cell migration through the matrix (Wong and Wahl 1990).
The elucidation of the intracellular signalling mechanisms controlling SMC migration may 
identify therapeutic targets that can inhibit this migration, but it is clear from the literature that 
there are many factors within lesions that contribute to SMC migration, acting through 
mechanisms which are not fully understood. Further research into all such mechanisms will be 
required before efficient therapeutic strategies directed against SMC migration can be developed.
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rV.7 EXTRACELLULAR MATRIX INDUCED MODULATION OF 
SMC BEHAVIOUR.
The vascular extracellular matrix (ECM) is a reinforced composite of collagen and elastic 
fibres embedded in a viscoelastic gel consisting of proteogycans, hyaluron, glycoproteins, and 
water. These components interact to form a biomechanically active polymer network that imparts 
tensile strength, elastic recoil, compressibility, and viscoelasticity to the vascular wall. In addition 
this network interacts with vascular cells and participates in the regulation of cell adhesion, 
migration and proliferation during vascular development and disease (Fuster et al 1996).
The pathogenesis of atherosclerosis and restenosis includes the abnormal production of 
extracellular matrix (ECM) proteins by neointimal SMC's (Liptay et al 1993). Several factors 
secreted by inflammatory macrophages within lesions may be responsible for stimulating ECM 
synthesis; TGF-P has been shown to stimulate the production of fibronectin (Ignotz et al 1987) 
and collagen (Lawrence et al 1994; Ritzentaler et al 1993); IGF stimulates the synthesis of type I 
collagen (McCarthy et al 1989). IL-1 and TNF also induce type I collagen synthesis (Kahari et al 
1987; Goldring and Krane 1987), PDGF, EGF and IFN-y have all been demonstrated to stimulate 
fibronectin synthesis (Blatti etal 1988, Francesci etal 1987). Thus macrophages may contribute 
to the formation and progression of atherosclerotic and restenoic lesions by inducing neointimal 
ECM production possibly via the induction of SMC phenotypic modulation. This is supported by 
in vitro studies which demonstrate that SMC's transformed into the synthetic phenotype 
synthesize 25-30 times more collagen than contractile cells. Non-collagen protein synthesis 
increased only 5-6 fold indicating a specific stimulation of collagen synthesis. Phenotypic 
modulation was also associated with an alteration in the relative proportions of types I and EH 
collagens synthesized, with contractile SMC's synthesizing 78% type I collagen and 17% type HI 
collagen, and synthetic cells synthesizing 90 % type I collagen and 5% type IQ collagen (Ang et al
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1990; Liau and Chan 1989). A similar enrichment of type I collagen has been reported to occur in 
vivo within atherosclerotic lesions (Hanson and Bentley 1983).
The accumulation of ECM components within lesions not only contributes to vessel 
stenosis by physically retarding blood flow, it is also known to have a significant influence on 
regulating local SMC behaviour. Studies investigating the phenotypic modulation of SMC's in 
vitro have revealed that the matrix components fibronectin and collagen promote transition of 
cells into the synthetic phenotype (Hedin et al 1988). In contrast elastin and laminin maintained 
the cells in the contractile phenotype (Yamamoto et al 1993; Hedin et al 1988). The ability of 
ECM to induce changes in cell differentiation and/or gene expression of a variety of cells has been 
well documented. Fibronectin decreases the expression of a-SM actin in SMC's (Hedin et al
1990). In fibroblasts fibronectin peptides induced collagenase and stromelysin gene expression 
(Werb et al 1989), and a variety of genes involved in inflammation are induced as a result of 
monocyte adherence to ECM (Spom et al 1990).
Cells respond to ECM through the interaction of cell surface adhesion receptors known as 
integrins, with specific recognition domains within matrix such as the arginine-glycine-aspartate 
(RGD) sequence which functions as a cell attachment site for a number of different ECM proteins, 
including fibronectin, thrombospondin, fibrinogen, von Willebrand factor and vitronectin (Kreis 
and Vale 1993). Studies have revealed that these interactions are not specific, individual integrins 
can often bind more than one ECM ligand. Equally, individual ECM ligands are recognised by 
more than one integrin (Hynes 1992).
The precise mechanisms whereby signals from the ECM are transduced via integrins to the 
intracellular machinery that controls SMC growth, migration, and differentiation, remains poorly 
defined (Juliano and Haskill 1993). However, it has been demonstrated that all integrins are 
alpha/beta heterodimers and their ligation by ECM ligands is followed by cytoskeletal 
reorganization such as the formation of focal adhesions. It seems reasonable that appropriate cell 
shape and cytoskeletal organization might regulate the biosynthetic capabilities of the SMC's and
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thus contribute to cell growth or differentiation. The formation of focal adhesions has provided a 
model to explain ECM signalling to the cytoskeleton. Focal adhesions are found primarily at cell 
borders where bundles of actin filaments terminate, and contain a large number of different 
proteins that link the cytoplasmic domains of integrin receptors to the actin filament system. The 
formation of focal adhesions is regulated in migrating and mitotic cells indicating their importance 
in such functions. Current evidence overwhelmingly points to the integrin p-subunit cytoplasmic 
domain as the structure that targets integrins to focal adhesions (Sastry and Horwitz 1993). Indeed 
it was recently reported by Carol Otley that the p subunits contain binding sites for many of the 
focal adhesion associated proteins such as a-actinin, talin and focal adhesion kinase (FAK)
(BSCB newsletter June 1994).
Integrin stimulated tyrosine phosphorylation of FAK has been observed in fibroblasts 
adhered to fibronectin. Since FAK is known to be a substrate for src family kinases (Kanner et al
1990), it is tempting to postulate that an interplay of src and FAK may be directly involved in 
integrin mediated signal transduction from the ECM. It has been hypothesized that integrin 
clustering induced by ECM ligand binding induces the cross-phosphorylation of adjacent FAK 
molecules, which could subsequently alter the phosphorylation and binding states of the other 
cytoskeletal associated proteins within focal adhesions including, paxillin, tensin, vinculin, talin 
and actinin as well as the GTP binding protein rho (Kanner et al 1990). Such events promote 
cytoskeletal reorganization that accompanies the induction of SMC proliferation and migration 
(Damsky and Werb 1992). It also seems likely that integrin-mediated activation of FAK is an 
early step in the signal transduction cascade that is responsible for the ECM induced SMC 
phenotypic modulation thought to occur within atherosclerotic and restenotic lesions (FIG.IV.4).
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FIG.IV.4 ECM Induced Cell Signalling.
a lp h a  ac tin in  
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Events downstream of FAK that are responsible for the regulation of gene expression 
remain almost totally unknown. However, it has been demonstrated that translocation of enhanced 
levels of Nuclear Factor kappa B (NF-kB) into the nucleus occurs after adhesion of human 
monocytes. This translocation is thought to be mediated by integrin dependent kinase events and 
would explain the altered gene expression induced upon monocyte adhesion (GrifiBn et al 1993).
It is tempting to place the increased tyrosine kinase activity of FAK in a cause and effect 
relationship with integrin induced gene expression, within SMC's by a similar mechanism. At this 
point, however, there is no current direct evidence that would implicate FAK activation with 
integrin induced gene expression (Juliano and Haskill 1993).
An alternative hypothesis on the mechanisms of integrin mediated signalling is based on 
the capacity of integrins to act as true receptors giving rise directly to biochemical signals within 
the cell. Supporting evidence for such a role comes from the observation that the pi integrin is 
tyrosine phosphorylated in transformed fibroblasts and this may account for the inability of these 
cells to reorganize their cytoskeleton in response to ECM signals (Damsky and Werb 1992). It is
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likely that these two views on the mechanisms of integrin-mediated signalling will turn out to be 
complementary rather than mutually exclusive.
Such signalling events, induced by the ECM which subsequently alter cell behaviour are 
termed outside-in signalling. There is also evidence that inside-out signalling can occur which 
ultimately controls how a cell behaves toward signals generated by the ECM. These signals arising 
from the cytoplasm probably act by modulating the afiBnity and/or specificity of integrins for their 
ECM ligands. These changes in afiBnity appear to arise from conformational changes in the 
integrin receptor (Sastry and Horwitz 1993). For instance the integrin pi subunit cytoplasmic 
domain becomes phosphorylated during mitosis. This modification reduces the afiBnity of the a5 
pi receptor for fibronectin and could provide an inside-out signal that accounts for cell rounding 
associated with the progression of mitosis (Damsky and Werb 1992). A similar mechanism 
reducing afiBnity with ECM may also promote migration (Dimilla et al 1993). It is possible that the 
induction of proliferation and migration by phenotypically modified SMC's is mediated by these 
inside-out signals.
There is also evidence that the ECM can influence SMC behaviour indirectly by regulating 
the concentration and delivery of growth factors within lesions. As stated previously heparan 
sulphate proteoglycans, many of which are constituents of ECM, can function as modulators of 
growth factors including the SMC mitogenic factors FGF and EGF (Ruoslahti and Yamaguchi
1991). The binding of FGF to proteoglycans deposited on the cell surface is thought to alter the 
conformation of the growth factor facilitating the interaction with its specific cell surface receptor 
(Yayon et al 1991). The binding of growth factors to the ECM provides a reservoir of growth 
factor activity that could be released upon ECM degradation induced by the synthesis and release 
of ECM degrading enzymes (Ruoslahti and Yamaguchi 1991). The synthesis of such proteolytic 
enzymes by SMC's and macrophages is commonly observed within atherosclerotic and restenoic 
lesions (Liptay et al 1993). The degradation products of fibronectin, elastin and collagen resulting 
from ECM proteolysis have chemotactic properties that may contribute to the migration of SMC's
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towards the vessel intima as well as promote macrophage influx into these areas, thereby 
contributing further to lesion development (Liptay et al 1993 and Wong and Wahl 1990).
It is clear that the ECM can modulate cell behaviour through multiple mechanisms. The 
construction of peptide fl-agments and monoclonal antibodies that can block or induce integrin 
receptors on SMC's may help elucidate some of the mechanisms that are involved in the 
development of atherosclerosis and restenosis.
The starting point of the work carried out in this study shall concentrate on 
investigating the influence ECM has on vascular SMC behaviour, in particular the role 
fibronectin plays in modulating SMC behaviour. Fibronectin is a 500Kd multifunctional 
adhesive glycoprotein found in the blood plasma and extracellular matrices. It consists of two 
subunit chains linked by disulphide bonds close to their carboxy terminal ends (Potts and 
Campbell 1994).
Fibronectin can bind to Smooth muscle cells, fibroblasts, monocytes and many other 
cell types. Fibronectin can also bind to collagens, heparin, and fibrin and so mediate the 
attachment and spreading of cells on a variety of substrates (Hynes 1985; Ruoslahti et al 
1985; Yamada e/ a / 1985). Fibronectin has been demonstrated to regulate the adhesion and 
migration of activated cells during acute and chronic inflammation (Springer 1990; Molossi et 
al 1995), wound healing (Grinnel and Phan 1983), tissue regeneration (Springer 1990) and 
tumour metastasis (McCarthy et al 1985).
Multiple cell binding sites have been characterised within the fibronectin molecule, 
including the RGD sequence, located within the central region of fibronectin and the CSl 
sequence, at the carboxy-terminal end (Ruoslahti et al\9% \\ Yamada 1991). The primary cell 
surface receptors that recognise these sites are the a5 p i integrin that recognises the RGD 
site and the a4p l integrin that binds the CSl site.
The cell’s response to fibronectin can be regulated by patterns of alternative splicing 
of the fibronectin transcript. Alternative splicing of fibronectin can involve the CSl site and
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generates a number of functionally different fibronectin isoforms (Kornblihtt et al 1985, 
Ffrench-constant 1995). The addition of type III repeats EIIIA and EIIIB by alternative 
splicing distinguishes cellular forms of fibronectin from plasma fibronectin (Hershberger and 
Culp 1990). Previous studies suggest that EIIIA and EIIIB containing fibronectin mRNAs 
predominate in the early embryo, whereas in the adult most of the normal tissue fibronectin 
lacks these domains (Oyama et al 1989; Ffrench-Constant and Hynes 1989; Pagani et al
1991). A recent study also revealed that alternatively spliced forms of fibronectin EIIIB and 
EIIIA were upregulated at 24-48 hours following balloon injury of rabbit aorta and illiac 
arteries (Bauters et al 1994). The appearance of the specific isoform containing the EIIIA 
domain has been described both in balloon injured intima from rat aorta and in atherosclerotic 
plaques from human arteries (Glukhova et al 1989). In addition to type III alternatively 
spliced fibronectins other fibronectin isoforms may be upregulated early in atherosclerotic 
lesions (Orekhov et al 1984; Shekonin et al 1987).
It has also recently been demonstrated that SMC attatchment to fibronectin resulted 
in activation of the p50/p65 heterodimeric form of NF-kB. NF-kB is a transcription factor 
that plays an important role in the inducible regulation of a variety of genes involved in the 
inflammatory and proliferative responses of cells. Using immunofluoresence and 
immunohistochemical techniques, activated NF-kB was detected in the fibrotic thickened 
intima/media and atheromatous areas of the atherosclerotic plaque. Activation of NF-kB was 
identified in SMC’s, macrophages and endothelial cells. Little or no activated NF-kB was 
detected in vessels lacking atherosclerosis (Brand et al 1996). The evidence described above, 
together with the observation that fibronectin promotes modulation of cultured rat arterial 
SMC’s from a contractile to a synthetic phenotype (Hedin et al 1988), suggests that altered 
expression of fibronectin plays a significant role in the pathogenesis of atherosclerosis and 
angioplasty induced restenosis.
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IV.8 FUTURE PROSPECTS FOR THERAPY.
It appears that a critical step in the development of all atherosclerotic and restenotic 
lesions is the phenotypic modulation of SMC's into the synthetic phenotype (Thyberg et al 1990). 
This is a process that has attracted most attention with regards to the development of an effective 
therapeutic strategy against atherosclerosis and restenosis. However as stated earlier, recent 
pathological evidence indicates that SMC phenotypic modulation within advanced atherosclerotic 
lesions may promote a beneficial clinical outcome, whereas in restenosis this phenotypic 
modulation has a deleterious effect (Davies et al 1993). It would, however, appear that therapy 
targeted against SMC phenotypic modulation would inhibit initial lesion development of both 
disorders. The prevention of the early atherosclerotic lesions (fatty streaks) by targeting SMC 
phenotypic modulation may not be practical, as these lesions develop in all children by the age of 5 
and have no serious consequences towards health until much later in life. Such therapy would 
however prove useful against the development of restenosis.
Recent insights into the biological mechanisms responsible for the development of 
atherosclerotic and restenoic lesions have identified targets for potential therapeutic exploitation. 
Platelets have a key role in atherosclerosis, restenosis, thrombosis and acute coronary syndromes. 
Platelets contribute towards lesion development, by releasing growth factors fi'om their alpha 
granules upon attachment to the vessel wall. Therapeutic manipulation of platelet function has 
focussed principally on the use of aspirin and dipyridamole which, despite their relatively weak 
antiplatelet action, have proved to be effective in promoting the antithrombotic functions of the 
endothelium. However, the use of these drugs in human clinical trials has so far been unsuccessful 
(Harker 1989). More recently the platelet glycoprotein nb/IQa receptor has been identified as the 
pivotal mediator of platelet aggregation, making it a logical target for the control of the platelet 
réponse to vascular injury (Lefkovits etal 1995). Monoclonal antibodies against platelet receptors 
have been demonstrated to effectively eliminate platelet aggregation in animal studies (Harker
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1989). Clinical trials have taken place to determine the efficacy of the antithrombotic drug 
Reopro,which is based the chimeric monoclonal antibody Fab fragment (c7E3). Reopro acts by 
blocking the nb/IQa receptor on platelets; initial results from clinical trials indicate that when 
administered as a bolus and 12 hour infusion Reopro reduces the incidence of myocardial 
infarction, restenosis and death in a significant number of individuals six months after angioplasty 
(Topol etal 1994).
The anticoagulant heparin has also been shown to effectively inhibit SMC proliferation in 
vitro as well as prevent intimai hyperplasia in animals. (Clowes and Clowes 1985; Reilly et al 
1989). Nevertheless, heparin is a potent stimulator of ECM production, a function thought to be 
related to its anticoagulant activity, and heparin may promote initial lesion development by binding 
growth factors. Thus, although heparin has not been shown to be effective in preventing restenosis 
in humans ongoing trials with genetically engineered nonanticoagulant heparin administered at 
later stages in lesion development may prove to be effective (Forrester et a l\99 \).
Tissue factor (TF) is a cell surface glycoprotein that interacts with clotting factor 
Vn/VTQa initiating the extrinsic pathway of coagulation. In atherosclerotic plaques TF can be 
found on SMC and macrophage surfaces and large amounts are trapped in the necrotic core. 
Induction of TF following PTC A can be found in the intima and adventitia of injured vessels 
suggesting a possible involvement in the pathogenesis of restenosis. Tissue factor pathway 
inhibitor (TFPI) is an endogenous inhibitor of TF. TFPI administered in the presence of the 
thrombin inhibitor. Hirudin, was found to reduce the mean ratio of neointimal formation from 0.68 
to 0.48 in rat carotids. The efficacy of this therapy is currently being studied in other animal 
models (Creasey 1995). Such anticoagulant therapy may prove useful at limiting stenosis resulting 
from plaque rupture. Such therapies targeted against the late stages of atherosclerosis could yield 
a beneficial outcome. Similarly research into the processes that govern atherosclerotic plaque 
stability and rupture could yield essential information that may lead to control over this clinically 
significant event. Studies into the architecture of atherosclerotic plaques have provided insights
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into the mechanisms that govern plaque stability such as the balance of ECM synthesis and matrix 
metalloproteinase activity (Galis et al 1994). It can be envisaged that any therapy which promotes 
a shift towards increased ECM deposition and decreased matrix degrading activity may increase 
the tensile strength of the plaque cap thereby promoting plaque stability. Results fi’om recent lipid 
lowering trials suggest one method by which plaque stabilization may be achieved. Lipid lowering 
treatment led to reductions in clinical events without substantial change in the degree of luminal 
stenosis. This could reflect a stabilization of the lesion (Blankenhom and Hodis 1994; Brown et al 
1993).
Because SMC migration and proliferation are critical events in both restenosis and 
atherosclerosis, the targeting of signalling pathways and elements that control them may yield 
exciting results. For example antisense oligonucleotides to a series of proto-oncogenes expressed 
in cells including c-myc, c-fos or c-myb, or even to cell cycle control proteins and other molecules 
involved in mitogenic signalling, and possibly also to some of the elements involved in SMC 
contraction such as smooth muscle myosin, smooth muscle Myosin Light Chain Kinase (MLCK) 
and caldesmon. Indeed antisense oligonucleotides targeted against c-myc and c-myb have proved 
effective in the inhibition of SMC migration and proliferation both in vitro and in vivo (Biro et al 
1993; Simons et al 1992; Bennett et al 1994). In addition efiforts have been undertaken to use 
antisense oligonucleotides directed against mRNA’s encoding several cell cycle regulatory 
proteins as a therapy to prevent restenosis following balloon injury of rat carotid arteries. 
Liposomes and a balloon catheter were used to deliver antisense oligonucleotides targeted against 
cdc2 K and cyclin B. Cyclin B and cdc2 K oligonucleotides reduced neointimal formation by up to 
50%; when used together the inhibitory effect was greater (Milner 1995).
Recent progress in identifying many of the signalling pathways involved in cell migration, 
have identified intracellular targets for the inhibition of the induction of SMC migration and 
therefore neointimal formation. Two tyrosine kinase inhibitors, methyl 2,5 -dihydroxycinnamate 
and genestein inhibit in vitro SMC migration (Shimokado et al 1994). Agonists against known
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SMC migration factors have only had limited success in vivo (Ross 1986). This probably reflects 
the complex variety of stimuli responsible for the induction of SMC migration in vivo.
It has been reported that the generation of superoxide anions and oxidized LDL play 
important roles in the induction of atherosclerotic and restenotic lesions. This has led to the 
indication that antioxidant therapy may combat lesion development. Antioxidants have been 
demonstrated to reduce intimai thickening following angioplasty in animals (Freyschuss et al 
1993). The benefit of such treatment in humans has proven effective in human trials (Tomeo et al 
1995; Odeh and Cornish 1995).
The upregulated expression of receptors including PDGF and EGF on phenotypically 
modified SMC's has provided the opportunity for using cytotoxic agents that specifically target 
proliferating SMC's. Targeted delivery of cytotoxins to specific cell surface receptors may be 
accomplished with recombinant fusion proteins (Pickering etal 1993). Restenosis would be 
particularly amenable to cytotoxic therapy since the location of the disease is predictable. There 
have been no clinical trials of cytotoxic agents in restenosis thus far.
Anti-inflammatory agents could inhibit the accumulation and activation of inflammatory 
cells within atherosclerotic and restenoic lesions. This would subsequently result in decreased 
expression of growth factors responsible for SMC phenotypic modulation and lesion 
development. Corticosteroids have been shown to inhibit SMC proliferation in animals (Liu et al 
1989), but the administration of steroids one week after coronary angioplasty did not reduce the 
rate of restenosis (Pepine et al 1990). The potential value of otherunflammatory agents also 
remain unresolved (Forrester et al 1991).
The administration of growth factor and cytokine agonists could inhibit SMC modulation, 
proliferation and migration. TGF-P has been shown to increase ECM production and integrin 
receptor expression. In rat and porcine models of restenosis, TGFP expression is increased within 
2-6 hours following injury and may remain elevated for as long as 2 years (Majesky et a l\9 9 \\ 
Miano et al 1993). The multifunctional nature of TGFp and its association with restenosis make
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this cytokine an attractive therapeutic target for the prevention of restenosis. The role of such 
growth factors in the development of atherosclerotic and restenotic lesions are inherently complex, 
and invariably depend on a network of positive and negative signals acting in concert, rather than 
through a single mediator. The characterization of these networks and the functions that they 
promote will stimulate the development of many new therapeutic approaches aimed at preventing 
the development of atherosclerosis and restenosis.
Evidence that viral infection is responsible for the loss in tumour suppressor function 
within lesions highlights the potential of antiviral therapies in the inhibition of restenosis (Speir et 
al 1994).
The failure to observe any beneficial efifects in humans with drugs previously successful at 
inhibiting restenosis in animal models raises the possibility that current animal models in use, such 
as the widely studied ballooned rat carotid model may not be suitable for studying the human 
disease (Forrester et al 1991). The rat balloon carotid model may poorly mimic restenosis in 
response to angioplasty performed on human vessels. This may be due to differences in the 
pathogenesis of the disease between animals and humans. Unlike the rat carotid artery, human 
arteries spontaneously develop a neointima after birth that increases rapidly until 6 months of age 
(Velican et al 1976; Sims et al 1989). Therefore, in the case of the rat carotid balloon injury model 
the formation of a new intima may poorly replicate the réponse to injury when an intima or even 
an atherosclerotic lesion may already exist. It follows that balloon injury of normal vessels fi’om 
such animal models may result in a type of vessel injury very different fi’om injury initiated by 
angioplasty carried out on human vessels that contain pre-existing atherosclerotic lesions. Such 
disparities may account for the limited success of clinical trials involving therapies that have 
proved successful in animal models (O'Brien et al 1993). Therefore it would seem that the 
development of new models may be required to test novel therapeutic applications against the 
disease. Recently the use of the c - FHC (complex - Familial Hypercholesterolemic) pig has been 
suggested as a solution to these problems. This is the only animal model that exhibits eccentric,
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stenotic coronory atherosclerotic lesions with cellular composition and calcification similar to 
humans (Prescott et a l\99 \). Future studies will show whether this animal provides a useful 
model of the human restenosis and atherosclerosis conditions.
A variety of ECM molecules have been implicated in the modulation of SMC behaviour. 
Some including fibronectin, laminin, and collagen affect phenotype switching (Yamamoto et al 
1993; Hedin et al 1988), others such as thrombospondin and vitronectin can influence the 
proliferation and migration of SMC's (Majack et al 1988). The work reported in this thesis is an 
examination of the effects of a range of ECM molecules on the behaviour and gene expression in 
human vascular SMC's.
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Section V AIM OF PROJECT
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The aim of this PhD research project was to characterise the role that ECM molecules 
have on modulating the phenotype of human vascular SMC’s in vitro and to identify any 
novel markers that may be associated with such alterations in phenotype.
The influence ECM molecules have on SMC behaviour was initially characterised by 
analysing alterations in the morphological growth patterns between SMC’s cultured on 
different matrix substrates. It has previously been reported that SMC growth morphology 
may be indicative of their phenotypic state (Shackelton et al 1995). Changes in the functional 
aspects of SMC behaviour as induced by ECM adhesion was investigated by performing 
SMC migration and proliferation assays on various ECM coated substrates.
Immunocytochemical and immunoblotting studies were carried out on SMC samples 
cultured on different ECM substrates in order to identify any clear phenotypic differences 
between these populations. Antibodies specific for previously identified as well as potential 
candidates of SMC phenotypic marker proteins were used for these studies.
The differential display technique was applied to reveal any differences that exist at 
the molecular level of gene expression between SMC’s cultured on different matrix 
substrates. However, before such analysis was initiated the differential display procedure was 
first optimized to allow for a more successful analysis of separate populations. Various 
improvements to the technique were developed and differential display analysis was 
performed on SMC’s cultured on fibronectin coated surfaces compared with SMC’s cultured 
on uncoated tissue culture plastic.
The identification of genes differentially expressed as a result of fibronectin adhesion 
may help elucidate the influence ECM has on cell phenotype; also for any genes identified as 
differentially expressed between distinct SMC populations their usefulness as SMC 
phenotypic markers could be determined by performing in situ hybridisation studies on 
normal and diseased vessel sections.
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Section VI
MATERIALS
AND
METHODS.
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VI.l. Materials (Results Chapter /.):
Fresh umbilical artery tissue
Tissue culture flasks (25mm^, 75mm ,^ 175mm  ^- Nunclon)
Fibronectin pre-coated tissue culture flasks (75mm^, 175mm^ - Falcon)
Tissue culture 96 well microtitre plate
37°C Incubater -humidified and flushed with 7% C0 2  (LEEC).
Ham's F12 medium (Gibco BRL)
Waymouth medium (Gibco BRL)
Fetal Calf Serum (FCS) (Gibco BRL)
Glutamine (Gibco BRL)
Penicillin/Streptomycin (Gibco BRL)
0.25% Trypsin / 0.05% EDTA solution (Gibco BRL)
Econospin Centrifuge (Sorvall)
Hanks Balanced Salt Solution (HBSS)
Phosphate Buffered Saline (PBS-a) -Dulbecco tablets (Oxoid) 
Deionised water
Plasma flbronectin (Sigma) ^
Cellular fibronectin (Sigma)
Collagen I (Sigma)
Collagen m  (Sigma)
Collagen IV (Sigma)
Laminin (Sigma)
Vitronectin (Sigma)
Matrigel (Becton Dickinson)
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Hoechst 33258 (Sigma)
Cytofluor 2350 plate reader (Millipore)
20x SSC (BDH)
SDS (Bio Rad)
Transwell inserts (Costar)
Low melting point agarose (Gibco BRL)
Protein assay reagent (Bio Rad)
Thermo max microplate reader (Molecular devices) 
PDGF BB (Promega)
HGF (R & D systems)
Basic FGF (Sigma)
Cotton wool buds (Costar)
Coomassie fixative stain (appendix I)
Methanol (Fisons)
Acetic acid (BDH)
Xylene (BDH)
Hydromount (National diagnostics)
Axioplan microscope (Zeiss)
Camera FX-35DX (Nikon)
ChemoTx 96 well chemotaxis chamber (Neuroprobe)
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VI.2. Methods (K<^sv\is-Chapter 1.);
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VI.3. Culture of Human SMC s.
Human umbilical artery vascular SMC’s (HUASMC's) were derived from umbilical 
artery tissue by the explant method. Human umbilical artery tissue was dissected from fresh 
umbilical cords. Adventitial tissue was removed from the artery prior to explant of 1mm cross 
sections of arterial tissue in culture. SMC’s were cultivated in a 50:50 mix of Ham’s F12 
medium (Gibco BRL) and Waymouth medium (Gibco BRL) supplemented with 16% (v/v) 
Fetal Calf Serum (FCS) (Gibco BRL), 2mM glutamine (Gibco BRL) and 50pg/ml 
penicillin/streptomycin (Gibco BRL) - (H:W 16% FCS). Cultures were incubated at 37°C in a 
7 % C 0 2  ( v / v )  /93% (v/v) air environment. SMC’s were routinely subcultured by treatment of 
confluent cultures with 0.25% trypsin / 0.05% EDTA solution (Imperial) and cultures were 
replated at 5.7x10^ cells per cm^. Human adult FW aortic SMC’s were a kind gift from Dr Cay 
Kielty University of Manchester. FW aortic SMC’s were cultured using identical conditions to 
those used for HUASMC’s.
All cells were cultured in standard tissue culture flasks (Nunclon) or microtitre plates 
(Nunclon) that were either uncoated or coated with equivalent concentrations (50pg/ml) of 
various extracellular matrix preparations.
Extracellular matrix substrates examined included;
Plasma Fibronectin (Sigma)
Cellular Fibronectin (Sigma)
Collagen I (Sigma)
Collagen III (Sigma)
Collagen IV (Sigma)
Laminin (Sigma)
Vitronectin (Sigma)
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Matrigel (Becton Dickinson).
These matrix substrates were chosen for analysis because they have previously 
been demonstrated to modulate SMC behaviour or have been implicated in the 
development of atherosclerosis and restenosis (Hedin et al 1990; Li et al 1994; Majack 
et al 1988; Salgar & Millis 1994; Thyberg et al 1990; Yamamoto et al 1993).
AU proliferation and migration assays, RNA extraction and protein isolation 
performed on SMC’s were carried out on cells between passages 5 to 10, 2 days prior to 
confluence following plating at 5.7x10^ cells per cm .^ Similarly morphological analysis 
(FIG’s. VII. 1 - VII.9) were performed on SMC cultures 2 days prior to confluence.
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VI.4. Extracellular matrix substrate preparation.
All matrix substrates for SMC culture were prepared and coated on to tissue culture 
grade surfaces in accordance with the manufacturer’s instructions. In order to compare the 
influence various matrix substrates have on SMC behaviour in vitro, where possible matrix 
preparations were coated at equivalent concentrations of 50pg/ml.
Bovine plasma fibronectin (Sigma), 1 mg/ml stock solution was diluted 1:20 with 
phosphate buffered saline (PBS) to give a 50pg/ml solution. Plasma fibronectin solutions were 
coated on to tissue culture plastic by incubation at room temperature overnight. Excess 
fibronectin is removed by aspiration prior to cell seeding.
Human cellular fibronectin (Sigma), 500pg lyophilised derived from human foreskin 
was dissolved in 10 mis of PBS to provide a 50pg/ml solution. Cellular fibronectin solutions 
were coated on to tissue culture plastic by incubation at room temperature overnight.
Collagen type I derived fi-om calf skin (Sigma) was used undiluted as a 0.1% (w/v) 
solution in 0.1 molar acetic acid.
Collagen type III (Sigma), Img lyophilised derived from calf skin was dissolved in 
20ml of 0.25% (v/v) acetic acid solution, to give a 50pg/ml solution.
Collagen type IV, Img lyophilised derived from human placenta was dissolved in 20ml 
of 0.25% (v/v) acetic acid solution to give a 50pg/ml solution.
All collagen solutions were coated on to tissue culture plastic at 4°C overnight. Excess 
collagen was removed by aspiration. Surfaces were left to air dry for several hours at room 
temperature and were washed twice with PBS prior to cell seeding.
Vitronectin, O.OSmg lyophilised derived fi-om human plasma was dissolved in 1ml of 
sterile deionised water to provide a 50pg/ml solution. Vitronectin was coated on to tissue
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culture plastic for a 2 hour incubation at 37°C. Excess vitronectin was removed by aspiration 
prior to cell seeding.
Thrombospondin, 20pg lyophilised derived from human platelets was dissolved in 
400pl of sterile deionised water to give a 50pg/ml solution. Thrombospondin was coated on to 
tissue culture surfaces overnight at room temperature. Excess thrombospondin was removed by 
aspiration prior to cell seeding.
Laminin, 500pg derived from human placenta was thawed overnight at 4°C and diluted 
in 10ml PBS to give a 50pg/ml solution. Laminin was incubated to cell culture surfaces for 2 
hours at room temperature.
Matrigel (growth factor depleted) (Becton Dickinson) was thawed overnight at 4°C and 
coated on to tissue culture plastic undiluted at a density of 2ml/cm^ in a 37°C incubator for 1 
hour prior to cell seeding.
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VI.5. SMC Proliferation.
SMC proliferation was assayed by measuring the amount of DNA present in each 
well of microtitre plates at sequential time points following cell seeding. The most reliable 
method of determining a proliferative or anti-proliferative response of cells in culture is the 
analysis of cell number. As DNA content per cell remains relatively constant, oscillating only 
by a factor of 2 during S phase of the cell cycle, the absolute amount of DNA can be used as 
a reliable indicator of cell number. DNA content can be quantified through the use of DNA 
binding dyes, therefore the application of such DNA binding dyes can be utilised to measure 
cell proliferation.
The SMC proliferation assay used in these studies is based on the binding of the 
fluorescent dye; bisBenzimide (Hoechst 33258) to double stranded DNA. When the dye 
intercalates into the DNA double helix the emission characteristics change from that of the 
free dye. Hence the emission at 460nm following excitation at 360nm, is directly proportional 
to the amount of dye bound to double stranded DNA. Fluorescence staining intensity was 
measured using the Cytofluor 2350 plate reader (Millipore) and from reference to a DNA 
standard curve, the DNA content of SMC cultures could be directly quantified.
SMC proliferation assay:
1. HUASMC’s (passages 5-10) were seeded at a density of 3x10^ cells per well 
in standard 96 well microtitre plates. Cells were cultivated in H:W 16% FCS 
and supplemented every 48 hours with fresh medium. SMC proliferation was 
assessed in a series of 5 replicate wells that were either uncoated or coated 
with the various matrix components described on p 53 for the exception of 
Matrigel which was excluded from proliferation analysis as a result of 
interference with Hoechst binding.
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2. At sequential time intervals following cell seeding (24; 72; 120; 168 & 216 
hours), culture medium was aspirated. Cells were washed twice in Hanks 
Balanced Salt Solution (HBSS) (Gibco BRL). Excess HBSS was removed 
and cells were stored at -20°C ready for subsequent DNA analysis.
3. Immediately prior to DNA analysis, plates were thawed and dried in a 37°C 
incubator.
4. For DNA concentration / Hoechst fluorescence staining intensity calibration 
curve, DNA standards were added to the outside wells of a microtitre plate; 
(500; 250; 125; 62.5 and 31.25 ng per well).
5. Cells and DNA standards were solubilized and stained in IxSSC (sodium 
chloride 3M sodium citrate 0.3M) solution (BDH), containing 0.05% (w/v) 
SDS (Bio Rad) and 0.5 pg/ml Hoechst 33258 (Sigma). Samples were 
incubated in this solution for 30 minutes in the dark.
6. Fluorescence emission was measured on the Cytofluor at 460nm following 
excitation at 355nm.
7. Data was exported into Microsoft Excel. Using an Excel macro program, 
fluorescent staining intensity was evaluated on the DNA standard calibration 
curve to calculate the mean DNA content in ng per well for each culture 
condition.
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VI 6. SMC Migration
Migration of SMC's was assayed by a modification of the Boyden’s chamber method 
using Transwell inserts (Costar) (FIG.VLl.).
(FIG. VI. 1.) Costar Transwell Insert:
Upper Compartment
Filter
Lower CompartmentFCS
Initially SMC migration was stimulated by seeding cells in the upper compartment in
0.1% (v/v) FCS supplemented H:W medium with 16% (v/v) FCS H;W medium added to the 
lower compartment to provide a positive chemotactic gradient of serum factors that would 
encourage cells to migrate from the upper surface to the lower side of the frlter. However, from 
carrying out protein assays on the medium from the upper compartment at regular time intervals 
following the addition of 0.1% (v/v) and 16% (v/v) FCS H:W media to the upper and lower
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transwell compartments, it became apparent that any chemotactic gradient initially set up was lost 
within 30 mins.
To quantify serum content of medium in the upper transwell compartment, a variation of 
the Bradford protein assay was performed:
Bradford Protein assay (Bio - Rad):
1. Bio Rad protein assay reagent was diluted 1 in 10 using deionised water.
2. 1 Opl of each unknown (medium sample from either the upper or lower transwell 
compartment taken at various time points) was added to triplicate wells of a
96 well microtitre plate.
3. lOpl of serum standards; 16; 8; 4; 2; 1; 0.5; 0.25; 0.125; 0.06% (v/v) FCS H:W 
medium was also added to triplicate wells of a 96 well microtitre plate.
4. 1 OOpl of diluted Bio Rad protein assay reagent was added to each well.
5. Optical density from each well was measured on the plate reader at wavelength 
650 nm.
6. From reference to the standard curve the serum content of medium samples 
obtained from the upper and lower transwell compartments could be calculated.
In order to provide longer lasting gradients; neat FCS was embedded in a 1 % (w/v) 
agarose gel. An equal volume of FCS (Gibco BRL) was added to an equal volume of molten 2 % 
(w/v) agarose (Gibco BRL). The agarose serum blend was mixed briefly and using an eppendorf 
pippette 200pl cast into the lower transwell compartment as a ring. This ring formation allows the 
upper transwell insert and filter to fit into the lower compartment un-obstructed.
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In order to compare SMC migration rates through uncoated and plasma fibronectin 
coated transwell filters the rates of SMC adhesion to both of these surfaces must first be taken 
into account to ensure that equal numbers of SMC's adhere to both uncoated and plasma 
fibronectin coated transwell filters.
SMC adhesion was assayed by quantifying the total DNA content using the Hoechst assay 
as described for SMC proliferation assays (Section VI.5.) SMC's were seeded at a density of 
IxIO* cells per well in uncoated and plasma fibronectin coated microtitre plates. At various time 
points following cell seeding; (30; 120; 240; 360; 480; 600 & 720 minutes), plates were removed 
from the incubator and mean DNA content per well was measured.
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Transwell Migration Assay:
1. Following 5 hours preincubation in 16% (v/v) FCS H:W, SMC's on uncoated filters were 
washed x2 HBSS and replaced in a transwell compartment containing 1% (w/v) 
agarose/neat FCS gel and 750pl (v/v) 0.1% FCS H:W added to the lower compartment 
and lOOpl (v/v) 0.1% FCS H;W was added to the SMC's in the upper compartments. At 
the same time SMC's were seeded onto fibronectin coated filters with 0.1% FCS (v/v) 
H:W in the upper and lower compartments and the 1% (w/v) agarose gel serum mix also 
in the lower compartment.
2. SMC’s in transwell inserts were incubated at 37°C in 93% (v/v) air/7% (v/v) CO2 
environment for the required time intervals (6, 12 and 24 hours).
3. Once incubation was completed, transwell inserts were removed and washed x3 HBSS.
4. Non-migrated cells were removed fi'om the upper surface of the filter by scraping with 
cotton wool buds.
5. Inserts were again washed x3 HBSS and stained for 10 minutes in Coomassie blue fixative 
stain (appendix I).
6. Inserts were washed x2 HBSS.
7. Filters were removed fi'om transwell inserts by dissolving the adhesive with Xylene 
(BDH).
8. Filters were subsequently mounted under glass coverslips with DPX (BDH) mountant.
9. The number of SMC's per high power field (xl 00 magnification) were counted under a 
Zeiss Axioplan microscope.
62
Applying the same method, SMC migration in response to various specific chemotactic 
factors was investigated. Human recombinant PDGF BB (Platelet Derived Growth Factor - 
Promega) and HGF (Hepatocyte Growth Factor - R&D systems) were added at increasing doses 
to the agarose gel and set in the lower compartment.
Although the transwell SMC migration assay proved successful, transwell migration 
experiments were laborious and time consuming to prepare particularly when investigating a 
number of different conditions. The 96 well plate format chemotaxis chamber ChemoTx 
(Neuroprobe) (FIG.VL2.) has the advantage over transwells in that a number of different 
chemotactic conditions can be investigated simultaneously. Also the measurement of SMC 
migration is probably more accurate as the number of migrated cells is quantified automatically by 
the measurement of optical density using the Thermo max microplate reader (Molecular Devices). 
(FTG.VL2.) Neuroprobe 96 well Chemotaxis Chamber.
Microdroplet containing Cells
Filter
Lower 96 well plate
Microdroplet containing Cells
ir Seal
" I  ‘
Lower Chamber
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The Neuroprobe chemotaxis chambers were used to measure SMC migration rates
through various matrix coated filters in response to a range of potential chemotactic factors.
Neuroprobe 96 well chemotaxis chamber (ChemoTx) migration assay:
1. Neuroprobe filters 8pm pore size were coated with the matrix substrates; plasma 
fibronectin, collagen’s I, IH, IV and laminin as previously described for coating other cell 
culture surfaces.
2. Chemotactic stimuli including; human recombinant PDGF BB (Promega), HGF (R & D  
systems) and basic FGF (Sigma) were diluted in 0.1% (v/v) FCS H:W to provide a 
30ng/ml concentration. Each chemotactic preparation was dispensed as 29pl aliquots into 
the wells of the lower chamber in a series of 5 replicated wells. A negative control 
consisting of 0.1% (v/v) FCS H;W media containing no additional chemotactic factors 
was also added to 5 replicate wells for each filter.
3. Filters were washed x2 HBSS and air dried prior to positioning on top of the bottom 96 
well plate containing the chemotactic stimuli. An aqueous seal forms between the filter 
surface and the walls of each well of the bottom plate.
4. 1x10* HUASMC's were added to the filter surface over each well in a 25pi droplet.
5. The top lid was set in place and chambers were incubated at 37°C in a 7% (v/v) CO'J93Vo 
(v/v) air environment for 6 hours.
6. Following incubation chambers were removed fi'om the incubator and dismantled. Filters 
were washed x2 HBSS.
7. Filters were stained and fixed in Coomassie blue fixative stain for 10 minutes.
8. Filters were placed in destain solution (appendix I) for 3 minutes and then allowed to air 
dry for 10 minutes.
9. Filters were then loaded into the Thermo max microplate reader to obtain mean 
absorbency values for total SMC adhesion to the filter for each chemotactic condition.
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10. The filter is withdrawn and all non-migrated cells are removed from the upper surface of 
the filter using moist tissues.
11. The filter is inserted once again into the plate reader to obtain absorbency values for 
migrated cells only.
12. From O.D. values corresponding to the total cell adherence to the filter and for migrated 
cells only. The percentage of adhered SMC's that have migrated to the lower side of the 
filter under each condition could be calculated. Migration results from each matrix coated 
filter were expressed as fold increase over the negative control present on the same matrix 
coated filter. The fold increase of percentage SMC migration over control values for each 
chemotactic condition can then be compared between different matrix coated filters.
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VI.7. Appendix I
Hoechst stain;
Hoechst 33258 (50 pg/ml stock) (Sigma) 50pl
20xSSC (BDH) 5ml
SDS (20% w/v solution) (Bio Rad) 50pl
-Make up with deionised water, shake and use immediately.
Destain Solution;
Methanol (Fisons) 20% (v/v)
Acetic acid (BDH) 7% (v/v)
-Make up solution with deionised water, shake and store at room temperature.
Coomassie brilliant blue fixative stain;
Coomassie brilliant blue (Sigma) 0.25%(w/v)
Methanol (Fisons) 50%(v/v)
Acetic acid (BDH) 10%(v/v)
-Make up solution with deionised water, stir and store at room temperature.
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VI.8. Materials (Results - Chapter 2.):
FW human aorta cells (Dr C Kielty, University of Manchester) 
Matrisperse (Becton Dickinson)
Matrigel (Becton Dickinson)
SMC Differentiation medium (Becton Dickinson)
Econospin Centrifuge (Sorvall)
50 ml tube (Falcon)
IXSDS sample buffer (appendix H)
Sapheneous vein tissue 
Aorta tissue 
Umbilical artery tissue 
Mortar and pestle 
Sonicator (Branson)
Modular Mini - PROTEAN H electrophoresis equipment (Bio Rad); 
Casting stand 
Gel clamp
Inner glass plates (7.3 x 10.2 cm)
Outer glass plates (8.3 x 10.2 cm)
1mm spacers 
15 tooth teflon comb 
Buffer tank and lid 
Power pack Ps 500X (Hoeffer Scientific Instmments)
Bis Acrylamide 30% w/v (37.5:1) (Anachem)
Deionised water
Tris.HCl 1.5M pH8.8 (Sigma) (appendix H)
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Tris HCl 0.5M pH6.8 (Sigma) (appendix II)
SDS (Bio Rad) 10% solution 
Tetramethylethylenediamine (TEMED) (Bio Rad)
Ammonium persulphate (APS) (Bio Rad) 10% solution
Methanol (Fisons) 50% solution
Postslip filter paper (Hollingsworth & Vose)
IxSDS running buffer (appendix H)
Prestained molecular weight standards (Sigma)
100°C water bath
Coomassie blue fixative stain (appendix I)
Destain (appendix I)
Gel dryer (Hoeffer Scientific Instruments)
Transfer cassette and electrophoresis unit (Hoeffer Scientific Instruments) 
Transfer buffer (appendix II)
Nitro-cellulose membrane (Hybond-ECL - Amersham)
Marvel (Premeir beverages) 5% solution in PBS-Tween 
PBS - Tween (appendix H)
Orbital shaker (Stovall)
Square petri dishes (lOOmm^) (Sterilin)
Monoclonal anti SM-a Actin antibody (Mouse IgG2a) (Sigma) 
Monoclonal anti Vimentin antibody (Mouse IgGi) (Sigma)
Monoclonal anti Tropomyosin antibody (Mouse IgGi) (Sigma) 
Monoclonal anti Desmin antibody (Mouse IgGi) (Sigma)
Monoclonal anti (3-Tubulin antibody(Mouse IgGi) (Sigma)
Monoclonal anti Collagen I antibody (Mouse IgGi) (Sigma)
Monoclonal anti Cytokeratin 8 antibody (Mouse IgGi) (Sigma)
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Monoclonal anti Vinculin/meta-vinculin antibody (Mouse IgGi) (Sigma) 
Monoclonal anti Myosin light chain kinase antibody (Mouse IgG2b) (Sigma) 
Monoclonal anti Cellular fibronectin antibody(Mouse IgM) (Sigma) 
Monoclonal anti Collagen IV antibody (Mouse IgGi) (Sigma)
Monoclonal anti Thrombospondin antibody (Mouse IgGi) (Sigma) 
Monoclonal anti Smooth muscle myosin antibody (Mouse IgGi) (Sigma) 
Monoclonal anti Laminin antibody (Mouse IgGi) (Sigma)
Monoclonal anti Caldesmon antibody (Mouse IgGi) (Sigma)
Anti-mouse IgGi FITC conjugate antibody (Sigma)
Anti-mouse horse radish peroxidase conjugate antibody (Sigma)
Saran wrap (Dow)
Hyperfilm ECL autoradiographic film (Amersham)
Hyperfilm cassette (Amersham)
Curix 60 developer (AGFA)
Camera FM2 (Nikon)
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VI.9. Methods (Results Chapter 2.)\
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VI.IO Immunoblotting Analysis;
Protein isolation; Cultured SMC samples were trypsinized from matrix substrates and 
cell pellets were obtained by centrifugation at 1,500 rpm for 5 minutes. Pellets were washed 
x2 PBS and centrifuged prior to protein extraction. SMC’s cultured in Matrigel were 
recovered using Matrisperse (Becton Dickinson) and the following protocol to depolymerise 
Matrigel;
1. Cell culture medium was aspirated from SMC cultures in Matrigel and washed 
x3 with HBSS.
2. Matrisperse solution was added to SMC cultures in Matrigel (2ml per 35mm 
dish)
3. The cell/gel layer was collected into an ice cold 50ml Falcon tube on ice.
4. Each culture dish was rinsed with an additional 2ml of Matrisperse and 
transferred to Falcon tube.
5. The Falcon tube was inverted several times and incubated on ice for 1 hour or 
until the Matrigel has completely depolymerized.
6. The cells were centrifuged at 500-800 rpm for 5 minutes at 4°C.
7. Cell pellets were washed x2 by gentle resuspension in ice cold PBS. Cells
were briefly centrifuged once again, excess PBS was aspirated prior to protein isolation.
Total cellular proteins were extracted from all cultured SMC samples by 
solubilization in IxSDS sample buffer (appendix H). Approximately 1x10^ SMC’s were 
solubilized in lOOpJ of IxSDS sample buffer
Fresh human tissue samples from; Sapheneous vein, aorta and umbilical artery were 
rapidly frozen in liquid nitrogen. Frozen tissue samples were ground using a mortar and 
pestle to obtain a powder. Tissue powder was dissolved in IxSDS sample buffer.
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All protein samples were sonicated in a Branson sonifier 250 to disperse protein 
aggregates.
Electrophoretic separation of proteins; Proteins were separated by one dimensional 
gel electrophoresis in vertical slab 10x7 cm minigels. All protein gels were carried out using 
Bio Rad glass plates (10.2 x 7.3 cm and 10.2 x 8.3 cm) and Bio Rad minigel cassettes and 
casting equipment. Protein gels and electrophoresis equipment were prepared as follows;
1. Wash glass plates thoroughly in deionised water and air dry. Wipe plates with 
absolute methanol immediately prior to use.
2. Assemble one 10.2 x 8.3 cm glass plate and one 10.2 x 7.3 cm glass plate as a 
sandwich between two 1mm spacers.
3. Lock the sandwich into the casting stand.
4. Prepare the separating gel solution as follows to give a 7.5% (w/v) acrylamide 
gel;
Bis Acrylamide stock 30% w/v (37.5:1) 5.62ml
Deionised water 9.08ml
Tris.HCL 1.5M pH 8.8 10ml
10% (w/v) SDS 200pl
TEMED 20pl
10% APS 100|ul
5. Apply 4ml of the separating gel solution to the glass plate sandwich.
6. Overlay top of separating gel with an even layer of 50% methanol, 200pl per 
gel. Allow gel to polymerize for 45 minutes.
7. Wash off 50% (v/v) methanol layer using copious amounts of deionised water. 
Remove excess H2O using filter paper inserted between glass plate sandwich.
8. Prepare stacking gel solution as follows;
Bis Acrylamide stock 30% w/v (37.5:1) 2.6ml
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Deionised water 12.2ml
Tris.HCL 0.5M pH 6.8 5ml
10% (w/v) SDS 200pl
TEMED 20nl
10% (v/v) APS lOOpl
9. Using a Pasteur pipette apply the stacking gel solution until the height of the 
solution in the sandwich reaches the top of the smaller glass plate.
10. Insert a 1mm 15 tooth teflon comb into the layer of the stacking gel solution. 
If necessary add additional stacking gel to completely fill the spaces in the 
comb.
11. Allow stacking gel solution to polymerize for 45 minutes at room 
temperature.
12. Carefully remove teflon comb from the gel.
13. Remove glass plate gel sandwich from casting rack and attach to the upper 
compartment of the gel running apparatus.
14. Place upper buffer chamber containing gel into the lower buffer chamber. Fill 
upper chamber with IxSDS electrophoresis running buffer (appendix II) so 
that the sample wells of the stacking gel are filled with buffer. Also partially 
fill the lower buffer chamber with IxSDS electrophoresis running buffer.
15. All protein samples and molecular weight markers (Sigma) are solubilized and 
denatured by heating at IOO°C for 2 minutes. Place samples on ice ready for 
loading onto the gel.
16. Using an Eppendorf pipetman the required amount of protein samples were 
loaded onto the gel. Also load 5pi of molecular weight standards. Add to 
empty wells at the extreme end of each gel lOpl of IxSDS Sample buffer.
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17. Fill the remainder of the upper and lower chamber with IxSDS electophoresis 
buffer. Connect power supply and run at 20 mA of constant current per
slab gel.
18. After the proteins have migrated the required distance through the gel, 
disconnect power supply and carefully remove gels from glass sandwich for 
either immunoblotting to membrane or protein staining.
Protein Staining; For detection of total protein bands, transfer gel into a suitable 
receptacle and cover with Coomassie blue fixitive stain. Agitate slowly overnight at room 
temperature. After staining is complete pour off stain and add destaining solution, swirl 
briefly and replace with fresh destain and agitate slowly for 4-6 hours. After destaining, the 
gels were washed in a destain/0.5% (v/v) glycerol solution for 10 minutes then rinsed in 
deionised water and dried between two dialysis sheets in gel dryer (Hoeffer Scientific 
Instruments) to maintain a permanent record.
Immunoblotting; Immunoblotting was performed to electrophoretically transfer 
protein from the gel to a nitro-cellulose membrane for subsequent analysis (Towbin et al 
1979). Blotting was carried out in a tank of transfer buffer (appendix H) with the gel in a 
vertical orientation, completely submerged in transfer buffer between two large electrode 
panels as described;
1. Transfer sandwich is assembled in a tray filled with transfer buffer using a 
plastic transfer cassette and 2 sponge sheets.
2. On bottom half of plastic transfer cassette place one sheet of sponge, prewet 
with transfer buffer 2 sheets of postslip filter paper (9x14cm) (Hollingsworth 
& Vose) and place on top of sponge.
3. Place gel on top of filter paper, remove any air bubbles that develop between 
gel and filter paper.
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4. Cut Hybond-ECL nitro-cellulose membrane (Amersham) to same size of gel 
plus an additional 1mm on each edge. Prewet in transfer buffer and apply to 
top side of the gel. Remove any air bubbles between the gel and membrane.
5. Prewet another 2 pieces of postslip filter paper and place on the anode (upper) 
side of the membrane ensuring all air bubbles are removed. Place another 
sponge sheet on top of this filter paper.
6. Complete assembly of transfer sandwich apparatus by locking top half of 
transfer cassette into place.
7. Fill transfer electrophoresis tank (Hoeffer scientific instruments) with transfer 
buffer and place transfer cassette containing sandwich into tank in correct 
orientation, (i.e. membrane side of sandwich adjacent to anode cathode).
8. Electrophoretically transfer proteins from gel to membrane at a constant 
current of 80mA overnight.
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Immunoprobing with conjugated secondary antibody; After the electrophoretic 
transfer of proteins to the membrane is complete the power supply is turned off. The 
membrane is removed from the transfer cassette to a dish ready for the immunoprobing 
procedure as described below;
1. Place membrane in a dish with PBS-tween (appendix U) and wash for 5 
minutes with agitation on an orbital shaker (Stovall) at room temperature.
2. Pour off PBS-tween and replenish with 100ml blocking buffer; 5% (w/v) 
Marvel (Premier beverages) in PBS-tween and incubate for 30 mins at room 
temperature with constant agitation.
3. Protein specific primary antibody was diluted in PBS-tween to obtain ideal 
working concentration (1 in 10,000 - for all antibodies used in this study). 
Blocking buffer was removed and replaced with diluted primary antibody 
(10ml per membrane). Membranes were incubated with primary antibody for 
1 hour at room temperature on shaker.
4. Following primary antibody incubation, membranes were washed x3 PBS- 
tween at room temperature on shaker (5 mins per wash).
5. Membranes were then incubated with suitable primary antibody-relevant anti 
horse radish peroxidase conjugated second antibody diluted 1 in 10,000 with 
PBS-tween. Secondary antibodies were also incubated with membranes 
(10ml per membrane) for 1 hour on shaker.
6. Following secondary antibody incubation, membranes were washed x5 PBS- 
tween (5 mins per wash).
7. Antibody staining was analysed using the ECL detection system and reagents 
(Amersham). Following the final membrane wash in PBS-tween, membranes 
were incubated in a 50:50 mix of ECL reagents 1 and 2 for 1 minute.
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8. Membranes were blotted briefly to remove excess ECL reagents and were
exposed to autoradiographic hyperfilm ECL (Amersham) in autoradiographic 
hyperfilm cassettes (Amersham) for variable exposure times. 
Autoradiographic film was developed in the automatic Curix 60 developer 
(AGFA).
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8. Membranes were blotted briefly to remove excess ECL reagents and were
exposed to autoradiographic hyperfilm ECL (Amersham) in autoradiographic 
hyperfilm cassettes (Amersham) for variable exposure times.
Autoradiographic film was developed in the automatic Curix 60 developer 
(AGFA).
Rat Balloon Carotid Injury;
Male Wister rats were anesthesized with sodium pentobarbiturate (50 mg/kg). A 2F 
Fogarty arterial embolectomy catheter (Baxter, USA) was introduced into the right common 
carotid artery (RCCA) from external carotid artery, swelled with saline and pulled three times to 
denude endothelial cells throughout the RCCA. 14 days following surgery, rats were killed by 
bleeding under diethylether anesthesia. The RCCA was removed, washed with ice-cold saline 
The tissue was then separated into neointima and media, freezed on dry ice, and stored at -40 C 
until used. The normal left common carotid artery was also removed and stored. Protein was 
extracted from these tissue samples by solubilization in Ix SDSSB.
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V Lll Immunofluorescence:
HUASMC’s were cultured on glass chamber slides (Nunclon) at a seeding density of Ix 
10" cells per chamber. Individual chambers were pre-coated with various matrix substrates as 
previously described. Once SMC’s within chambers were approximately 90% confluent they 
were fixed and proteins were stained by dual antibody fluorescence according to the following 
protocol;
1. Flick off culture medium from SMC cultures in chambers and wash x3 PBS.
2. Add Methanol (Fisons): Acetone (BDH) 50:50 mix at -20°C to half fill 
chambers.
3. Flick off and fill chambers with Methanol: Acetone 50:50 mix -20°C and 
incubate at room temperature for Imin.
4. Flick off and wash x2 PBS.
5. Add protein specific primary antibody at required dilution in PBS. Incubate 
cells with primary antibody for 1 hour at room temperature.
6. Wash x2 PBS.
7. Add diluted (1:100 in PBS) Fluorescein Isothiocyanate (FITC) conjugated 
secondary antibody of relevant species to primary antibody used. Incubate cell 
with secondary antibody for 1 hour at room temperature.
8. Wash cell x3 PBS and flick to dry.
9. Remove chambers and rubber seal from glass slide. Mount cells under glass 
coverslips (BDH) using; Hydromount mountant (National Diagnostics).
10. Analyse immunofluorescent staining using the appropriate wavelength filters 
to detect peak light emission at 520 nm on the Ziess Axioplan microscope
Incubation with FITC conjugated antibody and no primary antibody was performed as a control 
to monitor non specific fluoresence. A constant 1 minute exposure time was used when taking 
photographs of immunofluorescent staining.
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VL12 Appendix II
Ix SDS sample buffer;
Glycerol (BDH) lOg
p-Mercaptoethanol (Sigma) 5ml
SDS (20% solution) (Bio Rad) 25ml
Tris (IM  pH 6.8) (Sigma) 6.26ml
Bromophenol Blue (0.2% stock solution) (Sigma) 1ml
- Make up to 100ml with deionised water and stir to dissolve. Store at room temperature. 
Running buffer (xlO);
Tris Base (Sigma) 75.75g
Glycine (BDH) 360.5g
SDS (Bio Rad) 25g
- Make up to 21itres with deionised water. Store at room temperature, dilute 1/10 before use 
Tris pH 8.8 (1.5M);
Tris base 181.65g
- Dissolve in 950ml with deionised water adjust pH to 8.8 using concentrated HCL (BDH). 
Make up to 1 litre with deionised water, store at room temperature.
Tris pH 6.8 (0.5M);
Tris base 30.27g
- Dissolve in 200ml with deionised water adjust pH to 6.8 using concentrated HCL (BDH). 
Make up to 250ml with deionised water, store at room temperature.
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Transfer blot buffer;
Tris HCL (Sigma) 18g
Glycine (BDH) 84g
Methanol (Fisons) 1200ml
-Make upto 6 litres with deionised water.
SDS stock (20% solution w/v);
SDS (Bio Rad) 20g
-Make upto 100ml with deionised water.
Ammonium persulphate (10% solution w/v);
Ammonium persulphate 0.1 g
-Add 900p,l of deionised water and shake to dissolve, store at -20°C.
Destain/Glycerol solution;
Methanol (Fisons) 20% v/v
Acetic acid (BDH) 7% v/v
Glycerol (BDH) 0.5% v/v
-Make up solution with deionised water, stir and store at room temperature.
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VL13. Materials (Results Chapter 3.):
RNAzolB (TEL-TEST)
Hanks Balanced Salt Solution (HBSS) (Gibco BRL)
Chloroform (Fisons)
Speed Vac DNA 100 (Savant)
Diethyl pyrocarbonate (DEPC) (BDH)
MessageClean Kit (Genhunter), components; 1 Ox reaction buffer, Dnase I 
Phenol;Chloroform 3:1 (Sigma/Fisons)
3M sodium acetate (BDH)
1% agarose gel (appendix HI) (Gibco BRL)
IX TBE buffer (appendix HI)
RNA Map Kit (Genhunter), components;
5X Reverse Transcription Buffer 
MMLV Reverse Transcriptase (100 u/p.1) 
dNTP (250|iM)
T12MG, T12MA, T12MT, T12MC (all at lOpM) 
lOX PCR Buffer 
dNTP (25|iM)
AP-1 (2|iM), 5 -AGCCAGCGAA-3'
AP-2 (2pm), 5’-GACCGCTTGT-3’
AP-3 (2pm), 5’-AGGTGACCGT-3’
.AP 4 (2pm), 5’-GGTACTCCAC-3’
AP-5 (2pm), 5’-GTTGCGATCC-3’
Control RNA (0.1 pg/pl)
Glycogen (lOmg/ml)
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^^[S]-dATP (Amersham)
RNA Image Kit (Genhunter), components;
5X Reverse Transcription Buffer 
MMLV Reverse Transcriptase (100 u/pl) 
dNTP (250pM)
H-TiiG, H-TiiA, H-TiiC (all at 2pM) 
lOX PCR Buffer 
dNTP (25pM)
H-APl, H-AP2, H-AP3, H-AP4, H-AP5, H-AP6, H-AP7, H-AP8 (all at 2pM) 
Control RNA (1 pg/pl)
Glycogen (lOmg/ml)
^^[P]-dATP (Amersham)
Tag DNA Polymerase (Perkin Elmer)
Omnigene Thermocycler (Hybaid)
Thermowell thin-wall 96 well plate Model H (Costar)
6% Bis acrylamide (37.5:1) (Anachem)
Tetramethylethylenediamine (TEMED) (Bio Rad)
Ammonium persulphate (APS) (Bio Rad) 10% solution 
42mm X 32mm glass plate 
42mm X 39mm glass plate 
Gel slick (AT biochem)
0.4mm spacer x2 (BRL)
24 well sharkstooth comb x2 (BRL)
SE 1160 Slab Gel Dryer (Hoeffer Scientific Instruments).
3000Xi power pack (Bio Rad)
3 mm Chromatography paper (Whatman)
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Saran wrap (Dow)
Hyperfilm Cassette (Amersham)
Hyperfilm MP Autoradiographic film (Amersham) 
2M Sodium acetate (BDH)
TA Cloning Kit, components;
Amplification primer #1 
Amplification primer #2 
T4 DNA Ligase 
pCRn vector 
Control DNA template 
1 OX PCR Buffer 
lOX Ligation Buffer 
lOOmM dNTPs 
TE buffer
SOC medium (appendix HI)
p-mercaptoethanol 
INV ocF competent cells 
Microflow hood (envair)
Luria-Bertani (LB) Medium (appendix HI) 
bacto-tryptone (Difco) 
bacto-yeast extract (Difco)
Sodium chloride (Sigma)
Agar (Lab M)
Carbenicillin (Sigma)
42°C water bath (Grant)
Petri dishes 90mm diameter (Sterilin)
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0-Nitrophenyl-P-D-Galactopyranoside (X-Gal) (Sigma)
14 ml tubes (Falcon)
Microbiological spreader (L I P )
Innoculation hoops (Starstedt)
RNase A (Promega) 
lOX React 3 (Gibco BRL)
ECORI (Gibco BRL)
1.8% agarose gel (appendix HI)
Qiagen Plasmid Midi Kit (QIAGEN), components;
QIAGEN-tip 100 
Buffer PI 
Buffer P2 
Buffer P3 
Buffer QBT 
Buffer QC 
Buffer QF
Hybaid Recovery Plasmid Midi Prep Kit (Hybaid), components; 
Pre-lysis buffer 
Alkaline lysis solution 
Neutralising solution 
Binding buffer 
Wash solution 
Spin filters 
Catch tubes
Sequanase DNA sequencing Kit version 2.0, components; 
Reaction buffer
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Termination mixtures 
Labelling mix 
Sequenase polymerase 
Pyrophosphatase 
Glycerol enzyme dilution buffer 
Stop solution 
60°C water bath (Grant)
2N Sodium hydroxide (BDH)
IM Sodium acetate (BDH)
T7 primer; 5 -CGACTCACTATAGGGCGAATTG-3 ' 
SP6 primer; 5'-CGCCAAGCTATTTAGGTGACAC-3 ' 
QIAquick Gel Extraction Kit, components;
QIAquick spin columns 
Buffer QXl 
Buffer PE
2 ml collection tubes 
50°C hot block (Teeke)
lOmM Tris-HCL pH 8.5 (Sigma) (appendix IH) 
redipnmQ DNA labelling system, components;
Labelling mix (appendix HI)
Control DNA 
95°C hot block (Teeke)
^^[P] dCTP (redivue) (Amersham)
37°C hot block (Teeke)
0.2M EDTA (Sigma)
Nick Spin Column (Pharmacia Biotech)
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TE buffer pH 7.4 (appendix HI)
Centrifuge CPK R (Beckman) 
mRNA Isolation Kit (Stratagene), components; 
Denaturing solution 
P-mercaptoethanol 
Oligo (dT) cellulose 
High-salt buffer 
Low salt buffer 
Elution buffer 
NaCl (5M)
Sodium acetate (3M)
Glycogen (20mg/ml)
Transfer pipets 
Push columns 
Syringes (10 ml)
1.5% agarose/formaldehyde gel (appendix DI) 
Formaldehyde (37% solution) (Sigma) 
lOX MOPS (appendix HI)
Formamide (Sigma) -deionised 
Mixed bed Resin (Sigma)
65°C hot block (Teeke)
RNA size markers 0.16-1.77 Kb (Gibco BRL) 
RNA size markers 0.24-9.5 Kb (Gibco BRL) 
Formaldehyde gel loading buffer (appendix IQ) 
Power pack Ps 500X (Hoeffer Scientific Instruments) 
20X SSC (BDH)
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Hybond membrane (Amersham)
Ethidium Bromide 1% solution (appendix III) 
U. V. Crosslinker (Stratagene)
Rapid Hyb Buffer (Amersham)
65°C oven (Hybaid)
Oven flasks (Hybaid)
2X SSC/0.1% (w/v) SDS
IX SSC/0.1% (w/v) SDS
O.IX SSC/0.1% (w/v) SDS
Hyperfilm ECL autoradiographic film (Amersham)
Hyperfilm cassette (Amersham)
Curix 60 developer (AGFA)
Camera FM2 (Nikon).
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VI.14 Methods (Results Chapter 3.).
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VI.15 RNA ISOLATION;
Total RNA was isolated from tissue samples and cultured cell populations by a 
variation of the guanidinium thiocyanate method introduced by (Chomczynski & Sacchi 
1987);
1. Ground tissue powder obtained from vascular tissue samples (see methods VI. 10.), 
Cultured cell samples were washed x2 HBSS (Gibco BRL) and then solubilized with 
RNAzol B (5mls RNAzol B per confluent T175 flask of cells).
2. lOOpl chloroform (Fisons) was added per 1 ml of homogenate. The mixture was 
shaken vigorously for 15 seconds and incubated on ice for 5 minutes.
3. The suspension was centrifuged at 12,000 g for 15 minutes at 4°C.
4. An upper aqueous phase that develops was transferred to a clean tube and an equal 
volume of isopropanol was added. Samples were incubated at 4°C for 15 minutes.
5. Samples were then centrifuged at 12,000 g for 15 minutes at 4°C.
6. Supernatant was removed and the RNA pellet was washed once with 75% ethanol 
by vortexing and subsequent centrifugation at 7,500g for 8 minutes at 4°C.
7. The supernatant was removed, and the pellet was dried under vacuum for 3 
minutes.
8. The RNA pellet was dissolved in an appropriate volume of DEPC treated water.
9. RNA quantity and purity were assessed by reading absorbency values at 
wavelengths 260nm and 280nm on a spectrophotometer (Beckman).
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VI. 16 mRNA Differential Display;
Removal of contaminating genomic DNA; Total RNA was isolated using the 
RNAzol B method described above from HUASMC populations (passage 8) cultured on 
plastic and plasma fibronectin substrates.
Untreated RNA samples were amplified for original differential display experiments 
(FIGs IX. 1 a-d). However, in subsequent experiments RNA samples were subjected to 
DNase I treatment in order to remove contaminating DNA. DNase I treatment was carried 
out using the reagents and recommended protocol supplied with the MessageClean kit 
(Genhunter);
1. DNase I digestion, the following components were added in order;
Total RNA 50^1 (50p.g/p.l)
1 Ox Reaction buffer 5.7 pi
Dnase I 1 pi
Reactions were mixed well and incubated for 30 minutes at 37°C.
2. To each sample 40pl of phenol/chloroform (3:1) was added. Samples were then 
vortexed for 30 seconds and incubated for 10 minutes on ice.
3. Samples were centrifuged at 12,000g for 5 minutes at 4°C
4. The upper phase was removed to a clean tube. 5pi of 3M sodium acetate and 200pl 
of 100% ethanol were added to each sample and allowed to incubate for 1 hour at - 
70°C.
5. Samples were centrifuged at 12,000g for 10 minutes at 4°C. The supernatant was 
removed and the RNA pellet was washed with 0.5ml 70% ethanol.
8. RNA was redissolved in lOpl of DEPC treated water.
9. RNA concentration was quantitated by reading absorbance at 260nm on 
spectrophotometer.
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10. RNA integrity was assessed before use by running Ipg on a 1% agarose (Gibco 
BRL) mini gel made up in Ix TBE buffer prepared with sterile DEPC treated water.
10. RNA samples were stored as 1 pg/pl aliquots at -70°C. Immediately prior to 
differential display analysis RNA samples were diluted in DEPC treated water to give a 
concentration of (0.1 pg/pl).
Reverse transcription; Initially RNA was reverse transcribed and PCR amplified using the 
primers and reagents supplied in the RNAmap kit (Genhunter) and a radiolabelled dATP 
nucleotide. Later differential display experiments were performed using modified primers and 
reagents supplied with the RNAimage kit (Genhunter) together with ^^ P radiolabelled dATP. 
The following reverse transcription and PCR protocol was performed when using both kit 
reagents or different radiolabelled nucleotides;
The following components from the RNAmap kit were thawed on ice. Four reverse 
transcriptase reactions were set up as described;
dHzO 9.4pl
5xRT buffer 4.0pl
dNTP(250pM) 1.6pl
Total RNA (0.1 pg/pl) 2.0pl
TM12T, A ,C or G (one for each RT reaction) 2.Dpi
The following components from the RNAimage kit were thawed on ice. Three 
reverse transcriptase reactions were set up as described;
dHzO 9.4pl
5x RT buffer 4.0pl
dNTP (250pM) 1.6pl
Total RNA (0.1 pg/pl) 2.0pl
H-TiiC, G orA (one for each rt reaction) 2.0pl
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Reverse transcriptase samples were placed in a thermocycler (Hybaid) and incubated 
at 65°C for 5 minutes 37°C for 60 minutes and 75°C for 5 minutes. After 10 minutes at 37°C, 
1 pi MMLV reverse transcriptase was added to each tube, and mixed quickly by “finger 
tipping” incubation was then continued. Once reverse transcription completed RT reaction 
tubes were placed on ice ready for PCR step.
PCR amplification; The components used below were thawed on ice. A Master mix was 
prepared for each anchored and arbitrary primer combination. For samples run in triplicate, 6 
PCR reactions were required for each primer combination (3 PCR reactions per population);
1 reaction (pi) Master mix (x6.5) (pi)
dH20 10 65
lOx PCR buffer 2 13
dNTP (25pM) 1.6 10.4
H-AP/AP 2 13
H-TiiC, G or A/TM12T, C, G or A 2 13
^^SdATP/” PdATP 0.2 1.3
Ampli Taq (Perkin Elmer) 0.2 1.3
Master mixes were centrifuged briefly and kept on ice. 2pi of each RT reaction was 
aliquoted into individual wells of a multiwell plate (Costar) in a series of triplicates. The plate 
was briefly centrifuged. 18pl of each master mix was added to each relevant RT reaction 
(master mix containing H-TnC is added to RT reaction performed using H-TnC). Each PCR 
reaction was overlaid with mineral oil and briefly centrifuged. The Multiwell plate containing 
the reactions was placed in the PCR machine and incubated at 99°C - 30 seconds; 40°C - 2 
minutes, 72°C - 30seconds for 40 cycles and 72°C for 5 minutes.
6% Denaturing polyacrylamide gel electrophoresis;
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A 6% denaturing polyacrylamide gel for the separation of amplified differential 
display products was prepared as follows; One side of a 42mm x 32mm glass plate was 
coated with gel slick (AT Biochem) and formed a sandwich with a 42mm x 39mm glass 
plate. The glass plates were separated by two 0.4mm thick spacers. The bottom and sides of 
the sandwich were sealed with tape.
Acrylamide gel solution was prepared by adding to 100ml of 6% bis acrylamide 
(37.5; 1) (Anachem); 10% APS-266.6pl (Sigma) and TEMED-53.3pl (Bio Rad). The 
solution was briefly mixed and poured into the glass sandwich using a 50ml syringe. Two 
inverted 24 well sharkstooth combs were inserted into the upper side of the gel. The 
polyacrylamide gel was left to polymerize at room temperature for one hour.
Once gel polymerized the bottom tape on the glass sandwich was cut open and the 
sandwich was attached firmly to the 82 electrophoresis unit (BRL). Ix TBE running buffer 
was added to the upper and lower reservoirs of the electrophoresis unit. The gel was pre-run 
at 60 watts constant power for 30 minutes. Once the gel is pre-run the inverted sharkstooth 
combs were removed and the resultant trough formed was flushed with running buffer to 
remove settled urea. The sharkstooth combs were inserted into the gel in the correct 
orientation, each tooth was embedded 1mm into the gel.
Differential display PCR samples were prepared for electrophoresis as follows; 3.5|al 
of each PCR sample was added to 2|il of loading dye in a multiwell plate. The plate was 
incubated at 80°C for two minutes. After incubation samples (2.5|il) were immediately loaded 
on to the polyacrylamide gel. Identical duplicate or triplicate reactions were loaded side by 
side, adjacent to equivalent PCR reactions from the comparative population. Samples were 
electrophoresed for 4 hours at 60 watts constant power (with voltage not to exceed 2000) 
until the Xylene dye reaches the bottom of the gel.
Once electrophoresis complete the power supply was switched off and the 42mm x 
32mm glass plate removed from the sandwich. The acrylamide gel was then blotted onto
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3mm filter paper (Whatman). The gel was covered with saran wrap (Dow) and dried at 80”C 
for 1 hour 30 minutes in a slab gel dryer (Hoeffer Scientific Instruments). Stratagene labels 
were placed over each comer of the gel to allow orientation of autoradiograph film. 
Differential display gels were left to expose to autoradiographic film in cassettes for 24-72 
hours at room temperature.
Reamplification of cDNA probe;
After developing autoradiographic film, the gel was orientated with the 
autoradiographic film. Any bands that appeared reproducibly differentially expressed between 
HUASMC populations cultured on Plasma fibronectin and uncoated plastic were cut out of 
the gel using a clean razor blade. DNA was extracted from the gel as follows;
1. The gel slice along with the 3 mm paper (on which the gel was dried) was soaked in 
lOOjul of deionised water for 10 minutes.
2. The tube containing gel slice with cap tightly closed (sealed with parafilm) was 
placed in a boiling water bath for 15 minutes.
3. Sample tubes were then centrifuged at 12,000g for 2 minutes at room temperature to 
collect condensation, and pellet the gel and paper debris.
4. The supernatant was transferred to a new microfuge tube, to which was added lOp.1 
of 2M sodium acetate, 5p,l of glycogen (lOmg/ml stock) and 450|il of 100% ethanol. 
These samples were left to incubate at -70°C for 30 minutes.
5. Samples were centrifuged at 12,000g for 10 minutes at 4°C to pellet DNA.
6. The supernatant was removed and the pellet rinsed with 200pl ice-cold 85% ethanol. 
Samples were centrifuge briefly at 12,000g and residual ethanol was removed.
7. The pellet was dissolved in IOp.1 of deionised water and 4 p.1 was used for PCR 
reamplification. The remainder of sample was stored at -20°C.
8. Reamplification PCR was carried out using the same primer set and PCR conditions 
as used for differential display reactions from where the band was detected, with the
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exception that dNTP 250p.M stock was used instead of 25pM stock. Also a 40pl reaction 
is recommended;
Deionised water 20.4pl
1 Ox PCR buffer 4p.l
dNTP (250|iM) 3.2pl
Relevant TjjM or H-T,, anchored primer 4jal
cDNA template from differential display gel 4pl
AmpliTaq (Perkin-Elmer) 0.4)al
Each PCR reaction was overlaid with mineral oil and briefly centrifuged, reactions were 
incubated in the omnigene PCR machine at 99°C - 30 seconds; 40°C - 2 minutes, 72°C - 30 
seconds for 40 cycles and 72°C for 5 minutes.
Ligation and cloning of reamplified differential display products
Reamplified differential display products were ligated into the TA cloning vector pCR II 
(Invitrogen) and cloned into competent INVaF’ cells to allow sequencing using primers 
homologous to the Sp6 and T7 promoter sites. The TA cloning system (Invitrogen) is established 
as a universal method for the direct cloning of PCR amplified nucleic acid (Mead et al 1991).
Vector ligation and transformation reactions were performed using the reagents and 
protocol supplied with the TA cloning kit. Ligation reactions were performed by adding the 
following components in order;
Deionised water 5ml
Ligation buffer 1ml
pCR II vector 2ml
Differential display product 1ml
T4 DNA ligase 1ml
Ligation reactions were incubated overnight at 14°C.
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Transformation of competent E. coli cells;
LB agar plates were prepared prior to transformation; The L B and agar preparation 
(appendix III) were heated in a microwave oven to dissolve. Molten agar was left to cool at room 
temperature for 30 minutes. The antibiotic Carbenicillin (Sigma) was added to give a final 
concentration of 50 pg/ml and then the molten LB agar was poured into 90 mm diameter dishes 
(Sterilin). LB agar plates were left to set for 1 hour and stored at 4°C. Immediately before 
transformation of E. coli cells, agar plates were dried in a 37°C incubator for 30 minutes. To aid 
selection of positive inserts 0-Nitrophenyl-p-D-Galactopyranoside (X-gal) (25ml of 40ng/ml 
stock) (Sigma) was added to each plate and dispersed over the entire surface using a disposable 
microbiological spreader (L.I.P).
INVaF’ E.-coli competent cells were transformed with differential display reamplified 
PCR products as described;
1. An appropriate number of vials of competent “one shot” cells (Invitrogen) were thawed 
on ice.
2. 2pl of 0.5 M p-Mercaptoethanol was aliquoted into each vial of “one shot” cells and 
mixed by stirring with a pipette tip.
3. 2|il of each ligation reaction was aliquoted into a vial of competent cells and stirred gentl 
with pipette tip to mix.
4. The vials were incubated on ice for 30 minutes.
5. Vials of competent cells were heat shocked for exactly 30 seconds in a 42°C water bath.
6. The vials were then placed on ice for 2 minutes.
7. 450(il of SOC medium (appendix III) was added to each vial.
8. Vials were incubated in a 37°C incubator “shaking” at 225 rpm for exactly 1 hour. After 
incubation vials with the transformed cells were placed on ice.
9. 50pl and 200pl aliquots from each transformation vial was plated on an LB agar plate 
containing 50 pg/ml carbenicillin and X-Gal.
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10. Plates were incubated at 37°C for at least 18 hours and were then shifted to +4°C for 2-3 
hours for colour development.
Mini prep purification and analysis of cloned DNA;
Small scale plasmid DNA purification was performed using a modification of the method 
introduced by Ish-Horwicz & Burke (1981).
1. Positive colonies (white) were toothpicked and inoculated on LB-agar master plates and 
into 2ml L-broth 50)rg/ml carbenicillin cultures. Cultures were incubated overnight in the 
37°C shaker.
2. 2ml cultures were dispensed into sterile 2ml eppendorf tubes. Cultures were centrifuged 
at 12,000g for 2 minutes at room temperature.
3. Supernatants were removed and cell pellets were incubated on ice for 15 minutes.
4. lOOpl chilled solution I (appendix III) was added to each cell pellet. Samples were then 
vortexed and incubated at room temperature for 5 minutes.
5. Next 200pl solution II (appendix III) was added, samples were vortexed and incubated 
on ice for 5 minutes.
6. ISOpl chilled solution III (appendix III) was added to each sample, which were then 
once again vortexed and incubated on ice for 5 minutes.
7. Samples were centrifuged for 2 minutes at 12,000g at room temperature.
8. The clear supernatant was removed to a clean eppendorf to which was added 1/2 volume 
phenol/chloroform. Samples were vortexed and centrifuged at 12,000g for 2 minutes at 
room temperature.
9. The top aqueous layer was removed to a clean eppendorf. 900pl 100% ethanol was 
added and samples were vortexed and incubated at room temperature for 2 minutes.
10. Samples were centrifuge at 12,000g for 2 minutes at room temperature.
11. The supernatant was then removed. To the DNA pellet 1.4ml 70% ethanol was added, 
samples were vortexed.
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12. Each sample was centrifuged for 2 minutes at room temperature, the supernatant was 
removed and the DNA pellet was allowed to air dry.
13. DNA pellets were resuspended in T.E. pH 7.4 and Ipl RNase A was added.
14. Vector DNA and insert was digested using ECORl restriction enzyme as follows;
Add in order; Miniprep DNA 5 pi
React 3 buffer Ipl
ECORl Ipl
deionised H2O 3 pi
Digests were incubated at 37°C for 2 hours.
15. Cloned inserts were analysed to determine whether they correspond with the expected 
size of the differential display products. This was determined by running 9pl of plasmid 
digest on a 1.8 % agarose gel with appropriate molecular weight markers.
Preparation of plasmid DNA for sequencing.
Colonies from the master plate that contain the correct size insert (as determined by 
digestion of corresponding miniprep DNA) were innoculated into 20ml cultures of LB medium 
and incubated overnight in the 37°C shaker. Purification of plasmid DNA in preparation for 
sequencing was achieved using two methods. Initially the QIAGEN plasmid midi protocol and 
later the Hybaid Recovery plasmid midi prep kit were employed. Both protocols are outlined 
below;
QIAGEN Plasmid Midi Protocol;
1. ESrVccF’ E, coli cells were harvested from 20ml L-broth cultures by centrifugation at 4°C 
for 15 minutes at 6,000 g. Supernatant was removed.
2 .4 ml of buffer P2 was added to each sample, mixed gently, and incubated at room 
temperature for 5 minutes.
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3. 4 ml of chilled buffer P3 was then added to samples, mixed immediately but gently, and 
incubated at room temperature for 5 minutes.
4. Samples were centrifuged at 15,000 g for 30 minutes at 4°C. Supernatant was removed.
5. A QIAGEN-tip 100 was equilibrated by applying 4ml buffer QBT. The collumn was 
allowed to empty by gravity flow.
6. The supernatant from step 4 was applied onto the Qiagen-tip and allowed to enter the 
resin by gravity flow.
7. The Qiagen-tip was washed with 2 x 10ml of buffer QC.
8. DNA was eluted from the Qiagen-tip with 5ml buffer QC.
9. Eluted DNA was precipitated with 0.7 volumes of isopropanol at room temperature.
10. Samples were centrifuged at 8,000 g for 30 minutes at 4°C.
11. DNA pellets were washed with 5 ml of cold 70% ethanol, and left to air dry for 5 
minutes. DNA was redissolved in a suitable volume of deionised water (for automated 
sequencing Charing Cross/Durham) or TE pH 7.4 (for manual sequencing).
Hybaid Recovery Plasmid Midi Prep Kit Protocol;
The Hybaid Recovery Kit was employed in preference to the QIAGEN Midi Kit in 
response to the simpler handling of large sample numbers that the kit provided.
1. INVotF’ E. coli cells were harvested from 20ml L-broth cultures by centrifugation at 4°C 
for 5 minutes at 4,000 g.
2. Supernatant was decanted and cells were resuspended in 500pl of deionised water and 
then transferred to a 2ml microcentrifuge tube.
3. Samples were centrifuged for 30-60 seconds, the supernatant was removed, samples 
were briefly centrifuged again and residual liquid removed.
4. 200pl pre-lysis solution was added to each solution and mixed by vortexing or pippetting 
up and down until the cells are completely suspended.
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5. 400pj alkaline lysis solution was added to samples which were gently inverted 15 times. 
Samples were incubated at room temperature for 5 minutes.
6. 300pl ice cold neutralising solution was added to samples and vortexed for 5 seconds at 
full speed.
7. Samples were placed on ice for 5 minutes and centrifuged at 14,000 g for 5 minutes at 
room temperature. Supernatant was transferred to a clean 2ml tube.
8. To the supernatants 900pl of binding buffer (redissolved at 60°C) was added and 
sample tubes were inverted gently 15 times to ensure a uniform mixture for efficient DNA 
binding to the binding buffer.
9. Binding buffer/DNA complex was allowed to settle at room temperature for 1-4 minutes. 
Upper supernatant was removed and discarded. The binding buffer/DNA mix was 
transferred to a spin filter.
10. Samples were centrifuged at 14,000 g for 5 minutes at room temperature, supernatant 
was decanted fi-om the catch tube. 500p.l wash solution was added to the spin filter which 
was then centrifuged at 14,000 g for 2 minutes.
11. The catch tube was emptied and the spin filter was centrifuged again at 14,000 g for 5 
minutes to dry the filter contents. The filter was transferred to a new catch tube.
12. DNA was eluted fi"om the spin filter in lOOpl of deionised water, water was applied to 
filter by gently stirring binding mix with a pipette tip.
13. The spin filter placed within a catch tube was centrifuged at 14,000 g for 5 minutes at 
room temperature. The spin filter was discarded and eluted plasmid DNA stored at 4°C or - 
20°C.
DNA purified using QIAGEN and Hybaid protocols were diluted to a concentration of 
250ng/ml in deionised water and despatched for automated sequencing either at the; Advanced 
Biotechnology Centre, Charing Cross and Westminster Medical School or Department of 
Biological Sciences, University of Durham.
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Sequencing of differential display products;
QIAGEN purified differential display fragments; 19.1, 19.2 and 31.1 were sequenced 
manually using the SEQUENASE DNA sequencing kit, version 2.0 (USB) and the following 
protocol that represents a variation of the dideoxy Sanger method (Sanger et al 1977);
1. To 20|al of QIAGEN purified DNA (250 ng/pl),10pl of deionised water and 3 |l i1 of 
2N sodium hydroxide were added. Samples were then incubated at room temperature 
for 5 minutes.
2. 120|il chilled ethanol and 15pl IM sodium acetate pH 5 were added to samples and 
left to incubate at room temperature for 5 minutes.
3. Samples were centrifuged at 14,000 g for 5 minutes at room temperature and 
supernatant was removed.
4. The DNA pellet was washed in 70% ethanol and then centrifuged at 14,000 g for 5 
minutes at room temperature. The supernatant was removed and the pellet was left to 
air dry for 4 minutes.
5. To this denatured DNA; Ipl stock primer (6 pmole) (T7 or SP6) and 2pi reaction 
buffer were added.
6. DNA was resuspended and annealed at 65°C for 2 minutes.
7. DNA was left to cool at room temperature to 35°C over 15-30 minutes and then 
chilled on ice.
8. 2.5pl of termination mixes were aliquoted into each well of a microtray; A, G, C, T.
9. Termination mixes were prewarmed at 37°C.
10. Labelling mix was diluted 1:5.
11. Sequenase was diluted 1:8 in enzyme dilution buffer; Ipl Sequenase added to; 0.5pi 
Pyrophosphate and 6.5pi buffer.
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12. To ice cold annealed DNA mix (lOpl); Ipl DDT 0. IM, 2pl diluted labelling mix,
0.5.l dATP, 2pi diluted sequenase were added. Samples were mixed and incubated 
at room temperature for 2-5 minutes.
13. 3.5 pi of labelling reaction was transferred to each termination well, mixed and 
incubated for 5 minutes at 37°C.
14. 4pl stop solution was added to each sample. Samples were heated to 75-100°C for 
2 minutes immediately before loading onto a sequencing gel.
15. A 6% DNA sequencing gel was prepared and loaded as previously described for 
differential display analysis. The sequencing gel was run at 40 watts constant power for 
approximately 3 hours.
16. Sequencing gels were fixed by gently pouring over gel fixitive solution (appendix 
ni) and leaving for 5 minutes. This fixitive step was repeated once and the gel was 
then dried and placed in a cassette with autoradiographic film for exposure, as 
previously described for differential display gels.
Purification of differential display products;
Reamplified DNA fi’om differential display gels were gel purified using the QIAquick 
gel extraction kit and reagents (QIAGEN).
1. 30pl of reamplified differential display product was electrophoresed on a 1.8% 
agarose gel.
2. DNA band was excised from the gel with a clean scalpel.
3. The gel slice was weighed and 3 volumes of buffer QXl was added to one volume of 
gel.
4. Samples were incubated at 50°C for 10 minutes. Dissolution of the gel was aided by 
flicking and inverting the tube every 2-3 minutes.
5. A QIAquick spin column was inserted into a 2ml collection tube.
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6. Sample was loaded into the spin column and centrifuged for 60 seconds at 14,000 g. 
Elutant was discarded.
7. 0.75ml buffer PE was added to spin column. Columns were centrifuged at 14,000g 
for 60 seconds and elutant was discarded. Centrifugation was repeated and any 
remaining elutant was also discarded.
8. QIAquick columns were inserted into clean 1.5 ml microfuge tube.
9. DNA was eluted by adding 50p.l lOmM Tris-HCL pH 8.5 and centrifuged for 60 
seconds at 14,000 g
Radiolabelling of purified differential display products.
Purified differential display products were random primed labelled using the protocol 
and reagents supplied in the Rediprime kit (Amersham). This labelling method was originally 
based on the procedure developed by Feinberg and Vogelstein 1984;
1. The DNA to be labelled was diluted to a concentration of 25ng in 45pl of sterile 
water.
2. DNA was denatured at 95°C for 5 minutes and centrifuged briefly.
3. The denatured DNA was added to the labelling mix which was reconstituted by 
gently flicking the tube until the blue colour was evenly distributed. Labelling mix and 
DNA was centrifuged briefly.
4. 5 pi of Redivue ^^ P CTP (Amersham) was added to labelling preparation and mixed 
by gently pipetting up and down 4 to 5 times. Samples were centrifuged briefly.
5. Labelling reactions were incubated at 37°C for 10 minutes.
6. The reaction was stopped by adding 5pi of 0.2M EDTA.
The labelled reaction mixture was passed through a NICK Spin Column (Pharmacia) 
to separate unincorporated ^^ P - labelled nucleotides from ^^ P labelled nick translated DNA 
fragments. NICK Spin Columns were prepared and used as follows;
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1. The columns were inverted several times to resuspend the gel, then placed upright to 
allow the gel to settle.
2. The top cap and bottom cap were removed. The column was allowed to drain. To 
remove any air bubbles the column was tapped gently.
3. Columns were placed in centrifuge tubes and 1 ml of equilibration buffer (TE pH 
7.4 - appendix IH) was added. Columns were allowed to drain.
4. A further 2 ml of equilibration buffer were added to columns and allowed to drain.
5. Using a counterbalance, columns were centrifuged for 4 minutes at approximately 
500 X g in a swinging-bucket rotor centrifuge (Beckman). The column was removed 
from the supernatant and the eluate discarded.
6. The column was placed in an upright position and the labelled probe was applied to 
the centre of the flat gel surface.
7. An uncapped 1.5 ml microcentrifiige tube was placed inside the centrifuge tube. The 
loaded column was then placed inside the centrifuge tube, with the tip of the column 
inside the microcentrifuge tube. The sample was eluted by centrifugation for 4 minutes 
at 500 X g.
The microcentrifuge tube containing the labelled purified probe was removed from the 
centrifuge tube.
8. The labelled DNA probe was denatured by heating to 95-100°C for 5 minutes, then chilled 
on ice.
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Isolation of mRNA samples.
Polyadenylated mRNA from HUASMC’s cultured on plastic or fibronectin coated 
plastic were isolated using the Messenger RNA Isolation Kit from Stratagene. The procedure 
was carried out as follows;
1. HUASMC’s were trypsinized from culture substrates as previously described (see 
methods VI.3.). Cells were collected by centrifugation.
2. Denaturing solution was prepared by adding 50pl of P- mercaptoethanol to 5 ml of 
room-temperature denaturing solution.
3. 5 ml of the prepared denaturing solution was added to the cell pellet. The cells lyse 
immediately and the DNA was sheared by passing the sample several times through a 
21 - gauge needle.
4. 10 ml of room temperature elution buffer was added to the sample. Samples were 
mixed by inversion.
5. An RNase-free tube containing 1.3 ml of elution buffer was placed in a 68°C heating 
block.
6. Samples were centrifiiged at 12,000 xg for 10 minutes at room temperature. 
Supernatant was removed.
7. The tube containing the oligo(dT) cellulose slurry was gently agitated to evenly 
resuspend the material. 5 ml of oligo(dT) cellulose slurry was transferred to a 
microcentrifuge tube for every sample to be processed.
8. The supernatant from step 6 was transferred to the oligo (dT) cellulose.
9. Gently rotate the tube for 15 minutes at room temperature, only fast enough to keep 
the cellulose in suspension.
10. The cellulose resin was pelleted by centrifuging the sample mix at 1,500 rpm for 4 
minutes at room temperature. The supernatant was carefully removed and discarded.
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11. The oligo (dT) cellulose pellet was resuspended in 5 ml high salt buffer. Repeat 
steps 10. & 11. two more times
12. After the third and final high-salt wash, the resin was pelleted, the high-salt buffer 
removed and the oligo (dT) cellulose pellet was subsequently resuspended in 5 ml of 
low salt buffer.
13. The sample was mixed and centrifuged at 1,500 rpm for 4 minutes at room 
temperature. The supernatant was removed and the oligo (dT) cellulose was 
resuspended in 5 ml of low-salt buffer.
14. A sterile 10 ml syringe was removed from the protective covering and the plunger 
partially pulled out. The syringe was replaced inside its wrapper to keep it RNase-free.
15. Using a transfer pipette a push column was filled with 2.5 ml from the 5 ml oligo 
(dT) cellulose suspension. The end of the syringe was attached to the push column.
16. The buffer was gently pushed through the column by depressing the plunger 
allowing the resin to pack into the uniform bed at the bottom of the column.
17. An additional 2.5 ml of oligo (dT) cellulose suspension was added to the column 
using the transfer pipette. The syringe was reattached and used to push all the 
remaining solution out of the column.
18. 400|il of 68“C elution buffer (from step 5) was added to the top of the resin and 
slowly pushed through the column using the syringe. Eluted RNA was collected in 
sterile RNase-free microcentrifuge tubes.
19. To precipitate RNA for concentration or storage, added to each sample was 1/10^ 
volume of 3M sodium acetate and x2 volumes of 100% (v/v) ethanol. mRNA samples 
were stored at -70°C.
20. mRNA samples were resuspended by centrifugation at 12,000 g for 25 minutes at 
4°C. Supernatant was aspirated off and RNA pellet resuspended in DEPC water to give 
desired concentration.
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Northern blot procedure;
Electrophoretic separation and transfer of RNA to nylon membranes for analysis was 
achieved using a modification of the methods pioneered by (Alwine et al 1977 and Southern 
1975).
1. A 1.5% agarose gel was prepared; 1.5g agarose was dissolved in 74 ml Ix TBE 
(prepared in DEPC water).
2. Molten agarose was allowed to cool down to 60°C prior to the addition of 17 ml 
formaldehyde 37% solution (Sigma).
3. 9 mis oflOx MOPS (appendix HI) was added to agarose solution to give a final 
concentration of Ix.
4. Agarose solution was mixed gently ensuring no air bubbles develop.
5. 80 mis of agarose mix was poured into Horizon 11.14 RNase free electrophoretic 
chamber containing 14 tooth comb. Agarose mixture was left to set for 45 minutes - 1 
hour.
6. Sample loading buffer was prepared as follows;
Formamide (deionised) 12.5|il
Formaldehyde 5pl
10 X MOPS 2.5pl
DEPC 2.5pl
Formaldehyde loading buffer (appendix HI) 2.5pl
7. Loading buffer was briefly centrifuged and 25 pi was added to 5 pi of RNA samples 
(4pg/pl concentration) or 5 pi of RNA size markers.
8. Samples were briefly centrifuged, and incubated at 65°C for 15 minutes.
9. Samples were then placed on ice, 30pl of sample (20pg RNA) was loaded per well 
on the northern gel.
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10. RNA samples were electrophoresed through the gel at a constant 115 volts for 2 
hours 30 minutes.
Separated RNA species were transferred by capillary action to a nylon membrane for 
further analysis (Southern 1975);
1. 20x SSC was poured into a tray.
2. A glass plate was placed on top of an eppendorf pipette lid to provide a gel support.
3. 2 pieces of 3mm paper wick were prepared, 3mm paper was prewet in 20xSSC and 
laid over glass plate.
4. Once electrophoresis complete the power pack was switched off and the gel 
removed from the electrophoresis chamber. Marker tracks were cut off the gel and 
soaked in DEPC water.
5. The remainder of the northern gel was inverted on to the 3 mm paper wick.
6. The peripheral edges of the gel was surrounded with Saran wrap.
7. Hybond membrane (Amersham) was cut to just larger than the gel. The membrane 
was placed on the gel ensuring no air bubbles develop.
8. 2 pieces of 3mm paper, just larger than the membrane were soaked in 2xSSC. The 
filter paper was placed over the membrane ensuring no air bubbles develop.
9. A vertical stack of paper towels was placed on top of the 3 mm paper, and then a 
sandwich box containing an even 1 kg weight was placed on the towels.
10. The blotting apparatus was left overnight.
- Marker lanes were stained in 250 ml DEPC water + lOpi 1% ethidium bromide, 
for 3 minutes, the gel was then rinsed with DEPC water overnight and photographed 
with a ruler adjacent to the gel to record distance markers had migrated through gel.
11. 3mm filter paper and paper towels were removed following overnight incubation. 
The location of gel wells was marked on Hybond membrane with pencil.
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12. Membranes were placed on moist (DEPC water) 3 mm paper. Membranes were 
placed RNA side up in crosslinking oven (Stratagene) and subjected to autocrosslink 
procedure.
13. Membranes were wrapped in saran wrap and stored at room temperature in a dry 
place ready for probe hybridisation reactions.
Probe hybridisation to northern blot;
Membranes were pre-hybridised in Rapid-hyb buffer (Amersham) at 65°C for 15 
minutes. Membrane hybridisation reactions were performed in rotating flasks within a Hybaid 
oven. The radiolabelled probe was added to the Rapid-hyb prehybridisation buffer and 
allowed to hybridise to the membrane for 3-4 hours at 65°C. Following incubation of probe 
the hybridisation buffer was poured off and membranes were washed as follows;
20 minutes in 50ml 2 x SSC, 0.1% (w/v) SDS at room temperature.
2 x 1 5  minutes in 50 ml 1 x SSC, 0.1% (w/v) SDS at 65°C.
If membrane still contained widely dispersed radioactive label an additional wash in 
0.1 X SSC, 0.1% (w/v) SDS at 65°C was performed.
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VI. 17 Appendix ITT
lOXTBE
Tris base (Sigma) 108.8g
Boric acid (Sigma) 55.6g
EDTA disodium salt (Sigma) 9.3g
-Dissolve in 1 litre deionised water. For IX TBE dilute lOX TBE 1 in 10 with deionised water. 
1% ethidium bromide solution
Dissolve Ig ethidium bromide (Electran) (BDH) in 100 ml deionised water.
1% agarose minigel;
Add 25 ml of IX TBE to 0.25g agarose (Gibco BRL). Microwave to dissolve, let cool and add 
Ipl 1% ethidium bromide solution. Gently mix solution and pour into Horizon minigel casting 
equipment (BRL).
1.8% agarose minigel;
Add 25 ml of IX TBE to 0.45g agarose (Gibco BRL). Microwave to dissolve, let cool and add 
Ipl 1% ethidium bromide solution. Gently mix solution and pour into Horizon minigel casting 
equipment (BRL).
LB Medium
bacto-tryptone (DIFCO) lOg
bacto-yeast extract (DIFCO) 5g
NaCl (Sigma) lOg
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-Add 950 ml deionised water and stir to dissolve. Adjust the pH to 7.0 with 5 N Sodium 
Hydroxide (BDH). Make volume up to 1 litre with deionised water. Sterilise by autoclaving for 20 
minutes at 15 Ib/sq. in on liquid cycle.
Lb-agar
bacto-tryptone (DIFCO) lOg
bacto-yeast extract (DIFCO) 5g
NaCl (Sigma) lOg
-Add 950 ml deionised water and stir to dissolve. Adjust the pH to 7.0 with 5 N Sodium 
Hydroxide. Make volume up to 1 litre with deionised water. Add 15g agar (LAB M). Sterilise by 
autoclaving for 20 minutes at 15 Ib/sq. in. on liquid cycle.
SOC medium (Invitrogen) 
Tryptone 2%
Yeast extract 0.5%
NaCl
Kcl
MgS04
glucose
lOmM
2.5mM
lOmM
20mM
TE buffer
Tris Hcl pH 7.4(Sigma) 
EDTA pH S.O(Sigma)
lOmM
ImM
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Rediprime labelling mix
Each aliquot of labelling mix contains the following in a stabilized form;
- A buffered solution of dATP, dGTP, dTTP, exonuclease free Klenow enzyme and 
random primers (9 mers).
lOX MOPS
MOPS (Sigma) 41.2g
3M Sodium Acetate (BDH) 16.6 ml
SOOmM EDTA disodium salt (Sigma) 20 ml
-Make up to 1 litre with DEPC treated water and stir to dissolve. Sterilize by autoclaving for 20 
minutes at 15 Ib/sq. in. on liquid cycle.
1.5% agarose/formaldehyde gel
Add 74 ml IX TBE to 1.5g agarose, dissolve in microwave. Molten agarose is cooled down to 
60°C prior to the addition of 17 ml fomaldehyde (37% solution) (Sigma) and 9 ml of 1 OX MOPS. 
Agarose solution is mixed gently and poured into Rnase free Horizon 11:14 casting equipment.
Formaldehyde gel-loading buffer
50% glycerol (Fisons)
ImM EDTA (pH 8.0) (Sigma)
0.25% bromophenol blue (Sigma)
0.25% xylene cyanol FF (Sigma)
Solution I
Glucose(BDH) 9g
2M Tris HCL(Sigma) 12.5 ml
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0.2M EDTA disodium salt (Sigma) 50 ml 
-Make up to 1 litre with deionised water. Store at 4°C
Solution n
2N Sodium Hydroxide (BDH) 20 ml
10% SDS (Bio Rad) 100 ml
-Make up to 1 litre with deionised water and store at room temperature.
Solution m
5M Potassium acetate (BDH) 147.2Ig
Glacial acetic acid (BDH) 57.2 m
-Make up to 500 ml with deionised water adjust pH to 4.8 and store at 4°C.
Sequencing gel fixitive
Methanol (Fisons) 200 ml
Acetic acid (BDH) 200 ml
-Make up to 2 litres with deionised water.
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Chapter 1 (Section VIIL
Morphological and Functional Analysis of
Vascular Smooth Muscle Cells Cultured on
Different ECM Substrates.
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VII.l. Introduction - Vascular SMC behaviour in culture.
A number of previous studies characterising the behaviour of vascular SMC’s within 
an in vitro culture system, suggest that SMC’s freshly isolated from normal vascular tissue 
samples undergo spontaneous modulation from a contractile phenotype to a synthetic 
phenotype. This transition in phenotype is characterised by the reorganisation of the 
cytoskeleton that includes the loss of myofilament bundles and formation of actin containing 
stress fibres and radiating networks of microtublules and intermediate filaments. An increase 
in the amount of rough endoplasmic reticulum and golgi apparatus is also observed (Thyberg 
et al 1990). In parallel with such changes in the contractile and secretory apparatus a definite 
shift in the expression of SMC specific isoforms of contractile and cytoskeletal proteins to 
non-muscle isoforms can be observed. For example during the first few days in culture 
decreased expression of smooth muscle a-actin is accompanied by increased expression of j3 
- actin (Glukhova et al 1986). Similarly the expression of SM - Myosin heavy chain is 
downregulated, while the expression of non-muscle forms of myosin increase (Kawamoto & 
Adelstein 1991; Rovner et al 1986). In addition overall RNA and protein synthesis together 
with cell proliferation are also activated upon isolation of SMC’s in culture. Moreover the 
synthesis and secretion of extracellular matrix molecules such as; Collagen I; Elastin; 
Fibronectin; Thrombospondin and proteoglycans is also enhanced. (Ang et al 1990; Liau & 
Chan 1989).
The apparent "dedifferentiation” of SMC’s induced by cell culture correlates with the 
activation of synthetic and secretory functions, a process closely resembling the phenotypic 
modulation of SMC’s from a contractile to a synthetic phenotype that accompanies the initial 
development of atherosclerotic and restenotic lesions (Thyberg et al 1990). This spontaneous 
phenotypic modulation is thought to occur in response to the presence of serum derived
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growth factors and cytokines as well as an altered extracellular matrix environment that exist 
in culture conditions. Thus all SMC’s isolated in culture undergo modulation becoming 
representative of the synthetic phenotype.
Further studies characterising the progression of vascular SMC’s in vitro demonstrate 
that when SMC’s are grown on ordinary uncoated tissue culture surfaces, they form a 
preconfluent monolayer; subsequently regions of this monolayer develop characteristic 
multicellular foci that have been described as “hill and valley” structures. Observations by 
Thomas-Salgar and Millis 1994 and Li et al 1994 indicate that these structures generate 
functionally differentiated nodules that consist of quiescent SMC’s embedded in a 
carbohydrate rich extracellular matrix (Brennan et al 1982; Li et al 1994; Salgar & Millis 
1994). SMC’s within nodules contain myofilaments and express proteins including clusterin 
that appear to be related to cell differentiation (Diemer et al 1982; Li et al 1994). These 
characteristics indicate that SMC’s within such nodules maybe regaining previously lost 
differentiated contractile phenotypic properties.
It has been postulated that the formation of nodular structures is regulated by the 
presence of extracellular matrix (ECM) and some studies have demonstrated that fibronectin 
delays the onset of nodule formation and maintains cells in a synthetic phenotype (Brennan et 
al 1982; Hedin & Thyberg 1987). Therefore the analysis of vascular SMC growth 
morphology in vitro, particularly the transition from a monolayer to a nodular morphology, 
may be useful for studying regulators of SMC phenotypic modulation. To assess the role that 
ECM has on modulating human SMC phenotype in vitro my studies have included examining 
alterations in the growth morphology of human umbilical artery SMC’s induced by culture on 
various matrix coated substrates.
The initiation of SMC proliferation and migration by various inflammatory stimuli has 
been proposed as the underlying events responsible for the formation of the neointima and 
subsequent vessel occlusion that characterises restenosis and atherosclerosis (Ross 1986). In
117
order to investigate the role that ECM molecules play in regulating mitogenic and chemotactic 
responses of SMC’s, the studies described in this thesis have included the development of m 
vitro SMC proliferation and migration assays. These assays were designed to allow comparison 
of SMC proliferation and migration responses to various mitogenic and chemotactic stimuli 
between SMC’s cultured on different extracellular matrix substrates.
The morphological growth patterns of vascular SMC’s cultured on each matrix 
substrates together with growth patterns on ordinary uncoated tissue culture grade plastic 
(Nunclon) were assessed by light microscopy. Photomicrographs (X40 magnification) recorded 
SMC growth morphology (FIG s. VII.l- VII.9.) Each photomicrograph is a representative 
example from at least 3 separate plating studies of SMC morphology on each substrate.
It was observed that SMC’s cultured on uncoated tissue culture plastic form the 
characteristic “hills and valley” growth morphology with the majority of cells becoming rapidly 
incorporated within nodular structures (FIG. VII.l). SMC’s cultured on collagen I, plasma and 
cellular fibronectin grow in a clear monolayer pattern, the cells also appear elongated and 
orientate parallel to one another (FIG. VII.2 - V1I.4). SMC’s cultured on collagen types III and 
IV, laminin and vitronectin also grow in a monolayer like fashion, however, localised areas of 
multicellular aggregation progressively develop on these substrates and a proportion of cells 
become incorporated into nodular like structures (FIG. VII.5 - VII.8). All SMC’s cultured on 
Matrigel in serum free medium rapidly form nodular structures (FIG. VII.9). SMC cultures on 
Matrigel in medium supplemented with serum also form this nodular growth pattern.
118
(FIG.VII.l.) SMC’s cultured on tissue culture grade 
plastic:
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(FIG.VII.2.) SMC’s cultured on plasma fibronectin:
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(FIG.VII.3.) SMC’s cultured on cellular fibronectin:
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(FIG.VII.4.) SMC’s cultured on collagen I:
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(FIG.VII.5.) SMC’s cultured on collagen III:
(FIG.VII.6.) SMC’s cultured on collagen IV:
■
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(FIG.VII.7.) SMC’s cultured on laminin:
(FIG.VII.8.) SMC’s cultured on vitronectin:
m
m m m .
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(FIG.VIL9.) SMC’s cultured on Matrigel:
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Applying the Hoechst DNA stain proliferation assay, growth curves of HUASMC’s 
cultured on different matrix substrates were obtained. (FIG.VII. 10), displays typical growth 
curves for HUASMC’s (passage 5) proliferation on plastic and plasma fibronectin coated 
surfaces in response to H:W 16%FCS medium. These results demonstrate enhanced 
proliferation rates in response to H:W 16%FCS by HUASMC’s cultured on plasma fibronectin 
when compared with identical cells cultured on uncoated tissue culture plastic
(F IG .V II.1 0 .)
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(FIG.VII. 10) HUASMC Proliferation on Fibronectin Coated and Uncoated Plastic in
response to H:W 16% FCS. This is a representative result from 3 experiments. Error bars
are SEM. Data points at 24 hrs are not signifîcantly different between fibronectin and
plastic populations all subsequent data points are however significantly different between
populations (P < 0.05) as determined by the student’s t test.
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Similar studies on SMC cultures that have not been supplemented with fresh medium 
reveal that SMC’s cultured on fibronectin reach considerably higher cell densities than cells on 
plastic. Also the lifespan of the cells was significantly extended by growth on fibronectin
( F I G .V I L l l ) .
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(FIG. V II.ll) HUASMC Proliferation on Fibronectin and Uncoated Plastic in Response to 
H:W 16% FCS (no medium change). This is a representative result from 3 experiments. 
Error bars are SEM. Data points are significantly different between plastic and 
fibronectin SMC populations (P < 0.05) as determined by the student’s t test.
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Growth curves obtained from later passage HUASMC’s (passage 10) were calculated to 
demonstrate more clearly the different rates of proliferation in response to H:W 16%FCS 
exhibited by SMC’s cultured on different matrix substrates. (FIG.VII. 12.).
(FIG.VII.12.).
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(FIG. VH.12.) HUASMC (passage 10) Proliferation on Plasma Fibronectin, Collagen’s I, 
III, IV, Laminin and Plastic Substrates in Response to H:W 16% FCS. This is a 
representative result from 3 experiments. Error bars are SEM. All data points are not 
significantly different between various matrix cultured SMC populations with the 
exception that at 120 hours , the DNA content of SMC’s cultured on plastic are 
significantly less than fibronectin. Collagen’s I, III & IV cultured SMC’s (P < 0.05). Also 
at this same time point the DNA content of SMC’s cultured on Laminin is significantly 
less than that of SMC’s on plastic (P < 0.05) as determined by the student’s t test.
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Protein assays demonstrated that any chemotactic gradient initially set up within 
Costar Transwell inserts was lost within half an hour as indicated by the fact that the serum 
concentration in the upper compartment increased from 0.1% to 8% FCS (FIG.VII. 13.).
(FIG.VII.13).
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(FIG.VH.13.) Increase in Serum Concentration in the Upper Transwell Compartment 
Over Time.
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To provide longer lasting gradients neat FCS was embedded in a 1% agarose gel that 
was cast in the lower compartment of the transwell. This agarose gel resulted in slow release of 
FCS out of the agarose providing a chemotactic gradient between the lower and upper transwell 
compartments that was maintained up to 24 hours.(FIG.VII.14.).
(FIG.VII.14.).
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(FIG.VII.14) Increase in Serum Concentration in the Upper and Lower Transwell 
Compartments Over Time. This is a representative result from 2 experiments. Error bars 
are SEM. Data points at 1,4 and 8 hours are significantly different between the upper and 
lower transwell (P < 0.05) as determined by the student’s t test. All subsequent data points 
are not significantly different.
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In order to compare SMC migration through fibronectin and uncoated transwell filters, 
HUASMC adhesion rates to fibronectin and uncoated tissue culture surfaces were assessed by 
DNA quantification at sequential time points following SMC seeding in uncoated and plasma 
fibronectin coated microtitre plate wells. These adhesion assays demonstrated that HUASMC’s 
adhere much more rapidly to fibronectin coated surfaces than to uncoated surfaces. Also SMC 
adhesion was significantly enhanced in the presence of FCS (FIG.VII.15.)
(FIG. VII. 15.).
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(FIG.VII.15.) HUASMC Adhesion to Fibronectin Coated and Uncoated Surfaces in the 
Presence of Either H:W 16%FCS or H:W 0.1% FCS. This is a representative result from 
3 experiments. Error bars are SEM. Data points are significantly different between plastic 
and fibronectin SMC populations (P < 0.05) as determined by the student’s t test.
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Transwell SMC migration assay’s demonstrated that SMC migration rates in response to 
a positive gradient of FCS are significantly greater on plasma fibronectin than on uncoated 
tissue culture surfaces (FIG.VII.16.).
(FIG.VII.16.).
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(FIG. VII. 16). HUASMC Migration Through Fibronectin Coated and Uncoated Transwell 
Filters in Response to FCS. This is a representative result from 3 experiments. Error bars 
are SEM. Data points are significantly different between plastic and fibronectin SMC 
populations (P < 0.05) as determined by the student’s t test.
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A dose response of SMC migration towards increasing concentrations of PDGF BB and 
HGF was demonstrated through fibronectin coated transwell filters (FIG’s. VII. 17 & .18).
(FIG.VII.17.)
0 12.5 25 50 100 200
PDGF CONC ng
(FIG.VII.17.) HUASMC Migration Through Fibronectin Coated Filters in Response to 
PDGF BB. This is a representative result from several experiments. Error bars are SEM. 
Values are significantly different between 12.5 & 25ng concentrations, all subsequent 
values are not significantly different (P < 0.05) as determined by the student’s t test.
(FIG.VII.18.). «
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(FIG. VH.18.) HUASMC Migration Through Fibronectin Coated Filters in Response to 
HGF. This is a representative result from several experiments. Error bars are SEM. 
Values are significantly different between 12.5 & 25ng concentrations, all subsequent 
values are not significantly different (P < 0.05) as determined by the student’s t test.
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SMC migration rates in response to FCS differed through various matrix coated 
Neuroprobe 96 well migration chamber filters (FIG. VII. 19.).
(FIG.VII.19.).
COLI COL III COLIV LAM FIB
(FIG.VII.19.) HUASMC Migration Through Various Matrix Coated Filters in Response 
to H:W 16% FCS. This is a representative result from 3 experiments. Error bars are 
SEM. Migration values on collagen HI and fibronectin are significantly different from 
values on Collagens I & IV and laminin (P < 0.05) as determined by the student’s t test.
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Migration in response to specific factors also varies depending on what type of matrix 
the SMC’s are cultured on (FIG’s; VII.20-.22.).
(FIG.VII.20.).
FIB C O L I C O L  III C O L IV  LAM
(FIG.VII.20.) HUASMC Migration Through Various Matrix Coated Filters in Response 
to 30ng/ml PDGF BB. This is a representative result from 3 experiments. Error bars are 
SEM. Migration values on collagen HI and Fibronectin are significantly different from 
values on Collagen I also these values are all significantly different from migration on 
collagen IV and laminin (P < 0.05) as determined by the student’s t test.
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(FIG.VII.2L),
(FIG.VII.21.) HUASMC Migration Through Various Matrix Coated Filters in Response 
to 30ng/ml HGF. This is a representative result from 3 experiments. Error bars are SEM. 
Migration values on collagen I, Fibronectin and laminin are signifîcantly different from 
values on Collagen types HI & IV (P < 0.05) as determined by the student’s t test
(FIG.VII.22.).
C O L I C O L  III
(FIG.VTI.22) HUASMC Migration Through Various Matrix Coated Filters in Response to 
30ng/ml bFGF.. This is a representative result from 3 experiments. Error bars are SEM. 
Migration values on collagen III are significantly greater than values on all other matrix 
substrates. Migration values on Fibronectin and collagen are significantly greater than 
values on Collagen IV (P < 0.05) as determined by the student’s t test.
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Chapter 1. Results - Summary;
In accordance with previous morphological studies of vascular SMC's in culture by 
Thomas-Salgar & Millis (1994) and Li et al (1994), it could be inferred that the distinct 
morphological patterns exhibited by culturing HUASMC's on different matrix coated substrates 
provide an indication that the ECM molecules analysed in this study play a role in the modulation 
of human SMC phenotype.
SMC’s show an enhanced proliferation rate in response to serum when HUASMC's are 
cultured on the matrix substrates; Plasma fibronectin and collagens I, III and IV compared with 
SMC's cultured on plastic or laminin.
Protein assays carried out on samples from both Transwell compartments indicate that to 
obtain a long lasting chemotactic gradient between the upper and lower Transwell compartments, 
the chemotactic source must be embedded in a low melting point agarose gel within the lower 
compartment.
Adhesion assays demonstrate that SMC’s adhere much more rapidly to fibronectin coated 
surfaces than to uncoated surfaces. It was concluded from adhesion assays that to compare 
HUASMC migration through fibronectin and uncoated transwell filters, a 5 hour preincubation 
step in H:W 16%FCS was required for HUASMC’s seeded on to uncoated transwell filters prior 
to the initiation of the migration assay. This preincubation should ensure relatively equal numbers 
of HUASMC adhesion to plasma fibronectin and uncoated transwell filters.
SMC migration towards a positive gradient of FCS or PDGF BB and HGF was 
considerably enhanced over fibronectin coated filters when compared to migration through 
uncoated filters. SMC migration rates towards FCS were approximately two-fold greater on 
plasma fibronectin and collagen III coated filters compared with migration on collagen I, IV and 
laminin. Migration in response to specific growth factors also varied depending on the matrix 
substrate. PDGF BB induces significant levels of migration through plasma fibronectin, collagen
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Ill, and collagen I coated filters, whereas little or no migration was observed through collagen IV, 
and laminin. Basic FGF induced a high level of migration through collagen III, low levels of 
migration through fibronectin and collagen I, and once again no migration was observed through 
laminin or collagen IV. HGF induced significant levels of SMC migration through collagen I, 
plasma fibronectin and laminin, whereas no migration towards HGF could be observed through 
collagen FV and collagen III.
The demonstration from the SMC proliferation and migration assays that matrix 
molecules can alter the mitogenic and chemotactic responses of vascular SMC's to various 
stimuli provide further evidence of the importance that ECM may play in the control of 
vascular SMC behaviour that is associated with the pathogenesis of early atherosclerotic and 
restenotic lesion progression.
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Chapter .2. (Section VHP. 
Phenotypic characterisation of SMC's
cultured on different ECM substrates.
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VIII. 1 Introduction - Markers of SMC phenotype.
The transformation of vascular SMC's from a contractile to a synthetic phenotype that 
is associated with atherosclerotic or restenotic lesion development in vivo and also during the 
isolation of SMC's in vitro, is accompanied by alterations in the expression patterns of a 
number of proteins. Proteins for which expression is exclusive to a specific SMC phenotypic 
state are often referred to as SMC phenotypic markers. Many of the SMC phenotypic 
markers identified to date include cytoskeletal and ECM proteins. Such proteins are thought 
to play an integral role in the contractile and synthetic functions of SMC's and therefore are 
logical candidates for markers of contractile and synthetic SMC phenotypes.
The identification and subsequent analysis of these SMC phenotypic markers, 
provides a useful tool for studying the mechanisms that regulate SMC phenotypic modulation 
in vitro and in vivo. These markers may also prove useful for diagnostic and therapeutic 
purposes.
A number of SMC phenotypic markers have been described in the literature. The 
assignment of many of these markers to a synthetic or a contractile phenotype is somewhat 
controversial. This controversy arises fi'om the identification of many of these phenotype 
markers through the use of poorly defined in vivo and in vitro models of SMC phenotypic 
modulation, as well as from the comparison of protein expression levels between neonatal 
and adult vascular tissue samples from disparate animal species. The reliability of these 
models to mimic the differences between the contractile and synthetic SMC phenotypic states 
that are associated with restenosis and atherogenesis have not been firmly established.
However, in association with the transformation from a contractile to a synthetic 
phenotype, the following "contractile phenotypic markers" are thought to decrease; SM -a 
actin (Owens et al 1986; Liau et al 1990); SM myosin heavy chains (Aikawa e fa / 1988; 
Kuro-o et al 1991); a-SM tropomyosin (Muthuchamy et al 1993); Desmin (Kocher et al
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1986; Osbom et al 1987); Meta-vinculin (Glukhova et al 1986; Meyer et al 1994) Calponin 
(Dunband et al 1993); SM22a (Shanahan et al 1993) and Heavy chain caldesmon (Glukhova 
et al 1986; Ueki et al 1987).
The following "synthetic phenotypic markers" have been observed to increase upon 
the transition into the synthetic phenotype; Cytokeratin 8 (Jahn e ta l 1988); Collagen's, 1, 111, 
IV, V (Ang et al 1990; Hanson & Bentley 1983; Shekonin et al 1987); Fibronectin (Shekonin 
et al 1987; Banters et al 1995); Osteopontin (Giachelli et al 1992); Caldesmon light chain 
(Glukhova et al 1986; Ueki et al 1986); Non-muscle myosin (Aikawa et al 1987) and Non­
muscle p actin (Owens et al 1986).
A key to understanding the mechanisms that control SMC phenotypic modulation lie 
in the identification of the environmental signals and factors that govern the differentiated 
SMC phenotypic state. Inflammatory macrophages and injured endothelial cells found within 
atherosclerotic and restenotic lesions synthesize and release a large number of biologically 
active molecules including; growth factors, cytokines, proteolytic enzymes, prostaglandins 
and leukotrienes. Many of these substances have been proposed to play a role in the 
induction of SMC phenotypic modulation (Sjolund et al 1984; Palmberg et al 1989; 
Holycross et al 1992; Liptay et al 1993; Morisaka et al 1993; Majack 1987). It has been well 
established that the ECM within lesions has profound effects on SMC behaviour, including 
SMC migration and proliferation, and undoubtedly also plays a key role in the control of 
SMC phenotype. Indeed a number of in vitro studies that have been carried out mostly on rat 
SMC's, demonstrate that ECM molecules can regulate the SMC phenotypic modulation 
processes taking place in vitro (Hedin et al 1988; Li et al 1994). It has also been recently 
proposed that culturing human SMC’s in the reconstituted basement membrane matrix 
preparation Matrigel (Becton Dickinson) supplemented with serum free SMC differentiation 
medium (Becton Dickinson) encourages the transition into a contractile phenotype 
(Grushkin-Lerner and Flaherty 1995).
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In order to investigate further the role that ECM molecules have on the modulation of 
human SMC phenotype in vitro, monoclonal antibodies specific for previously identified and 
potential SMC phenotypic markers were utilised to carry out immunoblotting and 
immunocytochemical analysis of FW human adult aorta SMC’s (gift from Dr C Kielty 
University of Manchester) and HUASMC’s cultured on various matrix substrates. Protein 
samples were also obtained from the original umbilical artery tissue from where HUASMC’s 
were isolated from and also from normal human sapheneous vein and aorta tissue. These 
normal tissue protein samples provide a positive control for the SMC contractile markers and 
a negative control for synthetic markers.
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To ensure relatively equal protein loading between samples run on different tracks of 
a polyacrylamide gel, total protein was stained on duplicates of SDS-polyacrylamide gels that 
were used for immunoblotting. Protein staining was carried out using Coomassie blue fixitive 
stain as described in the Materials and Methods section VI. 10. Relative protein loading 
between samples was assessed by observation. Sample loading was adjusted on subsequent 
gels to provide approximately equal loading between samples. Loading adjusted Coomassie 
stained gels containing separated protein samples obtained from normal vascular tissue and 
HUASMC’s cultured on various matrix substrates are represented in (FIG s;V in .l. &
v m .2.)
(FIG.VIII.1.)-
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—26
(FIG .V m  i.)  Coomassie blue stained gel of separated protein samples obtained from 
human SMC’s or tissue; Lanes; 1- Umbilical artery 16 tissue, 2- HU A16 SMC ’ s-cultured, on 
plastic. 3- on collagen I; 4-on collagen III, 5- on collagen IV; 6 on vitronectin 7- in Matrigel. 
8- Aorta tissue. 9- Sapheneous vein tissue.
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(FIG.VIII.2.).
1 2  3 4
(FIG.Vin.2.) Coomassie blue stained gel of separated protein samples isolated from 
human SMC’s or tissue; Lanes; 1- Umbilical artery tissue. 2- HUASMC’s cultured on; 
plastic; 3- on plasma fibronectin and 4-on cellular fibronectin.
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Protein samples subjected to SDS-PAGE were transferred to nitro-cellulose membranes. 
Nitro-cellulose membranes were probed with monoclonal antibodies specific for various SMC 
phenotypic marker proteins. Photographs of the autoradiographs obtained from these 
immunoblots are represented in (riGs;VIII.3-VIII.20). Immunoblotting studies demonstrate 
that for most of the marker proteins studied no significant alterations in their levels can be 
observed between SMC’s isolated in culture and growing on different matrix substrates. Slight 
alterations in the levels of meta-vinculin protein were observed with upregulation of the protein 
on plasma and cellular fibronectin relative to SMC’s cultured on the other matrix substrates 
(FIG. VIII.21 & VIII.22). Also the 210Kd isoform of |MLCK was found to be upregulated on 
cellular fibronectin, collagen III and vitronectin (FIG.VIII.17 & VIII.18). Significant 
differences in the levels of synthetic and contractile marker can be observed between tissue 
samples and samples from SMC’s isolated in culture.
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(FIG .VIII .3 .) .
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(FIG.VIIL4.).
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SM -a Actin. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s 
cultured on various matrix substrates and also from human vascular tissue samples. 
Immunoblots were performed with a monoclonal anti-SM-a Actin antibody (Sigma);
(FIG.VIII.3.), Lanes; 1- Umbilical artery 16 tissue; 2- HU A 16SMC ’ s-cultured; on 
plastic. 3- on collagen I, 4-on collagen III, 5- on collagen IV; 6 on vitronectin 7- in Matrigel. 
8- Aorta tissue 9- Sapheneous vein tissue.
(FIG.VIII.4.) Lanes, 1- Umbilical artery tissue. 2- HUASMC’s cultured on; plastic;
3- on plasma fibronectin and 4-on cellular fibronectin.
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(FIG .VIII .5 .) .
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Desmin. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s cultured on 
various matrix substrates and also from human vascular tissue samples Immunoblots were 
performed with a monoclonal anti-Desmin antibody (Sigma),
(FIG.VIII.5.), Lanes, 1- Umbilical artery 16 tissue, 2- HUA16SMC’s-cultured, on 
plastic. 3- on collagen 1, 4-on collagen 111, 5- on collagen IV, 6 on vitronectin 7- in Matrigel 
8- Aorta tissue 9- Sapheneous vein tissue
(FIG .V III.6.) Lanes, 1- Umbilical artery tissue 2- HUASM C’s cultured on, plastic,
3- on plasma fibronectin and 4-on cellular fibronectin
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( F I G . V I I I . 7 . ) .
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I
(FIG.VIII.8.).
1 2  3 4
-#204Kd
SIM-Myosin. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s 
cultured on various matrix substrates and also from human vascular tissue samples 
Immunoblots were performed with a monoclonal anti-SM-Myosin antibody (Sigma),
(FIG.VIII.7.), Lanes, 1- Umbilical artery 16 tissue, 2- HUA16SMC’s-culturcd, on 
plastic. 3- on collagen I; 4-on collagen III, 5- on collagen IV, 6 on vitronectin and 7- in 
Matrigel. 8- Aorta tissue 9- Sapheneous vein tissue
(FIG .V III.8.) Lanes, 1- Umbilical artery tissue 2- HUASM C’s cultured on, plastic,
3- on plasma fibronectin and 4-on cellular fibronectin
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(FIG.Vm.9.).
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(FIG. VIII. 10.).
1 2  3 4
— 52Kd
Cytokeratin 8. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s 
cultured on various matrix substrates and also from human vascular tissue samples. 
Immunoblots were performed with a monoclonal anti-Cytokeratin 8 antibody (Sigma);
(FIG.VIII.9.), Lanes; 1- Umbilical artery 16 tissue, 2- HUA16SMC’s-cultured; on 
plastic. 3- on collagen I; 4-on collagen III; 5- on collagen IV; 6 on vitronectin 7- in Matrigel. 
8- Aorta tissue. 9- Sapheneous vein tissue.
(FIG.Vin.lO.); Lanes; 1- Umbilical artery tissue. 2- HUASMC’s cultured on; plastic;
3- on plasma fibronectin and 4-on cellular fibronectin.
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(FIG.VIII.il.).
1 2 3 4 5 6 7  8 9
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(FIG. VIII. 12.).
1 2  3 4
—  55Kd
P-Tubulin. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s cultured 
on various matrix substrates and also from human vascular tissue samples. Immunoblots were 
performed with a monoclonal anti-p-Tubulin antibody (Sigma);
(FIG.VIII.11.) Lanes, I- Umbilical artery 16 tissue; 2- HU A16 SMC ’ s-cultured ; on 
plastic. 3- on collagen I; 4-on collagen III; 5- on collagen IV; 6 on vitronectin 7- in Matrigel. 
8- Aorta tissue. 9- Sapheneous vein tissue.
(FIG.VIII. 12 ); Lanes; 1- Umbilical artery tissue. 2- HUASMC’s cultured on; plastic,
3- on plasma fibronectin and 4-on cellular fibronectin.
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(FIG. VIII. 13.).
1 2 3 4 5 6 7  8 9
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(FIG.VIII.I4).
1 2  3 4
-« 5 8 K d
Vimentin. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s cultured 
on various matrix substrates and also from human vascular tissue samples. Immunoblots were 
performed with a monoclonal anti-Vimentin antibody (Sigma);
(FIG.VIII. 13.), Lanes; 1- Umbilical artery 16 tissue; 2- HUA 16SMC’s-cultured, on 
plastic. 3- on collagen I; 4-on collagen III; 5- on collagen IV; 6 on vitronectin 7- in Matrigel. 
8- Aorta tissue. 9- Sapheneous vein tissue.
(FIG.VIII. 14 ); Lanes; 1- Umbilical artery tissue. 2- HUASMC’s cultured on; plastic,
3- on plasma fibronectin and 4-on cellular fibronectin.
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(FIG.VIIL15.).
1 2 3 4 5 6 7  8 9
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(FIG. VIII. 16.). 1 2  3 4
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— 7 2 K d
Caldesmon. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s 
cultured on various matrix substrates and also from human vascular tissue samples. 
Immunoblots were performed with a monoclonal anti caldesmon antibody (Sigma);
(FIG.VIII. 15 ); Lanes; 1- Umbilical artery 16 tissue; 2- HUA16SMC’s-cultured; on 
plastic. 3- on collagen I; 4-on collagen III; 5- on collagen IV; 6 on vitronectin 7- in Matrigel. 
8- Aorta tissue. 9- Sapheneous vein tissue.
(FIG.VIII. 16.); Lanes, 1- Umbilical artery tissue. 2- HUASMC’s cultured on; plastic;
3- on plasma fibronectin and 4-on cellular fibronectin.
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(FIG .VIII .17 .) .
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(FIG.VIII.18.).
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Myosin Light Chain Kinase. SDS-PAGE analysis of total protein extracts isolated from 
HUASMC’s cultured on various matrix substrates and also from human vascular tissue 
samples. Immunoblots were performed with a monoclonal anti-Myosin Light Chain Kinase 
antibody (Sigma);
(FIG.VIII.17.); Lanes; 1- Umbilical artery 16 tissue; 2- HU A 16SMC ’ s-cultured; on 
plastic. 3- on collagen I; 4-on collagen III; 5- on collagen IV; 6 on vitronectin 7- in Matrigel. 
8- Aorta tissue. 9- Sapheneous vein tissue.
(FIG.VIII.18.); Lanes; 1- Umbilical artery tissue. 2- HUASMC’s cultured on; plastic,
3- on plasma fibronectin and 4-on cellular fibronectin.
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(FIG .VIII .19 .) .
1 2 3 4 5 6 7  8 9
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(FIG.VIII.20.).
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Tropomyosin. SDS-PAGE analysis of total protein extracts isolated from HUASMC’s 
cultured on various matrix substrates and also from human vascular tissue samples. 
Immunoblots were performed with a monoclonal anti-tropomyosin antibody (Sigma);
(FIG.VIII.19.); Lanes; 1- Umbilical artery 16 tissue, 2- HU A 16SMC ’ s-cultured; on 
plastic. 3- on collagen I, 4-on collagen III, 5- on collagen IV, 6 on vitronectin and 7- in 
Matrigel. 8-Aorta tissue. 9- Sapheneous vein tissue.
(FIG.VIII.20.) Lanes; 1- Umbilical artery tissue. 2- HUASMC’s cultured on; plastic;
3- on plasma fibronectin and 4-on cellular fibronectin
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(FIG.VIII.2I.).
1 2 3 4 5 6 7  8 9
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(FIG.VIII.22.).
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■ i  ^  130Kd
Vinculin/Meta-vinculin. SDS-PAGE analysis of total protein extracts isolated from 
HUASMC’s cultured on various matrix substrates and also from human vascular tissue 
samples. Immunoblots were performed with a monoclonal anti-Vinculin/Meta-vinculin 
antibody (Sigma),
(FIG .V ni.21.) Lanes, 1- Umbilical artery 16 tissue, 2- HUA16SMC’s-cultured, on 
plastic. 3- on collagen I, 4-on collagen III, 5- on collagen IV, 6 on vitronectin and 7- in 
Matrigel 8-Aorta tissue 9- Sapheneous vein tissue
(FIG .VIII.22.), Lanes, 1- Umbilical artery tissue 2- HUASM C’s cultured on, plastic,
3- on plasma fibronectin and 4-on cellular fibronectin
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A summary of the analysis of SMC phenotypic marker protein expression between 
HUASMC’s cultured on various matrix substrates and also investigation into the expression 
levels of these proteins in normal human vascular tissue samples is represented in (Table
v m .i.)
The intensity of bands on immunoblots was scored as follows;
+ + + - H -  -Highly expressed.
++++ -Well expressed.
+++ -Moderately expressed.
++ -low level expression.
+ -Very low level expression.
-No detectable expression.
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Protein samples were obtained from HUASMC’s and also from FW human aorta 
SMC’s that were cultured in Matrigel and SMC “differentiation medium” (Becton 
Dickinson). These culture conditions are marketed by Becton Dickinson as a procedure for 
gradually promoting conversion of cultured rat and human aorta SMC’s into the contractile 
phenotype. Protein was extracted from HUASMC’s and FWSMC’s cultured on fibronectin 
coated flasks (Falcon) supplemented with H:W 16%FCS as a control for the synthetic 
phenotype. Protein was also extracted from the same cell types at sequential time points (24; 
72; 144, 216; 312 hours) following seeding in Matrigel and growth in “differentiation 
medium”. These protein samples were also immunoblotted and probed with antibodies 
specific for various SMC phenotype marker proteins.(FIGs; VTII.25-.36.). Protein loading 
between different HUASMC samples and FW aorta SMC samples was indicated by 
Coomassie blue stained SDS-PAGE gels (FIGs; Vin.23 & Vm.24.)
(FIG.VIII.23.).
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(FIG.Vin.23.). Coomassie blue stained gel of separated protein samples isolated from 
human SMC’s or tissue. Lanes; 1- Umbilical artery 16 tissue, 2- HUA16SMC’s cultured on 
plasma fibronectin; 3- Matrigel (24hrs), 4- Matrigel (72hrs), 5- Matrigel (144hrs), 6- 
Matrigel (216hrs),7.-Matrigel (312hrs).
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(FIG.VIII.24.).
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(FIG.VTn.24.). Coomassie blue stained gel of separated protein samples isolated from 
human SMC’s or tissue; Lanes; 1- aorta tissue, 2- FW aorta SMC’s cultured on plasma 
fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs), 6- Matrigel 
(216hrs),7.-Matrigel (312hrs).
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(FIG.VIII.25.).
1 2  3 4
4ÛKd
SM -a Actin. SDS-PAGE analysis of HUASMC’s cultured in Matrigel supplemented with 
differentiation medium (Becton Dickinson). Total protein extracts were isolated from 
HUASMC’s at sequential time points following seeding in Matrigel. Immunoblots were 
performed with monoclonal anti-SM-a actin antibody (Sigma).
(FIG .VIII.25.); Lanes; I- Umbilical artery 16 tissue; 2- HUA16SM C’s cultured on
plasma fibronectin, 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs); 6-
Matrigel (216hrs);7.-Matrigel (312hrs).
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(FIG.Vni.26.).
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-^4 0 K d
SM -a Actin. SDS-PAGE analysis of FW aorta SMC’s cultured in Matrigel supplemented 
with differentiation medium (Becton Dickinson). Total protein extracts were isolated from 
FW SMC’s at sequential time points following seeding in Matrigel. Immunoblots were 
performed with monoclonal anti-SM-a actin antibody (Sigma).
(FIG .VIII.26.); Lanes; 1- Human aorta tissue; 2- HUA16SM C’s cultured on plasma
fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel ( 144hrs); 6- Matrigel
(216hrs);7.-Matrigel (312hrs).
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(FIG.VIIL27.).
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SM-Myosin. SDS-PAGE analysis of HUASMC’s cultured in Matrigel supplemented with 
differentiation medium (Becton Dickinson). Total protein extracts were isolated from 
HUASMC’s at sequential time points following seeding in Matrigel. Immunoblots were 
performed with monoclonal anti-SM myosin antibody (Sigma).
(FIG.Vm.27.); Lanes; 1- Umbilical artery 16 tissue; 2- HUAlôSMC’s cultured on
plasma fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs); 6-
Matrigel (216hrs);7.-Matrigel (312hrs).
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SM-Myosin. SDS-PAGE analysis of FW aorta SMC’s cultured in Matrigel supplemented 
with differentiation medium (Becton Dickinson). Total protein extracts were isolated from 
FW SMC’s at sequential time points following seeding in Matrigel. Immunoblots were 
performed with monoclonal anti-SM myosin antibody (Sigma).
(FIG .VIII.28.); Lanes; 1- Human aorta tissue; 2- H U A lôSM C ’s cultured on plasma
fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs); 6- Matrigel
(216hrs);7.-Matrigel (312hrs).
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(FIG .Vin.29.).
-^ S z K d
Des min. SDS-PAGE analysis of HUASMC’s cultured in Matrigel supplemented with 
differentiation medium (Becton Dickinson). Total protein extracts were isolated from 
HUASMC’s at sequential time points following seeding in Matrigel. Immunoblots were 
performed with monoclonal anti-Desmin antibody (Sigma).
(FIG .V II.29.); Lanes; 1- Umbilical artery 16 tissue; 2- H U A lôSM C ’s cultured on
plasma fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs); 6-
Matrigel (21 ôhrs);7.-Matrigel (312hrs).
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(FIG.VII1.30.).
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Desmin. SDS-PAGE analysis of FW aorta SMC’s cultured in Matrigel supplemented with 
differentiation medium (Becton Dickinson). Total protein extracts were isolated from FW 
SMC’s at sequential time points following seeding in Matrigel. Immunoblots were performed 
with monoclonal anti-Desmin antibody (Sigma).
(FIG.VIII.30.); Lanes; 1- Human aorta tissue; 2- HUAlôSMC’s cultured on plasma 
fibronectin, 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs); 6- Matrigel 
(216hrs),7.-Matrigel (312hrs).
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(FIG.VIIL31.).
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Myosin Light Chain Kinase. SDS-PAGE analysis of HUASMC’s cultured in Matrigel 
supplemented with differentiation medium (Becton Dickinson) Total protein extracts were 
isolated from HUASMC’s at sequential time points following seeding in Matrigel 
Immunoblots were performed with monoclonal anti-MLCK antibody (Sigma)
(FIG .V III.31.), Lanes, 1- Umbilical artery 16 tissue, 2- H U A lôSM C ’s cultured on
plasma fibronectin, 3- Matrigel (24hrs), 4- Matrigel (72hrs), 5- Matrigel (144hrs), 6-
Matrigel (216hrs),7.-Matrigel (312hrs)
164
(FIG.VIIL32.).
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Myosin Light Chain Kinase. SDS-PAGE analysis o f FW aorta SMC’s cultured in Matrigel 
supplemented with differentiation medium (Becton Dickinson). Total protein extracts were 
isolated from FW SMC’s at sequential time points following seeding in Matrigel. 
Immunoblots were performed with monoclonal anti-MLCK antibody (Sigma).
(FIG .V III.32.); Lanes; 1- Human aorta tissue; 2- H U A lôSM C ’s cultured on plasma
fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (I44hrs); 6- Matrigel
;21ôhrs);7.-Matrigel (312hrs).
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(FIG.Vm.33).
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VincuIin/M eta-Vinculin. SDS-PAGE analysis of HUASMC’s cultured in Matrigel 
supplemented with differentiation medium (Becton Dickinson). Total protein extracts were 
isolated from HUASMC’s at sequential time points following seeding in Matrigel 
Immunoblots were performed with monoclonal anti-Vinculin/Meta-vinculin antibody
(Sigma).
(FIG.Vm.33.); Lanes; 1- Umbilical artery 16 tissue, 2- HUAlôSMC’s cultured on 
plasma fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs), 6- 
Matrigel (21ôhrs);7.-Matrigel (312hrs).
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(FIG.VIII.34.).
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Vinculin/M eta-Vinculin. SDS-PAGE analysis of FW aorta SMC’s cultured in Matrigel 
supplemented with differentiation medium (Becton Dickinson). Total protein extracts were 
isolated from FW SMC’s at sequential time points following seeding in Matrigel 
Immunoblots were performed with monoclonal anti-Vinculin/Meta-vinculin antibody 
(Sigma).
(FIG .V III.34.), Lanes; 1- Human aorta tissue, 2- H U A lôSM C ’s cultured on plasma
fibronectin, 3- Matrigel (24hrs), 4- Matrigel (72hrs), 5- Matrigel (144hrs), 6- Matrigel
(216hrs);7.-Matrigel (312hrs).
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(FIG.Vm.35).
1 2 3 4 5 6
Vimentin. SDS-PAGE analysis of HUASMC’s cultured in Matrigel supplemented with 
differentiation medium (Becton Dickinson). Total protein extracts were isolated from 
HUASMC’s at sequential time points following seeding in Matrigel. Immunoblots were 
performed with monoclonal anti-Vimentin antibody (Sigma).
(FIG.VIII.35.); Lanes; 1- Umbilical artery 16 tissue; 2- H U A lôSM C ’s cultured on
plasma fibronectin; 3- Matrigel (24hrs), 4- Matrigel (72hrs); 5- Matrigel (144hrs); 6-
Matrigel (21ôhrs).
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(FIG.VIIL36.).
Vimentin: SDS-PAGE analysis of FW aorta SMC’s cultured in Matrigel supplemented with 
differentiation medium (Becton Dickinson). Total protein extracts were isolated from FW 
SMC’s at sequential time points following seeding in Matrigel. Immunoblots were performed 
with monoclonal anti-Vimentin antibody (Sigma).
(FIG.VIII.36.): Lanes; 1- Human aorta tissue; 2- H U A lôSM C ’s cultured on plasma
fibronectin; 3- Matrigel (24hrs); 4- Matrigel (72hrs); 5- Matrigel (144hrs); 6- Matrigel
(21ôhrs).
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The relative levels of tropomyosin isoforms was analysed in protein samples obtained 
from cultured rat aortic SMC’s, intimai, and medial layers of balloon injured (right) and 
normal (left) rat carotid tissue.
(VIIL37.).
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(FIG.VIII.36.): Lanes; 1- Right media; 2- Left media; 3- Right media + intima; 4- 
Left media; 5- Right media; 6- Right intima; 7.-Rat aortic SMC’s cultured on fibronectin; 8 
Rat aortic SMC’s cultured on plastic.
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Immunofluorescent characterisation of HUASMC’s cultured on uncoated and plasma 
fibronectin coated surfaces was performed using SMC phenotype marker specific antibodies. 
This immunostaining was carried out to assess whether any alterations in the distribution of 
these protein markers could be associated with either a distinct nodular or monolayer growth 
morphology such as that exemplified by SMC’s cultured on fibronectin coated and uncoated 
surfaces respectively. Immunofluorescent antibody staining of SMC’s cultured on both 
substrates using those antibodies that resulted in clear staining patterns together with 
comparative phase photomicrographs at the same magnification on same field (x 400 
magnification) are represented in (FIGs; VII.38-.59). Immunofluorescent staining patterns 
obtained with the majority of monoclonal antibodies were not significantly different between 
SMC’s cultured on plastic with SMC’s cultured on plasma fibronectin, with the exception of 
MLCK which appears to have a higher degree of association with stress fibres in SMC’s 
cultured on fibronectin (FIG’s; VIII.46 & VIII.47). Immunofluorescent staining with the 
caldesmon antibody localised to the cell nucleus and appears to be upregulated in SMC’s 
cultured on fibronectin (FIG’s; VIII.56 & VIII.57) This nuclear localisation was somewhat 
suprising and may reflect non specific binding of the caldesmon antibody as previously 
indicated by the observation of numerous bands on the caldesmon probed immunoblot 
(FIG.VIII.15).
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(FIG.Vm.38a) (FIG.VIII.39a)
yfi
M M
(FIG.VIII.38b) (FIG.Vm.39b)
SM a-Actin. Phase contrast photomicrographs and immunofluorescent staining patterns of 
HUASMC’s cultured on plastic (FIG.Vin.38 a & b.) and also on plasma fibronectin 
(FIG.Vin.39 a & b.) were obtained using FITC conjugated second antibody specific for a 
monoclonal anti-SM a-actin antibody.
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(FIG.VIIL40a) (FIG.VIII.41a)
i
(FIG.VIII.40b) (FIG.VIII.41b)
Vimentin. Phase contrast photomicrographs and immunofluorescent staining patterns of 
HUASMC’s cultured on plastic (FIG.40 a & b.) and also on plasma flbronectin (FIG.41 a 
& b.) were obtained using FITC conjugated second antibody specific for a monoclonal anti- 
Vimentin antibody.
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(FIG.VIII.42a) (FIG.VIII43a)
(FIG.VIII.42b) (FIG.VIII.43b)
Vinculin/Meta-Vinculin. Phase contrast photomicrographs and immunofluorescent staining 
patterns of HUASMC’s cultured on plastic (FIG.Vin.42 a & b.) and also on plasma 
fibronectin (FIG.Vni.43 a & b.) were obtained using FITC conjugated second antibody 
specific for a monoclonal anti-Vinculin/Meta-vinculin antibody.
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(FIG.VIII.44a) (FIG.VIII.45a)
(FIG.Vm.44b) (FIG.VIII.45b)
Cytokeratin 8. Phase contrast photomicrographs and immunofluorescent staining patterns of 
HUASMC’s cultured on plastic (FIG.Vin.44 a & b.) and also on plasma fibronectin 
(FIG.Vin.45 a & b.) were obtained using FITC conjugated second antibody specific for a 
monoclonal anti-cytokeratin 8 antibody.
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(FIG.VIII.46a) (FIG.VIII.47a)
I
(FIG.VIII.46b) (FIG.VIII.47b).
Myosin Light Chain Kinase. Phase contrast photomicrographs and immunofluorescent 
staining patterns of HUASMC’s cultured on plastic (FIG.VHÏ.46 a & b.) and also on 
plasma fibronectin (FIG.Vni.47 a & b.) were obtained using FITC conjugated second 
antibody specific for a monoclonal anti-Myosin Light Chain Kinase antibody.
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(FIG.VIII.48a) (FIG.VIII.49a)
(FIG.VIII.48b) (FIG.VIII.49b)
Cellular Fibronectin. Phase contrast photomicrographs and immunofluorescent staining 
patterns of HUASMC’s cultured on plastic (FIG.Vin.48 a & b.) and also on plasma 
fibronectin (FIG.Vni.49 a & b.) were obtained using FITC conjugated second antibody 
specific for a monoclonal anti-Cellular Fibronectin antibody.
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(FIG.VIII.50a) (FIG.VIII.51a)
(FIG.VIII.50b) (FIG.VIII.51b)
Collagen I. Phase contrast photomicrographs and immunofluorescent staining patterns of 
HUASMC’s cultured on plastic (FIG.Vni.50 a & b.) and also on plasma flbronectin 
(FIG.Vni.51 a & b.) were obtained using FITC conjugated second antibody specific for a 
monoclonal anti-Collagen I antibody.
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(FIG.VIII.52a) (FIG.VIII.53a)
(FIG.VIII.52b) (FIG.VIII.53b)
Collagen IV Phase contrast photomicrographs and immunofluorescent staining patterns of 
HUASMC’s cultured on plastic (FIG.VIII.52 a & b.) and also on plasma fibronectin 
(FIG.Vni.53 a & b.) were obtained using FITC conjugated second antibody specific for a 
monoclonal anti-Collagen IV antibody.
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(FIG.VIII.54a) (FIG.VIII.55a)
(FIG.VIII.54b) (FIG.VIII.55b)
Thrombospondin. Phase contrast photomicrographs and immunofluorescent staining 
patterns of HUASMC’s cultured on plastic (FIG.Vni.54 a & b.) and also on plasma 
fibronectin (FIG.Vni.55 a & b.) were obtained using FITC conjugated second antibody 
specific for a monoclonal anti-Thrombospondin antibody.
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(riG.Vm.56a) (FIG.Vm.57a)
(FIG.VIII.56b) (FIG.VIII.57b)
Caldesmon. Phase contrast photomicrographs and immunofluorescent staining patterns of 
HUASMC’s cultured on plastic (FIG.VHI.56 a & b.) and also on plasma fibronectin 
(FIG.Vni.57 a & b.) were obtained using FITC conjugated second antibody specific for a 
monoclonal anti-Caldesmon antibody.
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(FIG.Vm.58a) (FIG.VIII.59a)
(FIG.VIII.58b) (FIG.VIII.59b)
Tropomyosin. Phase contrast photomicrographs and immunofluorescent staining patterns of 
HUASMC’s cultured on plastic (FIG.Vin.58 a & b.) and also on plasma fibronectin 
(FIG.Vni.59 a & b.) were obtained using FITC conjugated second antibody specific for a 
monoclonal anti Tropomyosin antibody.
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Chapter 2. Results - Summary;
Immunoblotting of protein samples obtained from HUASMC’s cultured on different 
matrix substrates using antibodies specific for SMC phenotypic marker proteins, basically 
confirms that all SMC’s in culture, irrespective of what type of matrix they are cultured on 
represent the de-differentiated synthetic phenotype. Well established synthetic markers such 
as cytokeratin 8  and light chain caldesmon are expressed in the cultured cells but are absent 
or only present at very low levels in normal tissue samples. Conversely, well known 
contractile markers such as Desmin and SM-myosin are absent in the cultured cells but well 
expressed in the tissue. This analysis also seems to indicate that the phenotypic status of 
cultured HUASMC’s is not drastically altered by ECM as determined by the phenotypic 
markers analysed in this study, since only slight differences in the protein levels of meta- 
vinculin and the 210Kd isoform of MUCK were observed. Meta-vinculin appears to be 
upregulated on fibronectin substrates and the 210Kd isoform of MLCK was upregulated in 
SMC’s cultured on cellular fibronectin, collagen III, and vitronectin substrates.
Interesting results to arise from this marker analysis were the identification of a 30Kd 
low molecular weight isoform of tropomyosin and a 210Kd isoform of MLCK as potential 
markers for synthetic SMC’s. The 30kd isoform of tropomyosin was well expressed in all 
cultured HUASMC samples but totally absent in all three tissue preparations. Also MLCK 
210Kd isoform was present at high levels in all cultured HUASMC samples but at 
significantly lower levels in tissue samples.
Further characterisation of tropmyosin isoforms demonstrated that a low molecular 
weight isoform of tropomyosin was expressed exclusively in cultured rat vascular SMC’s 
and balloon injured rat carotid tissue, but was absent in normal rat carotid tissue.
Immunoblotting with the SMC phenotype marker specific antibodies on protein 
samples obtained from FW aorta and HUA SMC samples that were cultured in differentiation
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medium and Matrigel supplied by Becton Dickinson did not reveal any transition from a 
synthetic to a contractile phenotype. The expression of SMC contractile markers; Desmin 
and SM myosin heavy chain were not induced by culture in Matrigel.
SMC growth in Matrigel did induce down-regulation in the expression of MLCK 
isoforms, vinculin, and meta-vinculin.This evidence suggests that culturing HUASMC’s and 
FW aorta SMC’s in Matrigel supplemented with differentiation medium induces phenotypic 
alterations. These alterations in phenotype do not however, appear to correlate with a clear 
transition from a synthetic to a contractile phenotype.
Immunofluorescent studies carried out on HUASMC’s cultured on uncoated and 
plasma fibronectin coated tissue culture surfaces revealed no clear differences between these 
two populations in either the levels or distribution of phenotype marker proteins; SM-a 
Actin; Vimentin; Cytokeratin 8 ; Vinculin; Fibronectin; Collagen I; Collagen IV; 
Thrombospondin and Tropomyosin. The association of Myosin light Chain Kinase (MLCK) 
antibody staining with fibrils did appear to be slightly upregulated in HUASMC’s cultured on 
fibronectin. Also antibody staining to caldesmon was of greater intensity in HUASMC’s 
cultured on plasma fibronectin.
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(Section IX)
Differential display analysis of SMC’s 
cultured on fibronectin compared with
plastic.
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IX. 1 Introduction - Differential display technique.
The differential display technique was first presented by Liang and Pardee in 1992. 
They described differential display as a method for the isolation of individual messenger 
RNAs (mRNAs) that are differentially expressed between various cell populations or upon 
altered conditions (Liang and Pardee 1992).
Differentially expressed mRNA species are identified by differential display by means 
of the polymerase chain reaction (PCR). The basic principle of the procedure is to 
systematically amplify up mRNA from separate populations by reverse transcriptase - PCR 
using a set of 3 ’ anchored degenerate primers to drive the reverse transcriptase reaction. 
These anchored primers are then used in combination with a selection of rationally designed 
arbitrary primers for PCR amplification. A radioactive nucleotide is included in the PCR step 
so that amplified products can be run side by side on a sequencing gel and visualised by 
autoradiography. Bands from the gel that appear differentially expressed between populations 
can be cut out of the gel, cloned and sequenced and also used as a probe to confirm 
differential gene expression by northern blotting or to obtain full length sequence by 
screening a cDNA library, (see methods section VI. 16.).
Differential display has the advantage over existing methods for the identification of 
differentially expressed genes such as subtractive hybridisation, in that it is simpler and faster 
to carry out, provides increased sensitivity and requires very little RNA (2|iig per population) 
as starting material for the initial identification of potential differentially expressed products.
In order to further investigate the influence that SMC adhesion to ECM has on cell 
phenotype, differential display analysis was applied to RNA samples extracted from 
HUASMC’s cultured on fibronectin and plastic. HUASMC’s cultured on fibronectin and 
plastic were selected for comparison, not only because of the clear morphological and
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functional differences observed between these two populations that are indicative of an 
alteration in phenotype {Chp, 1 Results Section VII), but also because large quantities of RNA 
can be obtained from SMC’s cultured on these two substrates. Such large quantities of RNA are 
essential for subsequent northern blot analysis that is required to confirm differential display 
results.
Differential display analysis was undertaken with the aim of identifying SMC genes 
whose expression levels were modulated by adhesion to fibronectin in vitro. The identification 
of fibronectin modulated genes will help elucidate poorly understood downstream molecular 
events induced by ECM adhesion as well as the role fibronectin has in modulating SMC 
phenotype. Also subsequent investigation into whether any of these in vitro differentially 
expressed genes are also differentially expressed in vivo between contractile SMC’s localised in 
normal vascular tissue with synthetic SMC’s within lesions as indicated by in situ hybridisation 
studies, will help evaluate the in vitro model by confirming whether any of the in vitro 
differentially expressed genes represent markers of either a contractile or a synthetic phenotype.
At the time when this analysis was first carried out one major disadvantage of the 
differential display technique was that it was so new and remained to be optimised to overcome 
serious limitations such as redundancy and under representation of certain mRNA species and 
also a high false positive hit rate (Liang et al 1994). The following results section outlines 
results obtained from differential display analysis of fibronectin and plastic modulated 
HUASMC’s (FIGs; IX.1-IX.5). Also described are the further optimisation and alterations to 
the procedure that were carried out during the course of these studies.
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Initial differential display experiments were performed on total mRNA samples from 
HUASMC’s cultured on uncoated and plasma fibronectin coated tissue culture plastic. RNA 
samples were isolated using the RNAzolB reagent and protocol (see methods VI. 15.) from 
HUASMC’s cultured on both substrates. Represented in (FIG. IX. 1.) is a preliminary 
differential display gel on which products from plastic and fibronectin modulated HUASMC’s 
amplified using the same arbitrary and anchored primer combinations were run in adjacent 
tracks. This differential display analysis was performed using the four 14 mer oligo dt anchored 
primers degenerate in the penultimate base; T12MT, TjjMA, TjjMG and T12MC in conjunction 
with five 10 mer arbitrary primers; A PI-5 that were supplied in the RNA map kit (Genhunter). 
Differential display PCR was carried out as recommended by Genhunter using ^^ S radiolabelled 
dATP (see methods VI. 16.). Thirteen differentially expressed products were selected from this 
gel for further analysis (FIG. IX .la,b,c& d.). Differential display gels were electrophoresed at a 
constant power of 60 mA for 3 hours resulting in the separation of amplified products ranging 
in size from a 1 OObp to 600bp.
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(FIG. IX .la.).
AP 5 4 3 2 1
T1 2 M GCATG CATG CAT GCAT GCAT
Pop PfPfPfPfPf PfPfPfpf Pf PfPf Pf PfPf Pf Pf PfPf Pf
*
4>
#
(FIG . IX .la .)  Differential display on fibronectin and plastic modulated HUASMC samples
using arbitrary primers AP 1-5 in combination with anchored oligo dt primers T 1 2 MA,
T 1 2 MC, T 1 2 MG and T 1 2 MT.
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(FIG.IX.lb.) .  (FIG.IX.lc.).
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IX. 1 b,c & d.) Higher magnification o f  differential display performed with primers,
T 1 2 MA, C; G and A in conjunction with primers A PI-8. Differentially expressed bands are
indicated by arrows ( —► ).
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The thirteen differentially expressed bands identified were cut out of the gel 
reamplified by PCR, using the relevant primer pairs, gel purified and sequenced manually or 
on an ABI automated sequencer (Advanced Biotechnology Centre - Charing Cross) (see 
methods VI. 16.) Table IX. 1 lists the results of homology searches of the differential display 
sequences with genes submitted to the Genbank/EMBL gene database.
(Table. IX.l.).
CLONE NO. SAMPLE PRIMER
COMBINATION
PRODUCT
SIZE
DATABASE
SEARCH
7.1 Fibronectin API/T12MG lOObp Novel
7.2 Fibronectin API/T12MG lOObp Novel
19.1 Fibronectin AP3/T12MA 600bp Novel
19.2 Fibronectin AP3/T12MA 400bp Novel
31.1 Fibronectin AP4/T12MG 330bp Novel
31.2 Fibronectin AP4/T12MG 200bp ALU region
31.4 Fibronectin AP4/T12MG 150bp Novel
32.1 Plastic AP4/T12MG 220bp Novel
32.2 Plastic AP4/T12MG 120bp Novel
32.3 Plastic AP4/T12MG 120bp Novel
32.4 Plastic AP4/T12MG llObp Novel
40.1 Plastic AP5/T12MG 320bp ALU region
40.4 Plastic AP5/T12MG 300bp ADP/ATP
translocase
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The identification of a large number of novel sequences and sequences rich in alu 
repetitive regions indicated that amplification of contaminating genomic DNA present within 
the RNA samples under study may have taken place. To reduce the possibility of amplifying 
contaminating genomic DNA which may contribute to the selection of false positives, all 
subsequent differential display studies were performed on DNAse treated RNA samples. Also 
to further reduce the possibility of selecting false positives each PCR primer combination 
amplification reaction was carried out in duplicate. Only those bands that were reproducibly 
differentially expressed between populations were selected for further analysis.
Subsequent differential display amplification reactions were performed using three 
17mer one base anchored oligo dt primers; H-TnG, H-TnC and H-TnA in conjunction with 
rationally designed 13 mer arbitrary primers supplied in the RNAimage kit (Genhunter). The 
use of three one base anchored oligo dt primers cuts down the number of reverse 
transcription reactions needed for each RNA sample, and also minimises the redundancy and 
under-representation of certain RNA species due to the degeneracy of the primers. The 
introduction of a restriction site at the 5’ ends on both the anchored and arbitrary primers 
makes the primers longer and more efficient in cDNA amplification while allowing the cloned 
cDNA to be more readily manipulated (Liang et al 1994). Also ^^ P dATP was used as label 
for differential display PCR. ^^ P was found to be a better alternative to labelled 
nucleotides which can undergo a high rate of decomposition when exposed to the high 
temperatures used in the PCR reaction often resulting in release of labelled gas and 
subsequent contamination of PCR blocks (Trentmann et al 1995).
(Fig.IX.2a,b,c). Represents a differential display gel performed using DNAse treated 
RNA samples amplified with the newly developed primers. Amplification reactions were 
performed in duplicate. Eight clear differentially expressed bands were identified between 
fibronectin and plastic modulated HUASMC populations.
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(FIG.IX.2a.).
A C G A C G A C G 
fp fp  f p f p  f P f p f P f P f P
(FIG. lX.2a.) Diflferential display on fibronectin and plastic modulated HUASMC samples
using arbitrary primers H AP 5-7 in combination ssith anchored oligo dt primers II-1 .,C. H
Ti;C and H -TnA
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(FIG. IX.2b.) (FIG. IX.2C.)
6  6 7
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F P F P  F P  F P
(FIG . IX.2 b. & c.) Higher magnification o f  differential display performed with primers; H-
TiiC; G and A  in conjunction with primers AP5-7. Differentially expressed bands are
indicated by arrows ( ~ ^  ).
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(FIG. IX.2d.).
5
G
F P
(FIG. IX .2d.). Higher magnification o f  differential display performed with primers. H-1 nC
G and .A in conjunction with primers AP5-7. Differentially expressed bands are indicated bv
arrows( )
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In order to obtain an estimate of the number of PCR artefacts amplified by each 
primer combination used for differential display, the number of bands differing between 
identical duplicate reactions were counted. These results are presented in (Table IX.2). 
Table. IX.2. Number of different DNA bands amplified between identical differential 
display PCR amplification reactions, from gel presented in (FIG.IX.2a.).
RNA SAMPLE NO. OF DIFFERENCES
H-AP5/H-TiiA Fibronectin 4
H-AP5/H-TiiA Plastic 5
H-AP5/H-TiiC Fibronectin 6
H-AP5/H-TiiC Plastic 3
H-AP5/H-TiiG Fibronectin 28
H-AP5/H-TiiG Plastic 27
H-AP6 /H-T11A Fibronectin 4
H-AP6 /H-T11A Plastic 5
H-AP6 /H-T11C Fibronectin 1 1
H-AP6 /H-T11C Plastic 14
H-AP6 /H-T11G Fibronectin -
H-AP6 /H-T11G Plastic 2 0
H-AP7/H-TiiA Fibronectin 13
H-AP7/H-TiiA Plastic 7
H-AP7/H-TiiC Fibronectin 2
H-AP7/H-TiiC Plastic 2
H-AP7/H-TiiG Fibronectin 25
H-AP7/H-TiiG Plastic 1 2
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From these values it seems that certain primer combinations, most notably H-AP5/H- 
TiiG, H-AP6 /H-T1 1G and H-AP7/H-TnG, result in the amplification of many PCR artefacts, 
whereas other combinations result in very few. The amplification of such a large number of 
PCR artefacts could lead to the mistaken selection of artefacts as differentially expressed 
genes, thereby further contributing to the high false positive selection rate. To reduce this 
possibility it was decided that future differential display PCR amplification reactions would be 
carried out in triplicate and only those differences reproduced in at least 2 out of 3 
corresponding pairs of PCR reactions would be selected for further analysis. Also only those 
differentially expressed bands greater in size than 150 base pairs were selected for further 
analysis to provide a greater rate of success during subsequent processing of the DNA such 
as reamplification and probe hybridisation reactions. (FIGs IX.3a,b,c,d; IX.4a,b,c & 
IX.5a,b).
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(FIG . IX.3a.).
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(FIG. IX .3a.) Differential display on fibronectin and plastic modulated HUASMC samples
using arbitrary primers H-AP 1 & 2 in combination with anchored oligo dt primers H-T,|G ,
H -T ,iC and H-TnA.
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(FIG.  IX.3b.).
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(FIG.IX.3c.).
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(FIG.IX.3d.).
2
(FIG . IX.3b,c&d.) Higher magnification o f differential display performed with primers; H-
TnC; G and A in conjunction with primers A P 1 &  2. Differentially expressed bands are
indicated by arrows ( “ ► )
199
(FIG.IX.4a. ) .
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(FIG. IX .4a.) Differential display on fibronectin and plastic modulated HUASMC samples
using arbitrary primers H-AP 3 & 4 in combination with anchored oligo dt primers H-TnG,
H-TnC and H-TnA.
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(FIG.IX.4b. ) .
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(FIG. IX.4b. & c.) Higher magnification o f  differential display performed with primers, H-
Tii C; G and A in conjunction with primers AP 3 & 4 Differentially expressed bands are
indicated by arrows ( ► ).
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(FIG. iX.5a.).
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(FIG . IX .5a.) Differential display on fibronectin and plastic modulated HUASM C samples
using arbitrary primer H-AP 8 in combination with anchored oligo dt primers H-Tn G, H-Ti
C and H -Tii A.
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(FIG.IX.5b.).
8
C
(FIG. IX.Sb.) Higher magnification of differential display performed with primers; H-Tn C; 
G and A in conjunction with primers AP 8 . Differentially expressed bands are indicated by 
arrows ( ^ ).
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From the differential display gels, (FIGs IX.2a, IX.3a, IX.4a & IX.Sa) carried out 
using the modified primers and reagents supplied in the RNAimage kit (Genhunter) 27 
differentially expressed bands were identified between plastic and fibronectin modulated 
HUASMC populations. 22 of these differential display fragments have been successfully 
cloned into the TA cloning vector and sequenced. Searches were carried out on the 
Genbank/EMBL gene database’s to identify any homology that exists between these 
sequences and known genes. As indicated in (TABLE IX.3) nine sequences were found to 
be homologous with known genes; the remaining thirteen did not reveal any significant 
homology and so may therefore represent novel genes. It is also possible that the preferential 
amplification by differential display of DNA fragments from the 3’end of genes, may result in 
the identification of sequences from known genes that have not been entered into the data 
base as a result of their extreme 3’ location.
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TABLE IX.3. Summary of data base search on sequences identified as differentially 
expressed between fibronectin and plastic modulated SMC populations.
CLONE. NO. SAMPLE
COMBINATION SIZE
DATA BASE 
^SEARCH .
A l.l Fibronectin H-AP5/H-TiiA 450bp 14 Iq JH
A3.1 Fibronectin H-AP5/H-TiiG ISObp Novel
A4.3 Fibronectin H-AP6 /H-T11G 2 0 0 bp Novel
A5.1 Plastic H-AP6 /H-T11G 2 0 0 bp Novel
A6.1 Plastic H-AP6 /H-T11G 325bp cSRP 72
B2.1 Fibronectin H-APl/H-TiiA 500bp I.R.R. protein
B3.6 Fibronectin H-APl/H-TiiA 450bp I-2-S’ase
B4.1 Plastic H-APl/H-TiiA 450bp Novel
B5.1 Plastic H-APl/H-TiiA 450bp Novel
B6.5 Fibronectin H-APl/H-TiiA 300bp Vinculin/meta-
vinculin
B7.1 Plastic H-AP2 /H-T11A 250bp Novel
B9.1 Fibronectin H-AP2 /H-T11G 140bp Novel
B10.2 Fibronectin H-AP2 /H-T11G 140bp Novel
C l.l Fibronectin H-APS/H-TiiA 250bp p54
C2.2 Plastic H-APS/H-TiiA 250bp Pentaxin 3
C3.1 Plastic H-APS/H-TiiA 225bp Pentaxin 3
C4.1 Plastic H-APS/H-TiiA 250bp PTPase
C5.1 Fibronectin H-AP3/H-TiiG 250bp Novel
C6.1 Plastic H-AP4/H-TiiA lOObp Novel
C7.1 Plastic H-AP4/H-TiiA lOObp Novel
C8.1 Plastic H-AP4/H-TiiC 225bp Novel
D2.2 Fibronectin H-AP8 /H-T11C 300bp Cyt p450
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As a result of the high number of false positives that are associated with differential 
display analysis it is important to confirm the differential expression of genes identified by 
differential display before studying them further. Confirmation of differential gene expression 
was carried out by screening northern blots containing RNA from HUASMC’s cultured on 
fibronectin and plastic (see methods Section VL16.). Northern blots were screened using 
CTP random primed labelled differentially expressed products as nucleic acid probes.
One important consideration that had to be taken into account before screening 
northerns was that differentially expressed bands cut out of a differential display gel may 
contain more than one product. Studies by Guimaraes et al 1995 and myself (results not shown) 
confirm this possibility does exist. Such a scenario may result in the amplification and 
sequencing of cDNA that may not necessarily represent the differentially expressed product 
observed on the gel. Thus using probes designed specifically to the sequenced differential 
display products listed in (Table IX.3) may result in additional false positives. To reduce the 
possibility of obtaining false positives on northerns as a result of using an incorrect probe, 
reamplified DNA from differentially expressed bands cut out of the differential display gel were 
random primed labelled with radioactive ^^ P CTP (see methods Section VI.). This method 
should allow labelling of all the products contained within a band.
Northern blots probed with random primed labelled differential display fragments that 
resulted in clear transcripts are represented in (FIGs IX.6-.14). These figures also reveal 
transcript signals obtained by screening the same northerns with a probe specific for 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH). The relative mRNA levels of the 
housekeeping gene GAPDH between fibronectin and plastic modulated HUASMC RNA 
samples provides an indication of loading between both samples that was used as a reference to 
estimate the relative mRNA levels of differential display products between HUASMC’s 
cultured on fibronectin and plastic. No significant differences in transcript levels were observed.
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(FIG.IX.6.)
C l. l
2-8
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1 *4
(FIG .IX .6 .) C l . l  (p54)/GAPDH probe. Northern blot analysis on RNA samples obtained 
from HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture plastic. 
This blot was probed with random primed labelled differential display product; Cl . l  
(originally found to be homologous with p54). and also a GAPDH probe.
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(FIG.IX.7.)
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(FIG.IX.7.) C2.2 (Pentaxin 3)/GAPDH probe. Northern blot analysis on RNA samples 
obtained from HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture 
plastic. This blot was probed with random primed labelled differential display product; C2.2 
(originally found to be homologous with pentaxin 3). and also a GAPDH probe.
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(FIG.IX.8.)
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(FIG.IX.8 .) C3.1 (Pentaxin 3)/GAPDH. Northern blot analysis on RNA samples obtained 
from HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture plastic. 
This blot was probed with random primed labelled differential display product; C3.1 ( also 
originally found to be homologous with pentaxin 3). and a GAPDH probe.
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(FIG.IX.9.)
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(FIG.IX.9.) B5.1/GAPDH probe. Northern blot analysis on RNA samples obtained from 
HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture plastic. This 
blot was probed with random primed labelled differential display product; B5.1 (originally 
found to have no homology with previously identified genes), and also a GAPDH probe.
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(FIG.IX.IO.)
C4.1
# 5 3
GAPDH
(FIG.IX.IO.) C4.1 (PTPase)/GAPDH. Northern blot analysis on RNA samples obtained 
from HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture plastic. 
This blot was probed with random primed labelled differential display product; C4.1 
(originally found to be homologous with phosphotyrosyl protein phosphatase), and also a 
GAPDH probe.
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(FIG.IX.11.)
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(FIG .IX .ll.) B7.1/GAPDH. Northern blot analysis on RNA samples obtained from 
HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture plastic. This 
blot was probed with random primed labelled differential display product; B7.1 (originally 
found to have no homology with previously identified genes), and also a GAPDH probe.
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(FIG.IX.12.)
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(FIG .IX .ll.) B3.1 (Iduronate-2-sulphatase). Northern blot analysis on RNA samples 
obtained from HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture 
plastic. This blot was probed with random primed labelled differential display product; B3.1 
(originally found to be homologous with Iduronate-2-sulphatase). and also a GAPDH probe.
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(FIG.IX.13.)
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(FIG.IX.13.) B4.1/GAPDH. Northern blot analysis on RNA samples obtained from 
HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture plastic. This 
blot was probed with random primed labelled differential display product; B4.1 (originally 
found to have no homology with previously identified genes), and also a GAPDH probe.
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(FIG.IX.14.)
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(FIG.IX.14.) C8.1/GAPDH. Northern blot analysis on RNA samples obtained from 
HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture plastic. This 
blot was probed with random primed labelled differential display product; C8.1 (originally 
found to have no homology with previously identified genes), and also a GAPDH probe.
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Differential display product B6.5 that was identified as being upregulated in 
fibronectin modulated HUASMC samples, failed to yield any transcript signal on a northern 
when used as a random primed labelled probe. B6.5 was found to be homologous to either 
vinculin or the meta-vinculin genes. Meta-vinculin is an alternatively spliced form of vinculin 
that contains an extra exon inserted at amino acid position 915. Vinculin and meta-vinculin 
run as 130Kd and 150Kd proteins respectively on SDS-polyacrylamide gels. Because my 
differential display product B6.5 was found to be homologous to the common 3’ end of both 
vinculin and meta-vinculin (FIG.IX.15.) it could not be determined whether it was vinculin 
or meta-vinculin that was apparently upregulated on fibronectin modulated HUASMC’s. 
(FIG. IX. 15.). Vinculin/Meta-vincuIin;
VINCULIN/ META-VINCULIN:
915 aa
Meta-Vinculin
Vinculin
- B6.5 Differential Display fragment
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Antibodies are, however, available that detect both vinculin and meta-vinculin. Such a 
monoclonal antibody from Sigma was used to carry out immunoblotting of protein samples 
obtained from HUASMC’s cultured on plasma fibronectin coated and uncoated tissue culture 
plastic (see methods IV.IO) (FIG. IX.16.)
(FIG.IX.16.).
150Kd Meta-Vinc, 
130Kd Vine.
(FIG.IX.16.) SDS-PAGE analysis of total protein extracts isolated from HUASMC’s on 
uncoated and plasma fibronectin coated tissue culture plastic Separated protein samples 
were transferred to nitro-cellulose membranes and probed with a monoclonal anti- 
Vinculin/Meta-Vinculin antibody Lanes 1 HUASMC’s cultured, on plastic - 5pl loading; 2; 
on fibronectin - 5|il loading. 3, on plastic - lOpl loading. 4, on fibronectin - lOpI loading.
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In order to characterise further some of the novel genes identified by differential 
display, their expression patterns between various cell types associated with vascular tissue 
and also between proliferating and quiescent SMC’s were examined. The novel differential 
display products B4,1 and B5.1 were selected for further analysis as they had previously been 
demonstrated to provide clear signals on northern blots (FIGs. IX.9 & IX.13.). These 
differential display products were further characterised by using specific probes to screen 
northern blots containing RNA isolated from various cell sources; Motile lymphocytes (M 
MOLT 4) and non motile lymphocytes (NM MOLT 4); Endothelial cells (HUVEC’s); 
Fibroblasts (lung MRC-5) and a myelomonocytic cell line (U937); (FIGs IX.17 & DL19). 
These probes were also hybridised to blots containing RNA from HUASMC’s at different 
stages in the cell cycle in response to the presence or absence of serum factors (FIGs. IX. 18. 
& IX.19.) A probe specific for the 28S ribosomal RNA subunit was designed and used to 
provide an estimation o f RNA loading between samples in the following blots. The analysis 
of 28S ribosomal RNA was preferred over GAPDH for these blots as transcripts obtained 
using B4.1 and B 5.1 probes were similar in size to the GAPDH transcript.
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(FIG.IX.17.).
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(FIG.IX.17.) B4.1/28S rRNA. Northern blot analysis on RNA samples obtained from 
various cell types. This blot was probed with a specific random primed labelled probe against 
the differential display product B 4.1 (novel) and also with a probe specific for 28S ribosomal 
RNA to estimate loading between samples. Lanes; 1. Motile MOLT 4. 2. Non motile MOLT 
4. 3.U937. 4. HUVEC's. 5. Fibroblasts. 6. HUASMC's on fibronectin. 7. HUASMC's on
plastic.
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(F1G.IX.18.).
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(FIG.IX.18.). B4.1/28S rRNA. Northern blot analysis on RNA samples obtained from 
proliferating HUASMC's and HUASMC's gradually entering quiescence as a result o f scrum 
deprivation This blot was probed with B4 1 and 28S ribosomal RNA specific probes. Lanes; 
1. - HUASMC's - 0 hours serum starvation. 2. 6 hours sérum starvation. 3 .1 2  hours serum 
starvation. 4. 24 hours serum starvation. 5 .48  hours serum starvation.
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(FIG.IX.19.).
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(FIG.IX.19.).B5.1/28S rRNA Northern blot analysis on RNA samples obtained from 
various cell types. This blot was probed with a specific random primed labelled probe against 
the differential display product 85.1 (novel) and also with a probe specific for 28S ribosomal 
RNA to estimate loading between samples. Lanes; 1. Motile MOLT 4. 2. Non motile MOLT
4. 3.U937. 4. HUVEC's. 5. Fibroblasts. 6. HUASMC's on fibronectin. 7. HUASMC's on 
plastic.
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(FIG.IX.20.).
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(FIG.IX.20.).B5.1/28S rRNA. Northern blot analysis on RNA samples obtained from 
proliferating HUASMC's and HUASMC's gradually entering quiescence as a result o f serum 
deprivation. This blot was probed with B 5.1 and 28S ribosomal RNA specific probes. Lanes,
1. - HUASMC's - 0 hours serum starvation. 2. 6 hours serum starvation. 3. 12 hours serum 
starvation. 4. 24 hours serum starvation. 5 .48  hours serum starvation.
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Quantitation of transcript levels for B4.1 and B5.1 were obtained by analysing the 
above northern blots using the Instant imager (Canberra Packard). The Instant imager uses a 
microchannel array detector to allow high-resolution radioactive detection of blots. The 
Instant imager software can then create image patterns of radioactivity directly from blots 
enabling quantitation in counts per minute of specific transcripts. Transcript levels for B4.1, 
B5.1 and also 28S ribosomal RNA present on identical blots were measured in counts per 
minute. Ratios of B4.1 and B5.1 levels against corresponding 28S ribosomal RNA levels on 
identical blots was calculated to obtain an accurate value of B4.1 and B5.1 mRNA levels 
between samples. These ratio values are represented in (FIGs.IX.21-IX.24).
(FIG.IX.21.).
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(FIG. IX.21.). Ratios of B4.1 mRNA transcript levels against 28S ribosomal RNA levels 
between RNA samples from various cell populations. - From northern blot depicted in 
(FIG.IX.17.)
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(FIG.IX.22.).
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(FIG.IX.22.). Ratios of B4.1 mRNA levels against 28S ribosomal RNA levels between RNA 
samples obtained from HUASMC's proliferating in the presence of serum and from 
HUASMC's at increasing time points following serum starvation. From northern blot 
depicted in (FIG.IX.18.).
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(FIG.IX.23.).
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(FIG. IX.23.). Ratios of B5.1 mRNA transcript levels against 28S ribosomal RNA levels 
between RNA samples from various cell populations. From northern blot depicted in 
(FIG.IX.19.).
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(FIG.IX.24.).
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(FIG.IX.24.). Ratios of B5.1 mRNA levels against 28S ribosomal RNA levels between RNA 
samples obtained from HUASMC's proliferating in the presence of serum and from 
HUASMC's at increasing time points following serum starvation. From northern blot 
depicted in (FIG.IX.18.)
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Chapter 3. - Results summary:
The mRNA difiFerential display technique was employed as a strategy to identify genes 
differentially expressed by HUASMC’s grown on fibronectin coated and uncoated plastic. 
Following initial differential display experiments several refinements and improvements to the 
technique were applied. These refinements included;
1. The use o f DNAse treated RNA samples as templates for differential display
reverse transcriptase PCR.
2. The use o f dCTP as a label for differential display PCR.
3. The use of longer arbitrary and anchored primers for PCR
4. The use of only three one base anchored oligo dT primers.
5. Each primer combination amplification reaction was carried out in triplicate.
6. Only differentially expressed bands greater than 150 base pairs were selected for
further analysis.
7. The use of random primed labelled probes generated fi“om differentially expressed
bands to screen northerns.
From the 4 differential display gels run after modifications to the procedure had been 
implemented (FIGs.IX.2a, DL3a, lX.4a & lX.5a), incorporating 24 separate PCR primer 
combination amplification reactions. 27 differentially expressed bands were identified between the 
two populations. 22 of these differentially expressed bands were successfully reamplified, cloned 
and sequenced. Searches were carried out on the EMBL/Genbank gene database to identify any 
homology that exists between our sequences and known genes. Nine sequences were found to be 
homologous with known genes. The remaining thirteen sequences did not reveal any significant 
homology with known genes and so may therefore represent novel genes (Table DL3.)
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Northern blots of RNA samples from HUASMCs cultured on plasma fibronectin and 
plastic substrates that had been probed with the random primed labelled differential display 
products; B3.6, B4.1, B5.1, B7.1, C l.l, C2.2, C3.1, C4.1, and C8.1, all revealed equal levels of 
mRNA between both SMC populations indicating that they represent fidse positives.
(FIGs DL16.-IX.14.). The possible reason for the persistence of 61se positive’s and additional 
refinements to the differential display procedure that may eliminate this problem are proposed in 
the discussion; Section X.
No signals were obtained on northern blots when differential display fi-agments; A l l,
B2.1, B6.5, C5.1 and D2.2 were used as random primed labelled probes. The Mure to observe 
any transcript \vith these probes may be due to low level expression o f  the homologous genes or a 
result of the small size o f the probes used (200-400bp).
Immunoblot analysis on proteins extracted fix>m HUASMC’s cultured on plastic and 
plasma fibronectin using a monoclonal antibody specific for vinculin and meta-vinculin indicated 
that both vinculin but to a greater degree meta vinculin proteins were present at higher levels in 
HUASMC’s cultured on plasma fibronectin coated surfiices, therd)y confirming the pattern of 
expression indicated by differential display product B6.5 (FIGJX.16.).
Although the novel genes BA . 1 and B5.1 identified by differential display proved to 
represent felse positives in that they are equally ejq)ressed between HUASMC’s cultured on 
plasma fibronectin and plastic, the feet that these two products produced highly oq)ressed 
transcripts as shown by northern blotting indicate that they may still serve as markers for the 
highly proliferative synthetic phenotype exemplified by such HUASMC’s in culture. To assess 
further the potential of these novel genes as useful phenotypic markers, their expression levels 
betwe@i various cell types associated with vascular tissue and expression in relation to HUASMC 
proliferation and quiescence was examined by northern blot (FIGs. IX.17. - IX.20.). Instant 
image analysis of relative B4.1 and B5.1 transcript levels indicated that transcripts from both
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genes were well expressed in all cell types, although the smaller 1.3 Kb B4.1 transcript appeared 
to be greater in U937 and motile molt 4 cells compared to the other samples (FIG.IX.21.). The 
levels of the B5.1 transcripts q)peared to be reduced in fibroblast samples when compared with 
the other cell types (F1GJX.23.). The small 1.3Kb transcript identified with the B4.1 probe 
appears to be cell cycle regulated as the level of this transcript gradually increased as time 
following serum starvation increased (Î1G.IX.22.). A transient 1Kb transcript identified with the 
B5.1 probe appears at 6 hours following serum starvation and then disappears by 12 hours 
following serum starvation (FIG.IX.24). All other transcripts identified with B4.1 and B5.1 
probes do not appear to be regulated between proliferating HUASMC’s and HUASMC’s entering 
quiescence.
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Section X DISCUSSION.
230
Knowledge accumulated over the last two decades has provided strong evidence 
implicating vascular SMC’s as having an important role in the pathology of atherosclerosis 
and restenosis. It has been demonstrated that initial atherosclerotic or restenotic lesion 
development is accompanied by the induction of vascular SMC;
(a) Phenotypic modulation
(b) Migration
(C) Proliferation
These events are thought to be responsible for the formation of the neointima that 
contributes to the vessel occlusion associated with atherosclerosis and restenosis (Bomfeldt 
e t a l 1994). As discussed in section IV.4 such alterations in vascular SMC behaviour are 
thought to be induced by the release of a variety o f inflammatory mediators (Ross 1996). 
Previous studies also suggest that the interaction of SMC’s with ECM may well be important 
in the regulation of SMC phenotypic modulation, proliferation, and migration (Hedin e t a l 
1988; Yamamoto e t a l 1993).
The following section will discuss each of these three aspects of SMC behaviour in 
turn, emphasising the influence ECM has upon them. The results fi'om research carried out 
on this area and presented within this thesis and their relevance to in  vivo  events associated 
with atherosclerosis and restenosis shall also be discussed.
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X. 1 Extracellular Matrix Induced Alteration in SMC Growth Morphology.
Vascular SMCs together with endothelial cells, are the principal cell types that 
constitute mammalian blood vessels. SMCs are responsible for maintmning vascular tone 
through their contractile activity and also participate in vascular growth and repair. During 
the normal development of the vascular system SMCs differentiate from a synthetic to a 
contractile phenotype. However, under pathological conditions such as atherosclerosis or 
restenosis, SMCs can de-differentiate and revert to the synthetic phenotype in a process 
widely termed phenotypic modulation.
Evidence from numerous studies suggests that phenotypic modulation of vascular 
SMCs also occurs spontaneously in  v itro  (Schwartz e t a l 1986; Campbell e t a l  1988). When 
cells are isolated from adult tissues they are initially in the contractile phenotype. Over a 
period o f days they undergo conversion to the synthetic phenotype (Li e t a l 1994). A variety 
of factors have been identified which induce such phenotypic modulation including; native 
and oxidized LDL (Rahm e t a l 1992); extracellular matrix components, fibronectin ^edin  e t 
a l 1988) and type I collagen (Yamamoto e t a l 1993). Growing cells on fibronectin or 
collagen type I has been demonstrated to speed up the conversion into the synthetic 
phenotype whereas growth on laminin or the commercially prepared matrix substrate matrigel 
retards this conversion and maintains the cells in the contractile phenotype for much longer 
periods of time (Yamamoto e t a l 1993; Hedin e t a l 1988; Li e t a l 1994)). A number of 
inflammatory cytokines and growth factors present in culture medium are also thought to act 
synergistically in promoting the synthetic phenotype.
Thus the behaviour of SMC’s in culture may be similar to that shown following the 
removal o f or damage to the endothelium that occurs prior to atherosclerosis and restenosis. 
The absence of a fimctional endothelium in  v ivo  as well as in  v itro  exposes SMC’s to a
232
variety o f serum derived growth factors and metabolites that can contribute to the induction 
of SMC phenotypic modulation.
Previous studies have demonstrated that as human SMC growth progresses through 
subculture the cells gradually lose many of their recently acquired synthetic characteristics. 
This progressive loss o f synthetic phenotypic activity is associated with a morphological 
modulation characterised by a change from a substrate attached monolayer culture, to a 
nodular culture in which most o f the cells are present within multicellular aggregations 
(nodules). After passaging, these vascular SMCs in  vitro  proliferate in a characteristic 
pattern, initially forming a pre-confluent monolayer that subsequently develops areas of 
multicellular foci that have been described as "hill and valley" structures (Ross 1986). These 
structures rapidly develop into morphologically distinct nodules that consist of quiescent 
SMCs embedded in a carbohydrate rich extracellular matrix (Diemer e t a l 1992). SMCs 
within these nodules have been described, contradictorily as being similar to both SMCs 
from atherosclerotic plaques (Diemer e t a l 1992) and differentiated quiescent SMCs 
representative o f a contractile phenotype (Thomas-Salgar and Millis 1994). The stronger 
evidence favours the theory that SMC’s within nodules exhibit more contractile phenotypic 
characteristics than their counterparts growing in a monolayer morphology. The results 
presented in this thesis provide further evidence supporting the suggestion that SMC’s 
growing in a nodular morphology exhibit fewer synthetic phenotypic characteristics than 
SMC’s within monolayer cultures.
Initial studies carried out for this thesis demonstrated that the formation of nodules 
during subculture can be inhibited by culturing HUASMCs on various ECM coated surfeces. 
HUASMC’s cultured on ordinary tissue culture plastic, laminin coated plastic and in Matrigel 
form the characteristic hills and valley growth morphology that could be indicative of a 
gradual progression into the contractile phenotype (FIG’s. V ILl, VIL7 &  VIL9.). 
HUASMC’s cultured on fibronectin and collagen I grow to form distinct monolayer cultures
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where the cells appear much more elongated and orientate parallel to one another forming a 
monolayer when confluent, suggesting that their synthetic-like phenotypic characteristics are 
being maintained (FIG’s. VIL2-.4.). HUASMC’s cultured on collagen m , IV, and 
vitronectin also form monolayer-like cultures but not as distinct as those observed on 
fibronectin and collagen I substrates, as occasional areas of cellular aggregation can still be 
observed on these substrates (FIG’s. VIL5, VIL6 & VIL8). This could indicate that SMC’s 
grown on these substrates may develop a phenotype that is intermediate between the 
contractile-like one observed on plastic, laminin and matrigel with the synthetic-like 
phenotype conferred by growth on fibronectin and collagen I.
The demonstration that ECM substrates can influence the growth morphology of 
human SMC’s cultured in  v itro  provides an indication that the phenotypic modulation of 
SMC’s in  v itro  can be influenced by ECM. This observation contributes to the suggestion 
that the ECM environment may play a significant role in regulating SMC phenotypic 
modulation associated with human atherosclerosis and restenosis.
It has previously been indicated that synthesis of the secreted glycoprotein, clusterin, 
by cultured SMCs is associated with the process of nodule formation (Thomas-Salgar and 
Millis 1994). This raises the possibility that the effect o f fibronectin on SMC cultures may be 
through the inhibition of clusterin secretion. This possibility was tested by treating fibronectin 
modulated SMCs with conditioned media fi'om SMCs cultured on plastic, which presumably 
contains clusterin. Such treatment was unsuccessful in promoting nodule formation in 
fibronectin modulated SMC cultures. Also antibodies against clusterin did not inhibit either 
the rate or quantity of nodule formation in plastic cultured SMCs (results not shown).
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X*2 Extracellular Matrix Induced Modulation of SMC Mitogenic and Chemotactic 
Responses.
Vascular SMC’s play a major role in the formation of arterial intimai lesions in 
atherosclerosis and are a major component of the accumulated fibrocellular mass in the 
neointima associated with restenosis following balloon angioplasty (Ross 1986; McBride e t 
a l 1988). The control of intimai SMC proliferation and migration have been demonstrated to 
be critical determinants of vessel closure following vascular injury associated with coronary 
bypass surgery, PTC A and atherosclerosis (Vlasic e t a l 1993). Although some vascular 
SMC’s reside in the tunica intima of normal human arteries that are susceptible to 
atherosclerosis, the majority o f vascular SMC’s reside in the tunica media where they are 
quiescent and express a variety of differentiation specific genes important for their fimction in 
the regulation of vessel tone and blood pressure (Pauly e t a l 1994).
The increased accumulation of vascular SMC’s within intimai lesional areas is thought 
to arise as a consequence of SMC phenotypic modulation. SMC’s that have changed to a 
synthetic phenotype demonstrate upregulated expression of a number o f growth regulatory 
genes and cytokines. Furthermore synthetic SMC’s can demonstrate an enhanced response in 
an autocrine manner to their own secreted products or paracrine manner to inflammatory 
stimuli o f non-SMC origin via the upregulated expression of receptors such as PDGF or c- 
jm s . Likewise synthetic SMC’s may regulate their response to the altered ECM environment 
of the neointima v ia  modified expression of cell surface integrins.
Such changes in SMC behaviour may be responsible for the increased responsiveness 
to various inflammatory stimuli that induces excessive SMC proliferation and migration 
thereby contributing to the development o f the neointima associated with restenosis and 
atherosclerosis.
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The role that various ECM substrates have on regulating the mitogenic and 
chemotactic behaviour of SMC’s in response to a range of stimuli was investigated during 
this study. Several in  vitro  SMC proliferation and migration assays were set up to compare 
HUASMC proliferation and migration rates on various ECM coated substrates.
Hoechst DNA proliferation assays (Section VI.4) demonstrated that HUASMC’s 
seeded on fibronectin, collagen I, collagen III, and collagen IV coated tissue culture plastic 
exhibit enhanced proliferation rates in response to serum when compared with HUASMC’s 
cultured on uncoated tissue culture plastic or laminin coated plastic (FIG’s.Vn.lO-VII.12.). 
Growth curves obtained fi’om SMC cultures that were not supplemented with fi’esh medium 
suggest that SMC’s cultured on fibronectin possess a reduced requirement for serum derived 
survival factors. SMC’s grown on fibronectin in unsupplemented cultures reach 
considerably higher cell densities than cells on plastic. Also the lifespan of cells was 
extended by growth on fibronectin (F IG .V n.ll.) These results indicate that the mitogenic 
response of vascular SMC’s to serum derived factors can be altered by the type of ECM 
substrate on which the cells are cultured.
ECM may modulate the SMC mitogenic response in a number o f ways. Cell surface 
integrin receptors can transduce signals that promote alterations in the cytoskeleton that can 
in turn directly influence cell adhesion and shape, properties that are tightly coupled with 
cell motility and proliferation. Integrins can also transduce signals co-operatively with 
growth factor receptors. It has been well documented that the majority o f cells require 
anchorage as mediated by ECM-ligand interactions in order to allow the growth factor 
initiated progression into S phase of the cell cycle (Zhu e t a l 1996). Such co-operative 
signalling is therefore likely to result in the generation of a variety o f intracellular signals 
that combine to influence the expression and function of the cell cycle regulatory elements 
thereby promoting cell proliferation.
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The identification of the ECM derived signalling networks that regulate such mitogenic 
responses remain to be fully elucidated. However, recent insights implicating an association of 
integrin function with cyclin/CDK activity (Fang e t a l 1996; Meredith e t a l 1995), may help 
elucidate the mechanisms underlying extracellular control o f mitogenesis and lead to novel 
therapeutic approaches to the control of SMC proliferation associated with atherosclerosis or 
restenosis.
ECM may contribute to the phenotypic modulation of SMC’s. The subsequent transition 
into the synthetic phenotype is associated with increased cell proliferation. This upregulation in 
cell proliferation is likely to result from the combination of enhanced growth factor receptor 
expression CSF-1, PDGF, and EGF receptors (Pickering e t a l 1993; Rahm e t a l 1992; Inaba e t 
a l 1992), and increased expression of autocrine growth factors such as, PDGF and bFGF 
(Walker et al 1986; ).
The ECM may also influence the cell response to certain growth factors, for example 
Heparan sulphate proteoglycans (HSPGs) can bind to bFGF protecting it from proteolytic 
degradation and providing a reservoir o f active bFGF in the ECM. Also bFGF binding to its 
receptor is significantly enhanced when it is present as a complex with HSPG. It has been 
postulated that HSPG may increase bFGF receptor-ligand complex stability by conferring 
conformational alterations on the growth factor molecule (Nugent e t a l 1993). Similar 
interactions may take place between other growth factor and ECM molecules.
SMC migration on different matrix coated substrates was assayed by two methods. Both 
methods are modifications of the Boyden chamber and incorporate either Transwell inserts or 
ChemoTx 96 well chambers (section VI.5).
Migration assays performed on transwell inserts demonstrated that rates o f SMC migration 
in response to a positive gradient of serum were significantly greater on plasma fibronectin than 
on uncoated polycarbonate filters (FIG.VII.16.). This result was further supported by time 
lapse video studies (results not shown) demonstrating increased SMC migration rates on
237
fibronectin coated tissue culture plastic compared with uncoated plastic. Dose responses of 
positive migration towards gradients of PDGF BB and HGF were also observed through 
fibronectin coated transwell filters. No such responses were observed through uncoated 
filters (FIG’S VIL17 & VIL18).
Migration assays performed using the ChemoTx migration chamber demonstrated 
that rates o f migration towards serum were greatest on fibronectin and collagen ID coated 
filters compared to migration on collagen IV, collagen I and laminin coated filters on which 
SMC’s migration rates were about half fold less than those observed on fibronectin and 
collagen ID (FIG.Vn.19.) High levels of SMC migration in response to PDGF BB were 
observed through collagen ID, collagen I and fibronectin coated filters. No migration in 
response to PDGF BB could be detected through laminin and collagen IV coated filters 
(FIG.Vn.20.) HGF induced significant levels of miration through collagen I, fibronectin 
and laminin coated filters, whereas no migration towards HGF could be observed through 
collagen IV and collagen ID (FIG.Vn.21) Significant levels o f SMC migration in response 
to bFGF could be observed on collagen ID filters with relatively low levels o f migration on 
fibronectin and collagen type I coated filters. Once again practically no migration was 
observed on laminin and collagen IV coated filters (FIG. Vn.22)
Therefore it seems clear that SMC’s on different ECM substrates produce differential 
migratory responses to chemokines. Results obtained fi'om these SMC migration assays seem 
to indicate that the ECM substrates collagen IV and laminin do not effectively promote SMC 
migration to the various chemotactic stimuli investigated.
ECM may be able to modulate the motility o f SMC’s in a number o f ways; as 
described in the previous section ECM-integrin interaction can contribute to SMC 
phenotypic modulation resulting in increased synthesis o f autocrine chemotactic factors and 
expression of chemotactic factor receptors, also co-operative signalhng between integrins and 
chemotactic factor receptors may take place contributing to SMC migration. Signalhng
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mediated via integrins has previously been described to influence cell migration directly. For a 
cell to migrate across a substratum under in  Wf/o conditions they must first adhere to it with 
suflBcient strength to allow subsequent spreading at the cell margin. One part o f the cell 
margin must become specialized to extend outwards while the opposing side retracts and 
continued locomotion requires the spatial and temporal regulation of the development and 
breaking o f cell-substratum contacts.
The most extensively studied and well characterised cell-substratum contacts are the 
focal adhesions (Lee e t a l 1993). Focal adhesions have been observed only under in  v itro  
conditions. Thus their relevance to SMC behaviour in  vivo  is unclear. Focal adhesions do 
however, provide a model to explain the link between the ECM, cell surface integrins and 
the intracellular cytoskeleton. The type of ECM integrin interactions taking place between 
SMC’s and the extracellular environment will govern the strength of cell anchorage and thus 
the propensity to migrate. Signalling events triggered by the clustering of integrin molecules 
at the sites o f cell substratum contact are involved in cell motility. Integrin clustering can 
result in the phosphorylation of the molecular components within focal adhesions, this may 
lead to the induced levels o f PIP2 activity which in turn may lead to an increased rate of actin 
polymerization via the binding of PIP2 to the actin binding proteins profilin and gelsolin 
(Wang e t a l  1993). Such integrin mediated alterations in cytoskeletal organisation that 
regulate actin filament dynamics can generate the necessary force required for cell motility. 
Also similar signalling through integrins can lead to the sequential development and 
breakdown of focal contacts between the cell surface and substratum, which is required to 
provide the necessary traction that enables the cell to migrate. Therefore ECM-integrin 
interactions have an essential involvement in the control o f SMC migration.
The correlation of low migration and proliferation rates with “hills and Valley” SMC 
cultures, such as those on uncoated plastic or laminin coated substrates, provides further
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evidence suggesting that SMC’s within nodules exhibit less synthetic phenotypic 
characteristics than SMC’s growing in a monolayer morphology.
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X.3 SMC Phenotypic Marker Analysis.
After establishing that morphological and functional differences do result fi-om 
culturing SMC’s on different ECM substrates, this project progressed to investigating 
whether sueh ECM substrates eould induee alterations in SMC phenotype. Phenotypie 
characterisation of SMC’s cultured on different ECM substrates was achieved by carrying 
out western blot analysis using antibodies that have previously been demonstrated to be or 
are possible candidates as SMC phenotypic markers. The expression of these markers was 
also examined in protein samples obtained from the same human umbilical artery tissue from 
which the cultured HUASMC’s were isolated, as well as from human sapheneous vein and 
aorta tissue samples. These tissue samples provided a positive control for the contractile 
phenotypic markers.
The results o f this marker analysis as summarised in Table VIILl. indicates that all 
SMC populations in culture appear to be representative of the synthetic phenotype 
irrespective of the type of ECM on which they are cultured. Well established synthetic 
markers such as cytokeratin 8 and light chain caldesmon are well expressed in the cultured 
cells but absent in the normal tissue samples. Conversely, well known contractile markers 
such as desmin and SM-myosin are absent in the cultured cells but well expressed in tissue.
These results seem to indicate that the phenotypic status o f cultured SMC’s as 
determined by the markers used in this analysis, is not drastically altered by extracellular 
matrix, as only slight differences in the levels o f meta-vinculin and the 210 Kd isoform of 
MLCK were observed. This result was perhaps not unexpected as many o f the putative SMC 
differentiation markers identified to date have not previously been found to be re-expressed 
under culture conditions and the majority of the synthetic markers are characteristic for 
SMC’s cultured under most conditions. Such observations provide support for the view that 
the contractile and synthetic SMC phenotypes do not represent a simple black and white
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comparison but are rather a consequence of a continuum of phenotypic alterations resulting 
in two distinct phenotypes (contractile and synthetic) at the opposing ends of this continuum. 
So it is likely that the phenotypic markers analysed in this study are only exclusively 
expressed at the extreme ends of the spectrum between contractile and synthetic SMC 
phenotypes and do not pick up the more subtle alterations in phenotype such as those 
possibly induced by ECM in culture. Indeed the failure to observe any clear differences in the 
expression levels of the phenotypic marker proteins studied, indicate that under in  v itro  
conditions ECM does not have the power to completely shift the phenotype of HUASMC’s 
from a classic synthetic to a contractile phenotype or vice versa . It is probable, however, in 
view of the alterations in growth morphology as well as proliferation and migration rates 
conferred by ECM (section X.1 & .2), that ECM molecules may have the ability to shift the 
phenotypic state of SMC’s towards a slightly more contractile or synthetic phenotype.
The identification that fibronectin, collagen HE and vitronectin can upregulate the 
expression levels of the 210 Kd MLCK isoform is interesting with respect to SMC fimction 
(FIG.Vin.16). MLCK is a Ca^Vcalmodulin dependent protein kinase that specifically 
phosphorylates smooth muscle myosin regulatory light chain (Stull e t a l 1986). The 
phosphorylation of the 20 Kd regulatory light chain of myosin by MLCK plays a key role in 
the initiation of smooth muscle contraction. In smooth muscle, a rise in intracellular Ca^  ^
levels results in the formation of regulatory calcium-calmodulin complexes that can interact 
with the catalytic subunit of MLCK thereby activating the enzyme to phosphorylate serine at 
position 19 on the regulatory light chain of myosin. Phosphorylation of serine 19 of myosin 
light chain allows the myosin ATPase to be activated by actin and the muscle to contract 
(Somlyo and Somlyo 1994). MLCK activity has also been demonstrated to play a role in the 
modulation of skeletal muscle contraction, receptor capping, shape change and cell motility 
as well as other ftmctions (Sellers and Adlestein 1987). It therefore seems likely that MLCK 
activity plays an important role in determining SMC behaviour that may be characteristic of
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either a contractile or synthetic phenotype. However, the use of the 210 Kd MLCK isoform 
as a phenotypic marker is limited because it has yet to be fully characterised. Only when 
specific probes and antibodies are designed to the 210 Kd isoform can the value of 210 Kd 
MLCK as a SMC phenotypic marker be fully assessed in  vivo .
The expression level of meta-vinculin was found to be upregulated in HUASMC 
cultures on plasma or cellular fibronectin (FIG. VIIL21). The potential use of meta-vinculin 
as a SMC phenotypic marker shall be further discussed in section X.4.
Another interesting result fi’om this phenotypic analysis is the identification o f a 30 
Kd low molecular weight (non-muscle) isoform of tropomyosin as a potential marker for 
synthetic SMC’s. This 30 kd isoform is well expressed in all cultured SMC’s but absent in all 
three tissue preparations (FIG. VIIL18 & V1ILI9). This is interesting because the low 
molecular weight 30 kd isoforms of tropomyosin (TM30pi and TM30nm) have not 
previously been proposed to be markers of synthetic SMC’s. Western blot analysis using an 
anti-tropomyosin antibody was performed on protein samples obtained fi’om intimai and 
m ^ a l layers fi’om balloon injured and normal rat carotid tissue. A low molecular weight 
isoform of tropomyosin corresponding in size to the rat homologue (TM4) o f the 30 kd 
human tropomyosins (TM30pi) was found to be well expressed in cultured rat cells and also 
in the intima o f the ballooned tissue which contains synthetic SMC’s, and less abundant in the 
vessel media which is composed predominantly o f normal contractile SMC’s. Also this 
isoform o f tropomyosin was not found to be present at all in the normal rat carotid artery 
(FIG. VnL36) This result provides strong evidence implicating a low molecular weight 
isoform of tropomyosin as a marker for the synthetic SMC phenotype.
The tropomyosins are a family o f actin associated cytoskeletal proteins that are 
thought to play a structural and/or regulatory role in the organisation of microfilaments into 
bundles o f stress fibres (Matsumura e t a l 1983). In skeletal and cardiac muscles, tropomyosin 
acts in concert with troponin, in regulating muscle contraction. The interaction o f F-actin
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with myosin and subsequent wave of muscle contraction is dependent on the conformation of 
the actin-bound troponin-tropomyosin complex, which is ultimately regulated by levels of 
intracellular calcium (Chalovich 1992). In smooth and non-muscle cells where the troponin 
complex is absent, the role of tropomyosin is less clear. A functional role for tropomyosin in 
non skeletal muscle tissues can however be inferred from its interaction with caldesmon, 
calponin and tropomodulin and also from studies implicating a possible role for 
tropomyosins in governing the stability of F-actin. (Matsumura and Matsumura 1985).
There appear to be two discrete classes of tropomyosins, a muscle type and a non­
muscle type. Considerable interest in the function of non-muscle tropomyosins has been 
generated by observations that the abundance of non-muScle isofoitns relative to muscle 
isoforms o f tropomyosin increase upon cell transformation (Lin e t a l 1985). A common 
phenomenon associated with cell transformation is that at least one muscle tropomyosin 
isoform appears to decrease or disappear and in parallel the level o f one non-muscle 
tropomyosin increases. This alteration in tropomyosin expression in transformed cells 
accompanies the reduction in the size and number of microfilament bundles and an increase in 
microfilaments associated as a meshwork structure. These observations have led to the 
postulation that a possible function of tropomyosins in non skeletal muscle cells is in the 
regulation o f actin stability.
The evidence suggesting that tropomyosin regulates actin stability originates from the 
observations that skeletal muscle tropomyosin binds strongly to F-actin, whereas the binding 
of non-muscle tropomyosin to actin is much weaker. This weaker binding of non-muscle 
tropomyosins can be attributed to the truncated length of these proteins. Although the overall 
structure o f muscle and non-muscle tropomyosins are similar, non-muscle tropomyosins have 
a 37 amino acid residue deletion at the amino terminal end of the protein. As a result o f this 
shorter length non muscle tropomyosins bind only 6 actin monomers compared with the 7 
monomers that muscle tropomyosin binds (Cote and Smillie 1981). Also in addition to the
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amino terminal deletion the sequence of the first 42 residues and last 27 residues o f non­
muscle tropomyosins differ fi'om the corresponding skeletal muscle tropomyosin sequence 
(Cote and Smillie 1981). This variability contributes to the relatively poor head to tail 
polymerization of non-muscle tropomyosins when compared to their muscle specific 
counterparts. A reduction in head to tail polymerization is thought to have an effect on the 
co-operative binding potential o f tropomyosin to actin and so also contributes to a decrease 
in binding affinity with F-actin.
Both muscle and non-muscle tropomyosins appear to decrease the binding of gelsolin 
to actin filaments and to diminish the ability o f gelsolin-Ca^  ^to fi'agment these filaments. Also 
tropomyosin binding to F-actin protects against the disassembly o f  F-actin by actin 
depolymerizing factor (ADF). It has been suggested that because non-muscle tropomyosins 
have lower binding affinity to F-actin they may be less effective at inhibiting gelsolin and 
ADF mediated destruction of actin filaments.
Therefore, the conversion to non-muscle tropomyosin during transformation may 
cause the transformed cell to rearrange the organisation of microfilaments, such as reducing 
the number and size of microfilament bundles (Lin e t a l 1984). The upregulated expression of 
non-muscle tropomyosins in transformed cells raises the question whether the expression of 
these isoforms is associated with proliferation and migration in other cell types. Indeed 
previous studies have revealed that antibodies directed against a non-muscle chicken 
tropomyosin isoform bound to stress fibres and membrane ruffles o f migrating fibroblasts, 
whereas antibodies directed to muscle isoforms of tropomyosin stained only stress fibres.
The associated expression of non-muscle isoforms of tropomyosin with cell 
proliferation and migration, taken together with its exclusive expression in cultured SMC’s 
and balloon injured rat carotid vessels, strongly suggest that it may be a potential candidate 
as a phenotypic marker characterising synthetic SMC’s. Further work will be required to 
identify which particular tropomyosin isoform is modulated before subsequent in  s itu
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hybridisation studies can be performed on diseased vessels that would confirm whether this 
tropomyosin isoform is a specific marker for synthetic SMC’s
Immunocytochemical analysis performed on HUASMC populations cultured on either 
plasma fibronectin or uncoated tissue culture plastic, revealed no great differences in either 
the levels or distribution of the phenotype markers studied (FIG* s. V11L37-58.). The 
association of MLCK antibody staining with fibrils did appear to be slightly upregulated in 
HUASMC’s cultured on fibronectin (FIG. VnL46b) Also antibody staining to caldesmon 
localised to the cell nucleus was of greater intensity in HUASMC’s cultured on plasma 
fibronectin (FIG. VnL56b.). The slight upregulation of MLCK and caldesmon activity in 
SMC cultures on fibronectin could be linked with the increased motility o f SMC’s observed 
on this substrate.
Matrigel matrix is a soluble basement membrane extract of the Engelbreth-Holm- 
Swarm (EHS) tumour that gels at room temperature to form a mafrix containing various 
basement membrane and ECM components (Kleinman e t a l 1986). The major components of 
Matrigel matrix are laminin, collagen IV, entactin, and heparan sulphate proteoglycan 
(Kleinman et al 1982; Bissel et al 1987). Growth factors, collagenases, plasminogen 
activators and other undefined components have also been reported in Matrigel matrix 
(Vukicevic et al 1992). Matrigel matrix has previously been used for attachment and to allow 
the differentiation of many normal and transformed cell type including, neurons, 
oligodendrocytes, hepatocytes, Sertoli cells, chick lens, melanoma cells, vascular endothelial 
cells, thyroid and hair follicle cells (Kleinman e t a l 1986; Hadley e t a l 1985; Kubota e t a l 
1988).
It has previously been reported that the induction of the differentiated contractile 
phenotype can be achieved by culturing human aortic SMC’s on growth factor-reduced 
Matrigel in serum fi*ee medium. This differentiation of SMC’s was characterised by 
multilayered nodular morphology and a low proliferative index. Also immunocytochemical
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studies demonstrated expression of the cytoskeletal differentiation markers a  smooth muscle 
actin, heavy chain myosin and caldesmon (Grushldn-Lemer and Flaherty 1995).
In this study both human aortic and HUASMC’s were cultured on growth factor 
reduced Matrigel supplemented with serum free medium. Total protein samples were 
extracted from these cultures at sequential time points following cell seeding. Protein samples 
from these Matrigel cultures were separated by polyacrylamide gel electrophoresis together 
with protein from SMC’s cultured on plasma fibronectin and protein isolated from human 
aorta and umbilical artery tissue. Immunoblotting studies were subsequently carried out on 
these samples using antibodies specific for known SMC phenotypic marker proteins (FIG’s. 
VIIL22-.35). Immunoblotting was preferred to immunocytochemisty as a high degree of 
non-specific antibody binding to nodules was observed. Results from this immunoblotting 
analysis did not demonstrate a clear alteration in phenotype as a result of culturing either 
human aortic SMC’s or HUASMC’s on Matrigel. The expression of the classic contractile 
SMC markers, desmin and smooth muscle myosin heavy chain were not induced upon 
growth in Matrigel (FlG’s, VnL26-Vm .29) These results, therefore, do not correlate with 
the previous study by Grushldn-Lemer and Flaherty indicating SMC growth on Matrigel 
induces the transition into the contractile phenotype.
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X.4 Differential Display Analysis of SM Cs Cultured on Different ECM Coated 
Substrates.
It seems likely that the induction of SMC phenotypic modulation which precedes 
atherosclerosis and restenosis development results in the activation of a group of genes which 
promote SMC growth and migration and the inactivation of others that may be pro­
differentiation. The phenotypic analysis of SMCs cultured on different ECM substrates using 
antibodies specific for known or candidate phenotypic marker proteins did not reveal any 
gross alteration in phenotype between SMC populations grown on each substrate, indicating 
that any alteration in phenotype induced by ECM in  v itro  is subtle. The aim of results chcq>ter 
5. (section IX) was to identify such subtle changes in SMC gene expression that are induced 
by ECM adhesion, and also subsequently discover whether they are associated with the SMC 
phenotypic modulation taking place in  vivo  that is involved with the development of 
atherosclerosis and restenosis.
The mRNA differential display technique was employed as a strategy to allow the 
phenotypic characterisation at the molecular level o f SMC populations cultured on different 
ECM substrates. Differential display is a recently developed PCR based technique that was 
conceived to allow the identification and molecular cloning of differentially expressed genes 
between related cell populations. Compared with standard methods for the identification of 
differential gene expression such as subtractive and differential hybridization, differential 
display has the advantages in that it does not need polyA+ RNA and requires only small 
amounts o f total RNA in each condition for screening, initial results can be obtained very 
rapidly, it is easy to compare gene expression in multiple conditions on a single gel with side 
by side analysis, and sensitivity is high since the differences are amplified by PCR.
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This method should therefore prove effective for identifying potential subtle changes 
in SMC gene expression induced by ECM adhesion.
Differential display analysis was applied to HUASMC's cultured on plasma 
fibronectin coated plastic compared with SMCs grown on uncoated plastic. These two SMC 
populations were chosen for comparison not only because of the clear morphological and 
functional differences that exist between these two populations but also because large 
quantities of RNA could be obtained firom cells cultured on these substrates which is 
important for running northern blots that are required to confirm differential display results.
It soon became apparent that one of the major pitfalls o f differential display is the 
high incidence of false positives that can be obtained. Several modifications to the original 
differential display procedure, the results o f which are represented in (FIG’s.IX .la-d.) were 
applied in an attempt to reduce the number of false positives. The most important of these 
modifications is probably the use of good quality uncontaminated RNA samples for RT-PCR 
template. Subsequent differential display experiments used RNA samples that are DNase 
treated. This prevents the amplification o f any contaminating genomic DNA within RNA 
samples which may result in the misleading appearance of a differentially expressed band. The 
amplification of genomic DNA most probably took place during the first attempt on 
differential display as indicated by the amplification of products rich in alu repetitive 
sequences (Table DLl).
Also fi'om early differential display gels it was observed that certain primer 
oombinations resulted in the amplification of a large number of PCR artefacts that also could 
be mistaken for differentially expressed genes. The differential display gel represented in 
(FIG’s.IX.2a-d) contains samples that were run in duplicates. In certain supposedly 
"identical reactions" clear differences can be observed (Table 1X.2). To reduce the possibility 
of selecting such artefacts it was decided to carry out each PCR primer combination 
amplification reaction in triplicate. Differential display gels represented in (FIG’s.IX.3-IX.5)
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are examples o f these later differential display experiments. The decision was made to select 
only those differences represented in at least two out of the three corresponding pairs o f PCR 
reactions. Also only those differentially expressed bands greater in size than 150bp were 
selected for further analysis, this was to allow for a greater rate o f success during subsequent 
processing of the DNA such as re-amplification, cloning and probe-hybridisation to northern 
blots.
A summary of the results from the modified differential display experiments are 
shown in (Table IX.3). From four differential display gels incorporating twenty four separate 
PCR primer combination amplification reactions, twenty seven differentially expressed bands 
were identified between the two populations.
Twenty two of these differentially expressed bands were successfully cloned and 
sequenced. Searches were carried out on the Genbank/EMBL gene database to identify any 
homology that exists between these sequences and known genes. Nine sequences were found 
to be homologous with known genes; the remaining thirteen did not reveal any significant 
homology and may represent novel genes.
The known genes identified included;
14 Iq JH:- This is a rearranged immunoglobulin switch mu fragment that is present in 
a number o f genes. This sequence is thought to act as a translocation site for a variety of 
genes including the bcl2 and bcl3 protooncogenes. Such translocation of bcl2 and bcl3 has 
been linked with the onset of uncontrolled cell proliferation and is often found associated 
with human lymphoma development (Crossen e t a l 1993; Siete e t a l 1993). Differential 
display indicated that I'llq  JH was upregulated in fibronectin modulated SMC's, but whether 
the gene identified plays a similar role in controlling cell proliferation to those genes 
previously described cannot be determined until the gene that carries this sequence has been 
further characterised. However, it is interesting to speculate that gone translocation maybe
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responsible for initiation of an altered cell phenotype such as that observed in fibronectin 
modulated SMC's.
Canine SRP 72:- The Signal Recognition Particle (SRP) is a cytoplasmic 
ribonucleoprotein particle consisting of six polypeptide chains, it binds to the signal sequence 
on nascent polypeptides when they emerge fi*om a translating ribosome. The SRP is 
responsible for targeting proteins to the endoplasmic reticulum. The SRP 72 polypeptide has 
been proposed to function specifically in targeting, but possibly participates also in the 
elongation arrest function of SRP (Lutke e t a l 1993). It is not clear what role upregulation of 
SRP 72 expression in plastic cultured SMC's could have on SMC phenotypic modulation, 
although it could be proposed that regulation of SRP 72 expression may ultimately control 
protein import into the endoplasmic reticulum. Alterations in protein import could have 
significant consequences regarding cell physiology which may be manifested as modulation of 
cell phenotype.
Human Ionising Radiation Resistance Protein:- This gene was indicated to be 
upregulated in fibronectin modulated SMC's. No information regarding the biological 
function o f this gene has been published, therefore the significance of differential expression 
of this gene in relation to SMC phenotypic modulation cannot be assessed at the present 
time.
Iduronate-2-sulphatase:- This gene encodes a lysosomal sulphatase enzyme. 
Deficiency of this enzyme results in storage of the glycosaminoglycans heparan sulphate and 
dermatan sulfete, which leads to the lysosomal storage disorder (mucopolysaccharidosis) also 
known as Hunter's syndrome. Degradation of glycosaminoglycans such as heparan and 
dermatan sulphate provides a mechanism for the release of growth factors sequestered by 
such molecules. The activity of enzymes involved in this matrix degradation are therefore 
often required to support cell proliferation. The potentially decreased expression of this
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particular enzyme in the plastic cultured SMC's may provide a possible explanation for the 
low proliferation rates of these cells.
P54:- This gene encodes a nuclear RNA binding protein that is highly homologous to 
the recently identified human splicing factor PSF (Dong e t a l 1993). Biochemical 
complementation, antibody inhibition, and immunodepletion experiments demonstrate that 
PSF is an essential pre-mRNA splicing factor required early in spliceosome formation (Patton 
e t a l 1993). P54 was initially identified as a gene upregulated in fibronectin modulated 
SMC's. It is possible that induction of spliceosome formation could result in alternative 
splicing o f specific genes involved in modulating the phenotypic properties o f SMC's cultured 
on fibronectin.
Pentaxin 3:- The pentaxin 3 gene encodes an acute phase protein whose plasma 
level is found to be considerably elevated during infiammatory responses (Allés e t a l 1994). 
Another member of the pentaxin family, serum amyloid A, also an acute phase protein, was 
found to be upregulated within atherosclerotic lesions (Meek e t a l 1993). Although the 
biological fimction of Pentaxin 3 remains to be elucidated it may be a promising marker for 
SMC phenotype. However, the potential upregulation of pentaxin 3 gene expression in our 
more quiescent plastic cultured SMC's as indicated by differential display conflicts with 
studies indicating that it is a marker for infiammatory disease.
Vinculin /  Meta-Vinculin:- These are intracellular cytoskeletal proteins found in 
both smooth and non-muscle tissues. They have been shown to be localized at the termini of 
actin bundles often associated within focal adhesions (Feramisco e t a l 1982). It is likely that 
vinculin and meta-vinculin within focal adhesions are involved in transducing intracellular 
signals induced as a result o f SMC adhesion to fibronectin. Differential display indicated that 
vinculin or meta-vinculin gene expression was upregulated in fibronectin modulated SMC 
cultures, the upregulation of either gene may therefore provide a mechanism by which 
fibronectin can induce phenotypic modulation of SMC's, presumably as a result o f as yet
252
unknown integrin derived signal transduction events. Vinculin and meta-vinculin have 
previously been demonstrated to be markers of SMC phenotype. Immunostaining studies 
suggest that the ratio o f meta-vinculin : vinculin decreases during the development of 
atherosclerotic lesions. Meta-vinculin is an alternatively spliced form o f vinculin, so it remains 
to be determined whether the gene upregulated or alternative splicing pattern observed in 
fibronectin modulated SMC’s represents vinculin or meta-vinculin (Meyer e t a l 1994).
Phosphotyrosyl protein phosphatase:- The PTPase, red cell acid phosphatase / 
adipocyte acid phosphatase was potentially found to be upregulated in plastic cultured 
SMC's. The precise fimction of these specific PTPases has yet to be published although all 
PTPases identified to date share the ability to regulate tyrosine phosphorylation. Studies have 
previously shown that PTPases can inhibit both PDGF receptor and EOF receptor signal 
transduction as a result of dephosphorylation of these receptors (Way & Mooney 1994; 
Gunaratne e t a l 1994). The inhibition of growth factor receptor activity can promote cell 
differentiation (Pani e t a l 1995). The activity of PTPase's in plastic cultured SMC populations 
could therefore promote a more differentiated phenotype.
Rat cytochrome p450 hydroxylase/aldosterone synthase:- This enzyme belongs to 
a family of enzymes that catalyses the detoxification of potentially harmful metabolites, its 
major site o f production is within the liver (Alberts e t a l 1989). The expression of this gene 
was suggested by differential display to be upregulated in fibronectin modulated SMC's. The 
significance of this in terms of SMC phenotypic modulation is unknown.
The thirteen novel gencs identified should not be discounted fi*om further analysis as 
they may also have the potential to play an important, but as yet umdentified role in SMC
phenotypic modulation.
Because o f the high number of false positives it is vital that differential expression of 
all genes identified by differential display is confirmed before studying them further and this 
was done by screening northern blots.
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Another very important consideration is that differentially expressed bands cut out of 
the differential display gel may contain additional undetectable overlapping, or unresolved 
cDNA products. Such a scenario may result in reamplification and sequencing of cDNA that 
may not necessarily represent the differentially expressed product observed on the gel. To 
check for this possibility random primed labelled probes were generated using reamplified 
DNA fi"om differentially expressed bands cut out o f the differential display gel. This method 
should allow labelling o f all products contained within a band. These probes were then used 
to screen northern blots containing the relevant plastic and fibronectin modulated SMC 
mRNA samples. Even after taking these precautions all the differential display products that 
were successfully labelled and produced a transcript have all failed to reveal any differential 
expression on a northern indicating that they represent false positives (Fig’s IX.6-K .14).
The persistence of false positives maybe due to the fact that the phenotypic differences 
between fibronectin modulated SMC's with SMC's cultured on plastic are not that great and 
those differences observed on the display gel were exa^erated and therefore misleading. 
Therefore the problem o f preferentially selecting PCR artefacts has not been eliminated. 
Alternatively difforentioUy expressed genes originally identified may be unique to the RNA 
samples used for the differential display amplification and do not represent true fibronectin 
modulated genes that would also be identified in equivalent RNA samples used for northerns.
However, one encouraging differential display product is B6.5 which was upregulated 
in fibronectin modulated SMC's and was found to be homologous to either vinculin or mcta 
vinculin. Vineulin is a 130 Kd cytoslccletal protein that has been shown to be localised at the 
termini o f actin bundles often associated within focal adhesions. Meta-vinculin is an 
oltemMively spliced form of vinculin that contains an additional exon inserted at amino acid 
position 915 and meta-vinculin encodes a 150 Kd protein. Because the differential display 
product B6.5 is homologous to the common 3' end of both genes it could not be determined 
whether it is vinculin or meta-vinculin that is apparently upregulated in fibronectin modulated
254
SMC's. Antibodies are however, available that detect both vinculin and meta-vinculin, which 
allowed a western blot to be performed on protein samples extracted from the two SMC 
populations (FIG.IX.16.). The intensity o f the protein bands observed on the western blot 
indicate that probably both vinculin but to a greater degree the meta-vinculin proteins are 
upregulated in fibronectin modulated SMC's, confirming the pattern of expression indicated 
by differential display.
Unfortunately previous studies carried out by other laboratories investigating the 
usefulness of meta-vinculin expression as a marker for SMC phenotypic modulation proposed 
it as a marker for contractile SMC’s. This somewhat contradicts the theory suggested in this 
thesis that its upregulation in fibronectin modulated SMC’s is associated with the onset of 
synthetic phenotypic characteristics. These previous studies, however, used in  s itu  
hybridisation studies to examine the level of meta-vinculin protein in the intima versus the 
media of atherosclerotic vessels, and they observed very small quantitative differences 
between these areas (Meyer e t a l 1994). The results obtained from these studies suggest that 
the meta-vinculin protein is not a distinctive marker of SMC phenotype. It is possible 
however, that in culture ECM molecules such as fibronectin may upregulate meta-vinculin 
expression, but under in  v ivo  conditions other additional factors govern the expression of 
meta-vinculin. Although the upregulation of meta-vinculin by fibronectin is interesting, its 
non-exclusive expression in either a synthetic or a contractile SMC phenotype limits its use as 
a phenotypic marker for studying atherosclerosis or restenosis.
Thus differential display analysis has not identified any differences in gene expression 
induced upon SMC adhesion to fibronectin that could prove useful in characterising the 
phenotypic shift towards a synthetic phenotype. This failure to identify clear differences in 
gene expression between fibronectin and plastic modulated SMC cultures has prevented the 
analysis o f ECM modulated genes by in  s itu  hybridisation on sections obtained from 
atherosclerotic and restenotio lesions. Such analysis would have allowed the evaluation of in
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v itro  models by determining whether any of our in  v itro  differentially expressed genes are 
also differentially expressed in  vivo  between SMC’s localised in normal vascular tissue with 
SMC’s from atherosclerotic and restenotic lesions.
One further simple optimisation step that could be applied to the differential display 
procedure is the incorporation of a time course of transition from one population into the 
other under study. For example differential display could be performed on RNA samples 
obtained at sequential time points following drug treatment or during cell transformation. The 
analysis o f such a time course on a differential display gel would allow the observation of 
either a stepwise increase or decrease in the level o f a product as the time course progresses. 
The chances that such a stepwise increase or decrease represents an artefact or false positive 
seems very slim. So the use of such a time course would have a significant effect at reducing 
the number of false positives obtained with the differential display procedure. Caution will 
still have to be taken when performing differential display on a time course o f RNA samples, 
for example if the modulation of SMC phenotype was investigated by comparing cells on 
plastic with a time course of adhesion to fibronectin it is likely that at the later time points 
differences resulting from cell confiuency rather than fibronectin modulation Could be 
identified. Therefore the choice of samples for analysis is important.
The identification of novel genes by differential display provides a useful additional 
application of the technique; Although all of the novel genes analysed so far have proved to 
represent false positives and are constitutively expressed between SMC’s cultured on plastic 
and fibronectin. The frict that some of these genes have produced highly expressed transcripts 
on northern blots indicates that they may still serve as markers for the highly proliferative 
synthetic phenotype exemplified by such SMC’s in culture. Therefore two of the novel genes 
(B4.1 and B 5.1) identified by differential display performed on plastic compared to 
fibronectin cultured SMC’s were characterised further.
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Ideally any really useful SMC phenotype marker would be SMC specific, therefore 
the expression patterns o f these genes between various cell types associated with vascular 
tissue (lymphocytes, monocytes, fibroblasts, endothelial cells, and smooth muscle cells) were 
examined (FIG’s.IX.17 & IX.18.).
The two novel differential display fi^ agments B4.1 and B5.1 both gave very similar 
transcript patterns when they were used to probe northerns; two clear bands o f around 2Kb 
and Ikb were observed.
Instant imager analysis allowed the accurate assessment of the level o f these 
transcripts between each RNA sample measured in cpm. By reprobing identical northerns 
with a 28S rRNA probe values in cpm were also obtained for the 28S rRNA gene transcripts. 
This allowed the calculation of the ratio o f the novel transcript levels to 28 S rRNA level for 
each sample (FIG’s. IX.21-.24.). The levels of B5.1 transcripts did not differ between 
mRNA samples fi*om SMC’s cultured on plastic or fibronectin, HUVECS, Ü937 cells and 
non-motile and motile Molt4 cells, but there was significantly less in the MRC-5 fibroblasts. 
Levels o f the smaller transcript o f B4.1 was increased in U937 cells and motile Molt4 
compared with the other samples. So this could be interesting in relation to motility. The 
expression of these genes in relation to cell cycle and proliferation was also investigated by 
examining their levels in SMC cultures gradually entering quiescence as a result o f serum 
starvation. These results demonstrate that the small 1 3kb B4.1 transcript, is cell cycle 
regulated as the level o f this transcript gradually increased with time following serum 
starvation (FIG.IX.18.) A transient 1Kb transcript identified with the B 5.1 probe appears at 
6 hours following serum starvation and then disappears by 12 hours following serum 
starvation (FIG.IX.20.) It can be speculated that this transcript could express some cell 
cycle inhibition molecule such as a specific cyclin dependent kinase inhibitor or may even 
represent a stress protein. But the fact that differences in the expression levels o f these novel 
gene transcripts are quite small and are not SMC specific indicates that these novel genes
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would not be useful SMC markers and accordingly no further work was carried out on them. 
This approach could, however, lead to the identification of novel genes that may well 
represent useful markers of SMC phenotype.
Although the identification of differentially expressed genes between fibronectin and 
plastic modulated SMC cultures was hampered by the limitations o f the differential display 
procedure, the inclusion of the optimisation steps described in this thesis together with 
incorporation o f a time course between comparative RNA populations under study would 
significantly improve the technique providing a relatively useful tool for the detection and 
characterization of altered gene expression in eukaryotic cells. Several problems remain to be 
addressed, not least, that the downstream characterisation o f  differentially expressed genes is 
labour intensive. Short cuts for the confirmation and cloning of full length products would be 
required if more than a few RNA species were to be further investigated. The question of 
how eflBciently rare mRNA species are displayed relative to abundant ones remains to be fully 
addressed (Liang e t a l 1993). Finally the problems of felse positives must be eliminated in 
order to reduce the labour of further screening.
It could be indicated fi’om the results presented in this thesis that quite dramatic 
alterations in SMC growth morphology and behaviour as induced by ECM may arise through 
quantitative rather than stark qualitative changes in cell phenotype. This suggestion raises the 
question o f whether the phenotypic alterations of SMC’s observed in  v itro  in response to 
alternative ECM substrate adhesion arise through mechanisms operating at a non-genomic 
level.
Numerous studies have characterised cell transformation or alterations in cell 
phenotype that are brought about by mechanisms that do not involve alterations in gene 
expression. Cellular transformation by many oncogenic viruses is mediated by alterations in 
signal transduction pathways that control normal growth and proliferation. Common targets 
for many transforming viruses are pathways regulated by protein phosphorylation. Thus the
258
alteration of phosphatase activity and subsequent changes in phosphorylation levels is an 
important step in transformation by these viruses (Mumby and Walter 1991). Morphological 
transformation of cells by the v-Src tyrosine kinase is incompletely understood. However, it 
is independent o f nuclear functions and probably involves phosphorylation of targets 
associated with the cytoskeleton and focal adhesions leading to alterations in cell shape and 
attachment that can be transduced into changes in cell proliferation and migration (Fincham 
e ta l 1995).
Both protein tyrosine kinases (PTKs) and protein tyrosine phosphatases (PTPs) have 
evolved to a level of structural diversity that allows them to regulate many cellular processes 
including proliferation, migration, and differentiation. The levels o f tyrosine phosphorylation 
required for each of these processes are achieved through the co-ordinated action of PTKs 
and PTPs. An imbalance between these enzymes may impair normal cell behaviour, leading to 
alterations in cell phenotype or transformation (Sun and Tonks 1994).
For example the treatment of cells with mitogens or the PKC activator 12-0- 
tetradecanoyl-phorbal-13-acetate (TP A) can lead to the activation of the kinase Raf-1. 
Activated Raf-1 triggers a protein kinase cascade by direct phosphorylation of mitogen 
activated protein (MAP) kinase kinase, resulting in phosphorylation of ternary complex 
factor and J im  by MAP kinase. Such co-operation between Raf-1 and PKC a  has been 
implicated in the transformation of NEH3T3 cells (Kolch e t a l 1993). Also Pharmacologic 
differentiation o f the promyelocytic leukemia HL60 is associated with an increase in cellular 
tyrosine phosphatase activity. Modulation of CD45 tyrosine phosphatase activity inay play a 
role in differentiation or in maintaining HL60 cells in a non proliferative state (Buzzi e t a l 
1992).
In imtotic cells abnormal activation of the protein kinase network at multiple points 
can contribute to oncogenic transformation (Pelech 1995). It can be envisaged that 
alterations in the activation of protein kinases associated with cell cycle control such as the
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cyclin dependent kinases (CDK) could yield significant consequences upon cell proliferation 
and phenotype. Similarly changes in the phosphorylation state of kinases associated with cell 
anchorage and cytoskeletal elements could result in alterations in the regulation of cell 
motility and phenotype.
Therefore the induction of phenotypic changes in SMC’s induced by ECM adhesion 
may arise fi"om alterations in the balance between phosphatase and kinase activity of various 
signalling pathways rather than fi’om alterations in gene expression. This proposal would 
explain the lack of variation in the levels o f protein markers between SMC populations 
cultured on different ECM substrates (section VIII) and the failure to identify large numbers 
of differentially expressed genes between fibronectin and plastic modulated SMC cultures by 
differential display analysis (section IX). More success in elucidating the role ECM has on 
SMC phenotype may be achieved by investigating the modification of candidate tyrosine 
phosphatase and kinase activity as markers o f ECM induced modulation o f SMC phenotype.
It seems more likely that the differences observed between cultured SMC’s and tissue 
samples are significant and involve differential gene expression by SMC’s. Phenotypic 
analysis o f protein samples isolated fi"om vascular tissue and SMC’s in culture indicated that 
SMC’s in culture are clearly representative o f the synthetic phenotype while SMC’s within 
the tissue samples are clearly in the contractile phenotype (section VlU). Therefore the 
comparison of SMC’s isolated in  v itro  with SMC’s present within normal tissue samples in  
v ivo  may provide a model for the identification of differences in gene expression that are 
associated with the phenotypic modulation of SMC’s fi*om a contractile to a synthetic 
phenotype taking place in early atherosclerotic and restenotic lesion development. However, 
the comparison of tissue samples with cultured SMC’s is technically difficult as a 
consequence o f the mixed cell population present within tissue samples. Maybe through 
advances in molecular technology such as further optimisation of the differential display 
procedure or other techniques for analyzing differential gene expression taken together with a
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cautious approach, the comparison of SMC gene expression patterns between in  v itro  and in  
vivo  conditions could identify potential candidate genes for SMC phenotypic markers.
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Section XI CONCLUSIONS
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In conclusion, adhesion to ECM substrates in  v itro  appears to modulate human 
vascular SMC phenotype, resulting in distinct differences in growth morphology and in 
cellular response to mitogenic and chemotactic signals. Plasma fibronectin, cellular 
fibronectin, collagen types I, m, IV and vitronectin seemingly promote synthetic-like 
phenotypic behaviour, whereas SMC growth on uncoated tissue culture plastic, Matrigel, and 
possibly also laminin suppresses these synthetic-like characteristics. Phenotypic analysis of 
SMC populations cultured on different ECM substrates using antibodies specific for SMC 
phenotypic marker proteins indicated that ECM did not induce a distinct switch fi'om a 
contractile to a synthetic phenotype. These results suggest that ECM may induce subtle 
alterations in phenotype slightly shifting the phenotype of SMC’s towards cither a more 
synthetic-like or contractile-like phenotype.
The differential display procedure has proven to be technically difficult to perform 
efficiently and may only be worth attempting on two populations where a time course for the 
transition of one population into the other can be incorporated into the procedure. 
Optimisation o f the differential display technique as performed for this thesis has, however, 
provided significant improvements to the procedure.
Differences in the protein levels o f meta-vinculin and the large isoform (210 Kd) of 
MLCK were confirmed to be regulated apon matrix adhesion, however, previous studies do 
not demonstrate that meta-vinculin is a suitable marker of SMC phenotype. It is not possible 
to examine the ^qiression of the large MLCK isoform between SMC phenotypes in  v ivo  as a 
probe or antibody specific for the 210 Kd isoform has not yet been developed.
One possible novel SMC phenotype marker identified during the course o f these 
studies is a 30 Kd low molecular weight isoform of tropomyosin. This protein is present in 
cultured human and rat SMC’s, but appears to be totally absent in tissue samples obtained 
fi'om normal human and rat vessels but is present in balloon injured rat intimai tissue. These
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observations provide strong evidence that this tropomyosin isoform is expressed exclusively 
in synthetic SMC’s.
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